Search results

LEMS explained

A short, plain-language path through Lambert–Eaton myasthenic syndrome, designed as orientation before the evidence detail.

General information. This describes LEMS as a condition, not your individual diagnosis, prognosis or treatment plan.

#The basic idea

1 · Immune responseThe immune system targets calcium channels on nerve endings.
2 · Less messengerThe nerve releases less acetylcholine.
3 · Weaker signalThe muscle receives a quieter instruction to contract.
4 · LEMS effectsStrength, stamina and automatic body functions can be affected.

#Six questions that explain the condition

1. What LEMS is

LEMS is an autoimmune condition that weakens the message travelling from a nerve to a muscle. The muscle itself may be capable of working, but it receives a weaker instruction to contract.

Why this matters: This explains why strength, stamina and automatic body functions can be affected even when the problem starts at the nerve-to-muscle connection.

The medical name for that connection is the neuromuscular junction.

2. Why the signal becomes weaker

The immune system mistakenly targets calcium channels on nerve endings. With fewer working channels, the nerve releases less acetylcholine—the chemical messenger that tells a muscle to contract.

Why this matters: Treatments such as amifampridine are intended to improve this communication; other treatments may address the immune response or an underlying cancer.

VGCC means voltage-gated calcium channel.

3. What it can feel like

LEMS often affects leg and hip strength first. It can also affect the arms, eyes, speech or swallowing, and automatic functions such as dry mouth, constipation and blood-pressure control. People do not all have the same combination.

Why this matters: A general symptom list is only a reference. Symptoms and their changes should be discussed with a clinician.

Autonomic symptoms involve body functions that normally happen automatically.

4. Why cancer screening comes up

In roughly half of adult LEMS cases, the immune reaction is associated with a cancer, most often small cell lung cancer. In the other cases, no cancer is found.

Why this matters: This is why clinicians discuss cancer screening after a LEMS diagnosis. The appropriate tests and schedule should be decided with an individual's clinical team.

Paraneoplastic LEMS means LEMS associated with a cancer.

5. How clinicians identify it

Diagnosis usually combines the symptom pattern, an electrical nerve-and-muscle test, blood tests for relevant antibodies, and evaluation for other possible causes. No single result should be read in isolation.

Why this matters: This is also why diagnostic delays can happen: early symptoms can resemble other neuromuscular conditions.

EMG is the commonly used shorthand for electrodiagnostic testing.

6. How it is treated and lived with

Treatment can include medicine that strengthens nerve-to-muscle signalling, treatment of an underlying cancer when present, and sometimes immune-directed treatment. Day-to-day management can also include pacing and addressing individual symptoms.

Why this matters: The research describes available approaches; medication, dosing, monitoring and symptom plans must be individualized with clinicians.

Amifampridine is the generic name; Firdapse is a brand name used in the US.

#Important numbers, with context

Numbers can make research look more certain or personally predictive than it is. They are collected here after the explanation, with their limitations.

Show the 12 research fact cards
Cancer association
~50% of cases
Historically ~75% in 1960s cohorts, ~50% in 2000s cohorts; small cell lung cancer is the driver.
Cancer detection window
~92% within 3 months
Of LEMS patients who turn out to have cancer, ~92% are found within 3 months of diagnosis, ~96% within a year.
Prevalence
2.6–3.3 per million
US Veterans Affairs population study, 12.5M patients, 1999–2013. Roughly 46x rarer than myasthenia gravis.
VGCC antibodies
Detectable in ~85–91%
Supportive, not confirmatory: low specificity when used alone, and a negative result does not rule LEMS out.
EMG threshold
≥60% CMAP increment
Lowering the cutoff from 100% raises sensitivity to 78–96% at ~99% specificity.
Diagnostic delay
Median 7.5 months
When manual strength testing reads normal despite real weakness, vs 1.5 months for MG. Small cohort (n=12) — direction is solid, magnitude is not.
First-line therapy
Amifampridine (Firdapse)
Strongest evidence base here: multiple randomized placebo-controlled trials. Approved for adults Nov 2018, ages 6+ Sept 2022.
Second approved drug
Guanidine, rarely used
Also FDA-approved for LEMS, but largely abandoned since the early 1990s over marrow, liver, and kidney toxicity.
Real-world treatment start
91% within 6 months
Leiden cohort, 70 patients over up to 30 years: amifampridine improved leg function in 57%.
Immunosuppressant drift
23% → 41–44%
Share of patients on immunosuppression at 6 months vs 5 years — therapy gets layered in gradually, not upfront.
Quality of life
34.2 vs 78.6
Physical functioning score, 46 LEMS patients vs matched general population (2024 German study).
Employment impact
71.4% limited
Share of previously working patients reporting employment limitations; 23.4% feared poverty in old age.

#Small glossary

VGCC
A calcium channel on a nerve ending; a main immune target in LEMS.
Acetylcholine
The chemical messenger a nerve releases to tell a muscle to contract.
EMG / electrodiagnostic testing
Tests that measure electrical activity and nerve-to-muscle signalling.
CMAP
A measurement of the muscle's electrical response after a nerve is stimulated.
SCLC
Small cell lung cancer, the cancer most often associated with LEMS.
Paraneoplastic
Caused by an immune response associated with a cancer rather than direct tumor spread.
Autonomic
Body functions that normally happen automatically, such as saliva or blood-pressure control.
Presynaptic
On the nerve side of the nerve-to-muscle connection.

Research map

The evidence organized by the questions it helps answer, with uncertainty shown alongside the findings.

7 trials tracked 685 catalogued articles

#What the research is trying to answer

Stronger: trials or multiple consistent sourcesModerate: observational or limited studiesEarly: case reports, small series or preclinical work

Treatment and longer-term care

Mixed evidence

Amifampridine has the strongest trial evidence for improving symptoms. Longer-term observational research suggests that additional treatments are often layered in over time, but individual treatment paths vary.

Still uncertain: Which sequence works best for a particular individual over many years.

Cancer-associated LEMS

Established link; details vary

The connection with small cell lung cancer is well established. Research is still refining risk estimates, screening practice and the smaller group of associations with other cancers.

Still uncertain: Which screening schedule is appropriate for a particular individual.

Diagnosis and diagnostic delay

Moderate evidence

Antibody testing and electrodiagnostic testing can support diagnosis, but neither should be treated as a stand-alone answer. Small studies and larger retrospective reports show that LEMS is often initially mistaken for another condition.

Still uncertain: How well newer thresholds and biomarkers perform across different populations.

Daily life and quality of life

Small observational studies

Available studies show substantial effects on physical function, employment and emotional well-being. They describe groups, not what any one person will experience.

Still uncertain: Which supports and symptom-management approaches make the greatest practical difference.

Rare presentations and international findings

Mostly early evidence

Case reports and small series broaden what is known about atypical symptoms, regional differences and access to treatment. They are useful signals, but weak foundations for general conclusions.

Still uncertain: Which unusual findings will hold up in larger, more representative studies.

Experimental directions

Early or preclinical

Researchers are exploring improved biomarkers, better ways to restore nerve-to-muscle signalling and more structured approaches to identifying cancer-associated disease.

Still uncertain: Whether these ideas will prove safe and effective in human trials.

#Clinical trials being tracked

Trial status and eligibility can change. Open the study record for current details.

StudyWhat it isStatus
NCT07478172Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseCurrently recruiting
NCT01793168CoRDS: Coordination of Rare Diseases at SanfordCurrently recruiting
NCT07072676The Use of Assistive Gait Devices to Reduce Fall Risk in Neuromuscular DiseaseEnrolling by invitation (not open to general sign-up)
NCT06605612Development and Validation of the FBIndex (Fall-risk Index) for Neuromuscular DisordersEnrolling by invitation (not open to general sign-up)
NCT07136844Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology (ActiLiège-Adult)Possibly relevant — flagged, not confirmed
NCT00716066Autologous Stem Cell Transplant for Neurologic Autoimmune DiseasesActive, not recruiting
NCT02189720Expanded Access Study, Amifampridine Phosphate in LEMS/CMS (EAP-001)Historical — how Firdapse got here

#Explore the evidence

Evidence library

Filter the full article catalog by category, evidence type and relevance tier.

Outside the US

Explore international approvals, access, trials and non-English findings.

Related websites & organizations

Disease references, literature and trial databases, patient communities, and treatment information beyond this guide.

Outside the United States

A reader-facing overview of LEMS beyond the United States: where amifampridine is approved or funded, which trials and registries operate internationally, what non-English literature adds, and where patient organisations exist.

Drug access and regulatory status

Amifampridine is not one global product. The EU and US rights sit with different companies, and approval does not imply funding — the UK approved it and then twice declined to pay for it.

JurisdictionStatusDetail
European UnionApproved — adults onlyEMA-authorised since 2009 (as Zenas, renamed Firdapse in 2010). Rights are held by SERB SA — a separate corporate chain from Catalyst/Angelini in the US, so the $4.1B acquisition did not touch it. No EU pediatric indication, unlike the US and Canada. Orphan exclusivity expired Dec 2019, and SERB now also holds an EMA-approved generic of its own product (2022).
United KingdomApproved, not NHS-fundedNHS England (2016) and the Scottish Medicines Consortium (2012) both declined funding on cost-effectiveness, not efficacy: roughly £29,448/year for Firdapse against ~£730/year for unlicensed base 3,4-DAP, a ~40x gap cited as the reason. Compounded base 3,4-DAP is available via Ascot Laboratories. Whether either decision has since been revisited is unconfirmed.
FranceReimbursedHAS (2010) rated it reimbursable but only moderate medical benefit and minor (Level IV) added clinical benefit, noting weak methodological quality in the underlying trial evidence.
GermanyReimbursed in practiceNo formal AMNOG/G-BA benefit dossier was pinned down, but pharmacy pricing data confirms real-world reimbursement: €2,325.97 per box against a €10 standard patient copay under statutory insurance.
ItalyBranded de-listed (2012)AIFA de-listed branded Firdapse in favour of cheaper pharmacy-compounded 3,4-DAP. A Milan neuromuscular specialist publicly objected on dosing-consistency and safety grounds. The source is patient-advocacy media rather than peer-reviewed, so treat the safety claim as one expert's asserted position.
JapanApproved Sept 2024Commercially launched January 2025 via DyDo Pharma under a 2021 sub-license from Catalyst — roughly six years behind the US. Before that, 3,4-DAP was classified in Japan only as an industrial reagent, so Japanese patients had no legally approved LEMS drug at all. Confirmed independently three ways.
CanadaApproved 2020Rights now held by Kye Pharmaceuticals. Pediatric label expansion approved June 2025 — Canada's first approved LEMS treatment for children.
South KoreaNo approval foundNo evidence of approval, orphan designation, or coverage. Reads as a genuine absence rather than a search gap.
ChinaNot approvedAccess reported via special-import hospital procedures or cross-border sourcing from Hong Kong and Singapore, per a Chinese commercial medical-tourism site. Another claim from that same source is contradicted by the EMA record, so it is weak evidence.
AustraliaApproved; subsidy unknownA TGA assessment report exists but could not be read (repeated timeouts). PBS subsidy status is an open gap.
Latin AmericaNo activity foundNo approval or access activity found anywhere in the region, including Brazil and Mexico.

Trials and registries outside the US

Pulled automatically from the trials tracker on every build, filtered to non-US sponsors.

StudyCountryWhat it isStatus
NCT07072676GermanyThe Use of Assistive Gait Devices to Reduce Fall Risk in Neuromuscular DiseaseEnrolling by invitation (not open to general sign-up)
NCT06605612GermanyDevelopment and Validation of the FBIndex (Fall-risk Index) for Neuromuscular DisordersEnrolling by invitation (not open to general sign-up)
NCT07136844BelgiumGait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology (ActiLiège-Adult)Possibly relevant — flagged, not confirmed
European LEMS Registry — 30 clinical centres across Germany, Italy, Spain, and the UK, with roughly 96–105 enrolled patients. Not a trial, and not listed on ClinicalTrials.gov, so it does not appear in the table above.

Found only in non-English sources

These did not appear in the English-language corpus. The first one is the reason this section is worth reading rather than skimming.

Anesthesia & medication warningGermany

The DMG patient brochure explicitly warns that anesthesia and many medications can worsen nerve-to-muscle transmission in LEMS, and tells patients to disclose the diagnosis before any surgery or new prescription. The research run flagged this as the single finding most worth raising with a care team directly rather than just filing.

Cerebellar ataxia in 9–14%Japan

Japanese national data reports 9–14% develop cerebellar ataxia (PCD-LEMS overlap) — a symptom that does not appear in the main symptom list at all.

LEMS predicts better SCLC survivalNetherlands / France

A 150-patient LUMC cohort reports 21% vs 4% five-year survival for LEMS+SCLC against SCLC alone, and Orphanet's French entry independently gives ~20% long-term remission vs <2%. Having LEMS is a favourable prognostic sign within small cell lung cancer.

HLA-B8 absence as a tumor signalNetherlands

Most LEMS patients who have a tumor lack HLA-B8, so its absence raises tumor suspicion. This is a different angle from the HLA-B8 idiopathic-risk association already documented.

Sex-linked subtype splitSouth Korea

A 12-patient Yonsei series found paraneoplastic LEMS predominantly in men, and primary autoimmune LEMS only in women, with good steroid response. Small and old — a lead, not an established fact.

Type II fiber atrophy on biopsyChina

A 12-patient Beijing series found selective type II muscle-fiber atrophy, with needle-EMG patterns not reliably correlating with biopsy findings — a histopathology angle absent from the English sources.

Atypical presentationsFrance

Revue Neurologique case reports document LEMS with a coexisting neurogenic EMG pattern, and a case presenting with status epilepticus and no classic EMG increment at all — the hallmark diagnostic sign simply absent.

Reclassification and lead timeGermany

The German patient association gives LEMS as reclassified idiopathic if no tumor is found within 2–3 years, and says neurological symptoms can precede tumor detection by up to 5 years — a longer lead time than implied elsewhere. Clinical convention from a secondary source, not a cited study.

Autonomic symptoms in 95%Netherlands

From the Dutch national oncology guideline, which also gives LEMS in 3% of SCLC patients — a denominator the English sources here only had in reverse.

Diagnostic delay by tumor statusJapan

A systematic review of 97 Japanese case reports gives median 3.0 months to diagnosis when tumor-associated and 6.0 months when not — different from the 7.5-month figure elsewhere here, likely because published case reports skew toward faster-diagnosed teaching cases.

Epidemiology by country

Netherlands
~100 patients
Nationally. LUMC's expertise centre reports 10–15 new diagnoses per year.
Japan
348 patients
National survey (2017); prevalence 0.27 per 100,000.
France
0.48–0.75 / million
Incidence, not prevalence — the only incidence figure collected here. Same source gives 52% female in non-tumor LEMS.
Netherlands
3% of SCLC patients
Have LEMS, per the Dutch national oncology guideline.
Europe
~96–105 patients
European LEMS Registry, spanning 30 clinical centres across Germany, Italy, Spain, and the UK.

the country evidence summary

The full global list, straight from the country note — the US is kept in for comparison rather than dropped, since removing a row would misrepresent the source table. The note cautions that this tracks publication activity, not where the disease actually occurs. Hover a country for its evidence.

Countries with strong evidence 10 countries

USA Netherlands Japan Turkey Germany UK Italy Spain South Korea Poland

Countries with published case reports/series, verified by author affiliation 8 countries

China Brazil India Canada Chile Qatar Australia Portugal

Patient organisations outside the US

DMG / DGM

Germany

Dedicated LEMS content hub with its own shorthand (aiLEMS vs pLEMS). Runs peer-led Zoom exchange calls and an annual in-person meeting — patient-run, structurally different from the pharma-run US webinar series. Gives cancer screening as every 3–6 months for at least two years.

AFM-Téléthon · Orphanet FR

France

AFM-Téléthon runs a dedicated myasthenia interest group. Orphanet's French entry (last updated Nov 2013, authored by Titulaer of the Leiden group) carries prognosis specifics. A French patient forum has an active LEMS thread, though its content could not be read.

Spierziekten Nederland · Spierfonds

Netherlands

The "Feiten over LEMS" page was eventually read in full via browser automation after a bot-check blocked plain fetching. Spierfonds notes, as a transparency point, that no active LEMS research project is currently underway in the Netherlands.

Myasthenia Patients Association (NPO)

Japan

A 2021 patient explainer documents that 3,4-DAP was classified only as an industrial reagent. There is no dedicated government designated-disease page for LEMS, reachable only via myasthenia gravis's differential list — so patients may not qualify for medical-expense subsidy depending on which bucket their presentation falls into.

EURORDIS · Orphanet

Pan-European

EURORDIS has no LEMS-specific content, operating at policy/umbrella level; Orphanet fills that role.

Open questions in the international picture

What the research run could not resolve, plus one place where two notes contradict each other.

  • Australia
    TGA assessment exists but was unreadable; PBS subsidy status unknown.
  • Germany
    No formal AMNOG/G-BA benefit-dossier history pinned down.
  • United Kingdom
    Whether the 2012 and 2016 funding rejections have been revisited since is unconfirmed, as is whether Ascot Laboratories' compounded supply is still active.
  • Japan
    The 2022 Japanese Society of Neurology MG/LEMS clinical guideline could not be read (403 errors). Flagged in the source as the single most promising unread document for a future pass.
  • France
    The available summaries conflict. the country evidence summary lists France as an unresolved gap, while the international research run cites French case reports (Revue Neurologique, 2007 and 2020) and a French incidence study (2014). Worth reconciling — this guide surfaces the conflict but does not resolve it.

Related Websites & Organizations

Other places to look beyond this guide — disease-reference sites, literature and trial databases, patient communities, and treatment information. Each link opens in a new tab. None of this is checked on every rebuild the way the tracked trials and article catalog are, so treat a dead link or a moved page as a sign to search the organization’s current site rather than a dashboard bug.

Disease information & rare-disease references

NORD

National Organization for Rare Disorders' patient-oriented disease report.

Orphanet

European rare-disease database (INSERM-curated): epidemiology, clinical practice guidelines, and disease detail (ORPHA:43393).

GARD — Genetic and Rare Diseases Information Center

NIH/NCATS rare-disease reference with a dedicated LEMS ("Eaton-Lambert syndrome") page and links to related research and support organizations.

NCBI Bookshelf / StatPearls

Free, physician-authored clinical reference chapter on LEMS, updated periodically.

Research & trial databases

PubMed / MEDLINE

NIH National Library of Medicine's index of peer-reviewed biomedical literature — the standard starting point for LEMS research.

Cochrane Library

Systematic reviews of treatment evidence.

ClinicalTrials.gov

The US clinical trial registry.

LEMS-01 Registry

EMA-catalogued real-world registry tracking LEMS natural history and treatment patterns across participating European centers.

Patient communities & advocacy

Lambert-Eaton LEMS Family Association

Patient-founded nonprofit: community, resource center, and the LEMS Patient Registry.

LEMS Aware

Disease-education site run by Catalyst Pharmaceuticals; includes a physician finder and a patient community section.

Real Life with LEMS

Catalyst Pharmaceuticals patient engagement: webinars and discussions featuring LEMS patients and caregivers.

Treatment & prescribing information

FIRDAPSE — official patient site

Catalyst Pharmaceuticals' official site for amifampridine (Firdapse): dosing guidance, starting treatment, and support programs.

FIRDAPSE full prescribing information (DailyMed)

The FDA label itself, hosted by the NIH's DailyMed — a direct government source rather than a pharma redirect link.

Doctors & Researchers

A reference directory of named clinical-trial contacts and the researchers behind the studies cited throughout this guide — not a vetted referral list, and not a claim that anyone here is accepting new patients. Every entry below was checked directly against a primary source (the live clinical-trial registry, or the actual published paper) before being kept; anything that couldn’t be confirmed was left out rather than repeated unverified. Even a confirmed entry can go stale — titles and affiliations change.

Named clinical-trial contacts

The people and offices actually named as contacts on trials that include LEMS as an eligible condition, each checked directly against the live registry record.

TrialContactInstitutionInfo
NCT07478172 — Whole-body EMS pilotKristina M. Kelly, DPT, MS, EdMUniversity of Missouri–Columbia573-884-2596 · kristina.kelly@health.missouri.edu
Both the study's central contact and the Columbia site's principal investigator.
NCT01793168 — CoRDS rare-disease registrySanford Research CoRDS teamSanford Health, Sioux Falls, SD1-877-658-9192 · cords@sanfordhealth.org
Free international registry covering 7,000+ rare diseases, including LEMS. Shares de-identified data with approved researchers rather than putting enrollees in direct contact with them.
NCT07072676 / NCT06605612 — Munich fall-risk studiesMarko Mijic (responsible party)LMU Klinikum, MunichGeneral switchboard: +49 89 4400-0
The two studies run at different sites — Medical Park, Bad Feilnbach (NCT07072676) and the Friedrich-Baur-Institut in Munich (NCT06605612) — not one shared address.
NCT07136844 — ActiLiège-AdultNicolas Bovy (contact) · Laurent Servais, MD (PI)CHU de Liège / Citadelle, Belgium+32 4 321 8095 · Nicolas.Bovy@citadelle.be
Its myasthenic arm requires MG-specific (MGFA) staging — confirm LEMS eligibility directly before assuming this trial applies.
NCT02970162 — LMS-003 (completed 2017)Perry B. Shieh, MD, PhDUCLA Health310-794-1195
Principal investigator on the confirmatory Firdapse trial. Listed for historical context, not as a currently recruiting contact.

Researchers behind the cited literature

Real people confirmed via their current institutional profile or the actual paper's byline — not a claim that any of them treats patients outside their own clinic.

Leiden / Rotterdam, Netherlands

  • Jan J.G.M. Verschuuren — Leiden University Medical Center. Head of the clinical neuromuscular section; leads the group behind the 30-year LEMS treatment-pattern study and the EMG-threshold research cited throughout this guide.
  • Maarten J. Titulaer, MD, PhD — Erasmus MC, Rotterdam. First author of the DELTA-P score for predicting SCLC risk in newly diagnosed LEMS.
  • Martijn R. Tannemaat, MD, PhD — Leiden University Medical Center. Head of Clinical Neurophysiology.

Berlin, Germany

  • Andreas Meisel — Charité – Universitätsmedizin Berlin. Co-lead, with Hannah Preßler, of the published European LEMS Registry and paraneoplastic-LEMS analysis cited in this guide.

Japan

  • Hiroaki Yoshikawa, MD, PhD — Kanazawa University (at time of publication). Lead author of Japan's 2022 nationwide LEMS survey (348 estimated patients, 2.7 per million).
  • Masakatsu Motomura, MD, PhD — Nagasaki Institute of Applied Science. Long-standing Nagasaki-area LEMS and neuromuscular-junction researcher.

Lyon, France

  • Jérôme Honnorat, MD, PhD — Hospices Civils de Lyon. Leads the French national reference center for paraneoplastic neurological syndromes; co-author of the 2021 updated PNS diagnostic criteria.

Uppsala, Sweden

  • Anna Rostedt Punga, MD, PhD — Uppsala University. Professor of Clinical Neurophysiology; co-author of the 2022 Lancet Neurology review of autoimmune neuromuscular-junction disorders.

United States

  • Amanda C. Guidon, MD, MPH — Massachusetts General Hospital. Chief, Neuromuscular Division; 2020 MGFA Physician of the Year.
  • Ahmet Höke, MD, PhD — Johns Hopkins (Drachman Division of Neuromuscular Medicine). Director of the division.
  • James F. Howard Jr., MD — UNC Chapel Hill. Neuromuscular-junction clinical trials, including FcRn- and complement-inhibitor mechanisms.
  • Mazen M. Dimachkie, MD — University of Kansas Medical Center. Director, Neuromuscular Division.
  • Donald B. Sanders, MD (Professor Emeritus) & Vern C. Juel, MD — Duke University. Long-standing LEMS/myasthenia diagnostic and treatment research; Juel currently leads Duke's Neuromuscular Division.
  • Shin J. Oh, MD — University of Alabama at Birmingham. Distinguished Professor Emeritus; established the modern ≥60% CMAP-increment EMG threshold used in LEMS diagnosis.
  • Sean J. Pittock, MD; Andrew McKeon; Divyanshu Dubey; Vanda A. Lennon, MD, PhD — Mayo Clinic. Mayo's autoimmune-neurology group; Lennon pioneered the P/Q-type VGCC antibody assay used in LEMS diagnosis.
  • Gil I. Wolfe, MD, FAAN — University at Buffalo. SUNY Distinguished Professor directing Buffalo's neuromuscular and MDA clinical programs.

Specialist locators and registries

Tools for finding a LEMS-experienced clinician or connecting with the broader patient/research community — each confirmed live and doing what it claims.

LEMS Aware Physician Finder

Zip-code search for neurologists, neuromuscular specialists, and physiatrists experienced with LEMS. Run by Catalyst Pharmaceuticals.

MediFind — LEMS doctor index

Ranks specialists by publications, trial involvement, conference activity, and patient volume; filterable by location.

MDA Care Center Network

150+ US multidisciplinary neuromuscular clinics, searchable by state or zip code.

Orphanet expert-center directory

European directory of specialized centers for LEMS (ORPHA:43393) — Orphanet notes its list isn't necessarily comprehensive.

Lambert-Eaton LEMS Family Association registry

Patient-led, opt-in research registry; partners with the CoRDS rare-disease registry.

Evidence library

Start with the category guide and highlights rather than the full article list. The 31 papers with written annotations receive article-specific takeaways; the remaining 654 catalog-only records are clearly labeled rather than given invented conclusions. Citations and external article links remain available in each record.

For clinicians: articles and full-text access

Every category now contains an expandable list of all its articles, and the access button is also visible on every article card. 455 records are explicitly marked open access in the source metadata and link to full text. 225 link to a publisher or research database and may require institutional access; 5 use a PubMed title lookup. Downloaded subscription copies are not embedded in this public-facing page because possession of a copy does not by itself grant redistribution rights.

685 articles 16 categories 48 LEMS-primary 31 article-specific takeaways 654 catalog-only records 20 articles tagged with new findings 455 open-access full texts

Browse the 16 categories

Choose a category for its plain-language explanation, selected highlights, and a complete article list with access links.

Category syntheses & highlights

Each synthesis combines the category definition with the relevance notes already written for its articles. Highlights favor papers that were read more deeply, changed another note, or were tagged as a major finding. Expand “See all articles” in any category for its complete reading list and full-text access routes.

LEMS-primary

48 articles

Directly about LEMS

These papers study LEMS itself: its symptoms, diagnosis, cancer connection, treatment, biology and day-to-day burden. This is the category to read first.

What to take away: The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

See all 48 articles and where to read them
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC-ND 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textOpen access
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Amifampridine overdose leading to refractory status epilepticus
2024 · The American Journal of Emergency Medicine
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Guideline for the management of myasthenic syndromes
2023 · Therapeutic Advances in Neurological Disorders
Open-access full textCC BY 4.0
Lambert-Eaton myasthenic syndrome
2025 · BMJ Case Reports
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC-ND 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textOpen access
Show 3 useful article highlights
Autopsy-Confirmed Non-Paraneoplastic Lambert–Eaton Myasthenic Syndrome with Cerebellar Degeneration: A Case Report

First autopsy-confirmed case of non-tumor LEMS (NT-LEMS) with cerebellar degeneration — a 79-year-old man, progressive ataxia over 40 months, no malignancy found even at comprehensive autopsy. Postmortem showed severe Purkinje cell loss with Bergmann gliosis, previously documented only in cancer-associated (tumor-associated) LEMS.…

For cliniciansOpen-access full textCC BY 4.0
Lambert–Eaton myasthenic syndrome and solitary cerebellar metastasis in a patient with occult small-cell lung cancer: a rare experience

Case of LEMS with a solitary cerebellar metastasis, both preceding detection of the primary (occult) small-cell lung cancer.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
3 Things You Should Know About Treating Paraneoplastic Lambert-Eaton Myasthenic Syndrome

The most clinically detailed single source in this batch: gives the actual FDA pivotal-trial data behind amifampridine's approval — LMS-002 (NCT01377922, n=38) and LMS-003 (NCT02970162, n=26), with muscle-strength score (QMG)/SGI effect sizes and p-values — a specific titration protocol (start 15–30 mg/day divided, +5 mg every 3–4 days, max single dose 20 mg, max total 100 mg/day; seizure risk specifically at 100 mg/day), and older but concrete response-rate data for intravenous immunoglobulin (IVIG) (Bain et al.…

For cliniciansPublisher / database full textInstitutional or personal access may be required

Paraneoplastic neurological syndromes (broader)

93 articles

Important cancer context

These papers cover neurological problems caused by an immune response to cancer. LEMS is one member of that larger family, but is often not the main subject.

What to take away: They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

See all 93 articles and where to read them
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 3.0
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Autoimmune encephalitis
2025 · Nature Reviews. Disease Primers
Publisher / database full textInstitutional or personal access may be required
Autoimmune Encephalitis and Related Syndromes
2023 · Journal of Clinical Medicine
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-SA 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textOpen access
Open-access full textCC BY 4.0
Neuropsychiatric Disorders Due to Limbic Encephalitis: Immunologic Aspect
2021 · International Journal of Molecular Sciences
Open-access full textCC BY 3.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 3.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Paraneoplastic syndromes in patients with melanoma
2024 · Postepy Dermatologii i Alergologii
Open-access full textCC BY-NC-SA 4
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Find full text on PubMedNo direct article URL was captured
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 3.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
Open-access full textCC BY-NC 3.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Show 2 useful article highlights
Clinical characteristics and prognosis of paraneoplastic syndromes: a single-center cohort study in Northern China

Northern China PNS cohort (n=114): LEMS was the 3rd most common PNS subtype at 16.7% (19/114), behind encephalomyelitis (34.2%) and limbic encephalitis (17.5%) — a data point on where LEMS sits within the broader PNS spectrum, not used for a LEMS-specific estimate (which already has LEMS-specific epidemiology from dedicated LEMS cohorts, a better source for LEMS-specific rates than its share of a mixed-PNS cohort).

For cliniciansOpen-access full textCC BY 4.0
Incidence of paraneoplastic antibodies in United Kingdom – An estimate from a regional centre

UK regional incidence study of high-risk cancer-associated antibodies (2012–2021, Walton Centre, Liverpool) — but note its headline incidence figure (3.8/million/year) covers only antibodies classified high-risk (>70% cancer association) under the Graus et al. 2021 criteria.…

For cliniciansPublisher / database full textInstitutional or personal access may be required

ICI-related neurotoxicity / paraneoplastic syndromes

92 articles

Relevant if cancer immunotherapy is involved

Immune checkpoint inhibitors help the immune system attack cancer, but can occasionally trigger neurological autoimmune problems, including rare LEMS or LEMS-like cases.

What to take away: This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

See all 92 articles and where to read them
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 3.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Beneficial autoimmunity improves cancer prognosis
2021 · Nature Reviews. Clinical Oncology
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textOpen access
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 3.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Myasthenia gravis: the future is here
2024 · The Journal of Clinical Investigation
Open-access full textOpen access
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
2023 · Journal of Ophthalmic Inflammation and Infection
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 3.0
Open-access full textOpen access
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
What Are the Biomarkers for Immunotherapy in SCLC?
2021 · International Journal of Molecular Sciences
Open-access full textCC BY 4.0
Show 1 useful article highlight
Evaluation of warning strategies for paraneoplastic neurological syndromes associated with PD-1/PD-L1 inhibitors

Retrospective study of 224 patients with PD-1/PD-L1 inhibitor-related cancer-associated neurological syndromes: among neuromuscular-junction diseases specifically, LEMS was the most frequently triggered by checkpoint inhibitors.…

For cliniciansOpen-access full textCC BY 4.0

Myasthenia gravis (adjacent NMJ disease)

111 articles

Related condition, not LEMS

Myasthenia gravis also disrupts nerve-to-muscle communication, but on the muscle side of the connection rather than primarily on the nerve side.

What to take away: MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

See all 111 articles and where to read them
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 4.0
Clinical features of double seronegative ocular myasthenia gravis
2024 · Graefe's Archive for Clinical and Experimental Ophthalmology
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Development of a Model Care Pathway for Myasthenia Gravis
2021 · International Journal of Environmental Research and Public Health
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Diagnosis of Myasthenia Gravis
2021 · Journal of Clinical Medicine
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Eculizumab versus rituximab in generalised myasthenia gravis
2022 · Journal of Neurology, Neurosurgery and Psychiatry
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Eye-Opener- A case report of eyelid taping as presenting symptom of Myasthenia Gravis
2025 · Journal of Education & Teaching in Emergency Medicine
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Lower Urinary Tract Symptoms in Myasthenia Gravis
2021 · Case Reports in Neurology
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC-ND 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textOpen access
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 3.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC 3.0
Open-access full textCC BY-NC 3.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
The epidemiology of myasthenia gravis
2021 · Journal of Medicine and Life
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Unusual presentations of myasthenia gravis and misdiagnosis
2025 · Scientific Reports (Nature Publisher Group)
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC 4.0

Congenital Myasthenic Syndromes

4 articles

Inherited look-alikes

These are inherited disorders of nerve-to-muscle signalling. They can resemble LEMS but have different causes and often different treatments.

What to take away: Their main value here is helping distinguish autoimmune LEMS from genetic conditions, especially in younger patients or unusual presentations.

See all 4 articles and where to read them
Open-access full textCC BY 4.0
Open-access full textOpen access
Congenital myasthenic syndromes
2024 · Practical Neurology
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0

CAR-T / engineered cell therapy in autoimmune neurology

10 articles

Experimental background

These papers explore highly engineered immune-cell treatments for autoimmune neurological disease. Most are not LEMS studies.

What to take away: They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

See all 10 articles and where to read them
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 4.0
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0

Neuromuscular junction biology & channelopathies

30 articles

Mechanism and background

These papers study how nerves communicate with muscles and how ion-channel problems disrupt that communication.

What to take away: They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

See all 30 articles and where to read them
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Find full text on PubMedNo direct article URL was captured
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required

Ion Channel & Synaptic Pharmacology

23 articles

Drug-mechanism background

These studies examine ion channels, chemical messengers and drugs that change nerve signalling. LEMS may be mentioned because calcium channels are central to the disease.

What to take away: Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

See all 23 articles and where to read them
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Experimental Zebrafish Models of Synaptopathies
2023 · Journal of Evolutionary Biochemistry and Physiology
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Modulating ion channels with nanobodies
2025 · Synthetic and Systems Biotechnology
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0

Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent)

21 articles

Mechanistic comparison

Botulinum and related toxins also interfere with the nerve's release of acetylcholine, so they illuminate the same side of the nerve-to-muscle connection affected in LEMS.

What to take away: This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

See all 21 articles and where to read them
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Botulism in emergency department
2023 · Internal and Emergency Medicine
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
High risk and low prevalence diseases: Botulism
2024 · The American Journal of Emergency Medicine
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update
2022 · Archives of Toxicology. Archiv für Toxikologie
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 3.0

Kept for completeness; no LEMS-specific reading list is recommended.

SCLC & Oncologic Screening

28 articles

Important cancer context

These papers focus on small cell lung cancer, cancer screening and tumor markers. LEMS is often one clue among many rather than the main topic.

What to take away: They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

See all 28 articles and where to read them
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textOpen access
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Find full text on PubMedNo direct article URL was captured
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Publisher / database full textInstitutional or personal access may be required
Investigating suspected lung cancer
2022 · BMJ : British Medical Journal (Online)
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Lung neuroendocrine tumors: A systematic literature review (Review)
2022 · Experimental and Therapeutic Medicine
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Neuroendocrine neoplasms of the thymus
2024 · Frontiers in Immunology
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Signal pathways and precision therapy of small-cell lung cancer
2022 · Signal Transduction and Targeted Therapy
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0

Autoimmune Encephalitis & CNS Neuroimmunology

25 articles

Related immune-neurology context

These papers cover immune attacks on the brain and central nervous system. LEMS affects the peripheral nerve-to-muscle connection, so this is a different disease area.

What to take away: The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

See all 25 articles and where to read them
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Autoantibodies in neurological disease
2021 · Nature Reviews. Immunology
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Blood–Brain Barrier Disruption in Neuroimmunological Disease
2024 · International Journal of Molecular Sciences
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0

Kept for completeness; no LEMS-specific reading list is recommended.

Neuromuscular Differential Diagnoses

73 articles

Conditions that can resemble LEMS

These papers concern other causes of weakness, fatigue or abnormal electrical tests that can be confused with LEMS.

What to take away: They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

See all 73 articles and where to read them
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
The Eyes Have It
2026 · The New England Journal of Medicine
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Aggregating the Loose Threads
2024 · The New England Journal of Medicine
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textOpen access
Open-access full textCC BY 4.0
Axial muscle weakness
2021 · Practical Neurology
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Case 19-2023: An 80-Year-Old Man with Left Foot Drop
2023 · The New England Journal of Medicine
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textOpen access
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Find full text on PubMedNo direct article URL was captured
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Dysphagia caused by ptosis
2025 · BMJ Case Reports
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Gasping for Strength
2025 · The New England Journal of Medicine
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
High risk and low prevalence diseases: Guillain-Barré syndrome
2024 · The American Journal of Emergency Medicine
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
In‐depth peripheral CD4+ T profile correlates with myasthenic crisis
2021 · Annals of Clinical and Translational Neurology
Open-access full textCC BY-NC-ND 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textOpen access
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Sensory Ganglionopathy
2020 · The New England Journal of Medicine
Publisher / database full textInstitutional or personal access may be required
Skin Biopsy as a Novel Diagnostic Aid in Immune-Mediated Neuropathies
2022 · Journal of Neuropathology and Experimental Neurology
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Weakness in the intensive care unit
2022 · Practical Neurology
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required

Immunotherapy & Immunomodulation (non-LEMS)

23 articles

Treatment ideas from other diseases

These papers study steroids, antibodies and other immune-directed treatments in conditions other than LEMS.

What to take away: They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

See all 23 articles and where to read them
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textOpen access
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Sequential immunotherapy: towards cures for autoimmunity
2024 · Nature Reviews. Drug Discovery
Publisher / database full textInstitutional or personal access may be required
Therapeutic Plasma Exchange: For Cancer Patients
2022 · Cancer Management and Research
Open-access full textCC BY-NC 3.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0

Autonomic Dysfunction / Dysautonomia (non-LEMS)

7 articles

Symptom context

These papers study automatic body functions such as blood-pressure control, sweating and digestion outside the setting of LEMS.

What to take away: They provide background for symptoms that can occur in LEMS, but are not evidence about how common or treatable those symptoms are in LEMS.

See all 7 articles and where to read them
Open-access full textCC BY-NC 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 3.0
Autoimmune Autonomic Neuropathy: From Pathogenesis to Diagnosis
2024 · International Journal of Molecular Sciences
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0

Kept for completeness; no LEMS-specific reading list is recommended.

Quality of Life / Disease Burden (non-LEMS)

1 article

General measurement context

This category contains quality-of-life research from another disease that the search happened to capture.

What to take away: It may help interpret measurement tools, but it should not be used to estimate the burden of LEMS.

See all 1 article and where to read it
Open-access full textCC BY 4.0

Kept for completeness; no LEMS-specific reading list is recommended.

Genuinely tangential / search artifact

96 articles

No useful LEMS conclusion

These papers were caught by broad full-text searching but have no meaningful LEMS focus—often only a passing mention or an unrelated use of the same term.

What to take away: They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

See all 96 articles and where to read them
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
A 29-year-old woman with recurrent syncope: CMAJ
2023 · Canadian Medical Association. Journal:
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
A Novel Type of Extreme Insulin Resistance: Nonhypoglycemic Insulin Autoimmune Syndrome
2021 · The Journal of Clinical Endocrinology and Metabolism
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Altered glycosylation profiles of serum IgG in Takayasu arteritis
2023 · European Journal of Medical Research
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Clonal redemption of B cells in cancer
2023 · Frontiers in Immunology
Open-access full textCC BY 4.0
Coenzyme Q10 and Autoimmune Disorders: An Overview
2024 · International Journal of Molecular Sciences
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
COVID-19 ve Nöroloji
2021 · Dicle Tip Dergisi
Open-access full textCC BY-NC 4.0
Open-access full textCC BY-NC 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Editors’ commentary
2025 · Practical Neurology
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Glycobiology of rheumatic diseases
2023 · Nature Reviews. Rheumatology
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Health anxiety in a neurological setting
2025 · Practical Neurology
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textOpen access
Open-access full textCC BY 4.0
Find full text on PubMedNo direct article URL was captured
Neurological eponyms? Take your Pick
2024 · Practical Neurology
Publisher / database full textInstitutional or personal access may be required
Neurological gait assessment
2023 · Practical Neurology
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Orphan Drugs in Neurology—A Narrative Review
2023 · Journal of Personalized Medicine
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
Possessions to Discern by Every Healthcare Professional
2021 · Asian Journal of Research in Pharmaceutical Science
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY-NC-ND 4.0
Open-access full textCC BY-NC 3.0
Open-access full textCC BY-NC-ND 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Readability analysis of ChatGPT's responses on lung cancer
2024 · Scientific Reports (Nature Publisher Group)
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
RETHINKING INNOVATION AT FDA
2024 · Boston University Law Review
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY-NC-ND 4.0
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Soft Tissue Ewing Sarcoma Cell Drug Resistance Revisited: A Systems Biology Approach
2023 · International Journal of Environmental Research and Public Health
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Open-access full textCC BY 3.0
Open-access full textCC BY 4.0
Open-access full textCC BY-NC 3.0
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Publisher / database full textInstitutional or personal access may be required
The theory of tumor ecosystem
2022 · Cancer Communications
Open-access full textOpen access
Transfusion Service Response to the COVID-19 Pandemic
2020 · American Journal of Clinical Pathology
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0
Open-access full textCC BY 4.0
Why do patients with cancer die?
2024 · Nature Reviews. Cancer
Publisher / database full textInstitutional or personal access may be required
Open-access full textCC BY 4.0

Kept for completeness; no LEMS-specific reading list is recommended.

What the 20 new findings add

A synthesis first, followed by optional article-by-article takeaways. “New” means new to this collection when the articles were reviewed—not necessarily a new discovery this year.

Treatment evidence

Amifampridine remains the best-supported symptomatic treatment in this group: a six-trial meta-analysis and a small real-world study both found improvement. Subcutaneous immunoglobulin and efgartigimod are interesting possibilities, but each is represented here by a single case.

Severe and unusual presentations

Several reports show that LEMS can rarely present with respiratory failure or unusual automatic-body-function signs. These reports expand what clinicians may recognize; they do not tell us how likely those events are for a particular person.

Cancer relationship

The new material reinforces the small cell lung cancer connection while showing that other cancers can occasionally be involved. SOX1 antibodies may add diagnostic context, but they are not a stand-alone cancer or LEMS test.

Cancer immunotherapy

Immune checkpoint treatment can very rarely trigger LEMS or an overlapping neuromuscular syndrome. In other cases, successfully treating the tumor can improve cancer-associated LEMS. The direction depends on the individual situation.

Diagnosis, epidemiology and mechanism

A Japanese national survey supports the same broad rarity seen in Western estimates. Other papers add detail on reflex testing and show that the damaged nerve ending is not only losing calcium channels; its release machinery can also become disorganized.

Safety

One overdose report documents seizures and other severe toxicity after a large acute dose. It is a poisoning case, not evidence that prescribed use commonly causes this outcome.

Show all 20 article takeaways
3 Things You Should Know About Recognizing LEMS in Patients With SCLCnew finding

A CME review (Oncology, 2025, Catalyst Pharmaceuticals-supported) adds granularity to several evidence summaries. It cites a retrospective analysis of 81 patients showing small cell lung cancer (SCLC)-LEMS patients had significantly longer overall survival than non-LEMS small cell lung cancer (SCLC) patients (17 vs 7.0 months, P<.0001), despite significantly worse physical-health quality-of-life scores (55.9 vs 76.3, P<.0001) — cited secondarily, not independently verified here.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trialsnew finding

A systematic review and meta-analysis (Zhang et al., BMC Neurology, 2021, https://doi.org/10.1186/s12883-021-02405-3) pooled 6 RCTs of 3,4-DAP/amifampridine in 115 adult LEMS patients (McEvoy 1989, Sanders 2000, Oh 2009, Wirtz 2009, Oh 2016 [Phase 3, likely = LMS-002], and Shieh 2019 [confirmatory Phase 3 = LMS-003]).…

For cliniciansOpen-access full textCC BY 4.0
A Unique Case of Non-paraneoplastic Lambert-Eaton Myasthenic Syndrome Treated With Subcutaneous Immunoglobulin: A Case Report and Review of Literaturenew finding

A single case report describes a 27-year-old woman with not cancer-associated LEMS (initially misdiagnosed as fibromyalgia/chronic fatigue syndrome) who could not tolerate intravenous immunoglobulin (IVIG) (headache, myalgias) and was successfully transitioned to subcutaneous immunoglobulin (SCIG, 400mg/kg/week), with excellent clinical response — improved proximal motor strength (hip flexion/extension 3-4/5 to 5/5) and reflexes sustained at one-year follow-up, plus improved post-exercise electrical muscle-response measurement (CMAP) facilitation on repeat electrical nerve-and-muscle testing (EMG).…

For cliniciansOpen-access full textCC BY 4.0
Acute Respiratory Failure Resulting From Lambert-Eaton Myasthenic Syndrome: A Case Report and Literature Reviewnew finding

The first systematic literature review of LEMS presenting with respiratory failure (reviewing 15 prior published cases plus a new small cell lung cancer (SCLC)-associated case) found: ambulatory dysfunction in 33% (5/15), dyspnea in 27% (4/15), and generalized weakness in 27% (4/15) as presenting features; 66% (10/15) were diagnosed with small cell lung cancer (SCLC) during the same hospitalization (one additional case postmortem); 93% (14/15) showed the classic electrical nerve-and-muscle testing (EMG) post-exercise/high-frequency facilitation pattern; and 33% (5/15) died during hospitalization.…

For cliniciansOpen-access full textCC BY 4.0
Amifampridine overdose leading to refractory status epilepticusnew finding

Gooley et al. (American Journal of Emergency Medicine, 2024, https://doi.org/10.1016/j.ajem.2024.04.023) report what they state is the first published case of acute 3,4-DAP/amifampridine overdose toxicity: a 67-year-old man with LEMS ingested 100 mg amifampridine (10x his prescribed 10 mg dose) plus 24.5 g acetaminophen in a suicide attempt.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
Atezolizumab-Induced Lambert-Eaton Myasthenic Syndrome in a Patient With Small-Cell Lung Cancernew finding

Case report of a 70-year-old man who developed LEMS as an immune-related adverse event (immune-related side effect) during maintenance atezolizumab therapy for extensive-stage small cell lung cancer (SCLC) (onset after 9 cycles/8 months of atezolizumab), diagnosed via positive P/Q-type calcium-channel antibody (VGCC) antibodies and repetitive nerve stimulation (waning phenomenon at 3Hz, 688.5% waxing increment at 50Hz).…

For cliniciansOpen-access full textCC BY 3.0
Combined treatment with radiotherapy, chemotherapy and avelumab results in regression of metastatic Merkel cell carcinoma and improvement of associated Lambert-Eaton myasthenic syndrome: A case reportnew finding

Immune-checkpoint-inhibitor treatment of cancer-associated LEMS (single case): Green et al. (Oncology Letters, 2022, https://doi.org/10.3892/ol.2022.13513) report a 67-year-old man with Merkel cell carcinoma (MCC)-associated LEMS (VGCC Ab 65.2 pmol/L) — the first case of MCC-LEMS treated with avelumab (anti-PD-L1 checkpoint inhibitor) reported by this group, and only the second MCC-LEMS-avelumab case in the literature overall.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
Dilated fixed pupils and respiratory failure: a rare clinical course of Lambert-Eaton myasthenic syndromenew finding

A case report of a 62-year-old woman with LEMS presenting with early respiratory failure (post-cardiac-arrest) AND bilateral dilated, fixed pupils (7-8mm) — an atypical autonomic manifestation rarely described in LEMS and not typically included in standard differential diagnoses of fixed dilated pupils; pupils normalized with 3,4-DAP/IVIg treatment, supporting a cholinergic autonomic-dysfunction mechanism analogous to the muscle weakness.…

For cliniciansOpen-access full textCC BY-NC 4.0
Efgartigimod for the treatment of Lambert–Eaton syndrome: a case reportnew finding

A case report (Zhang et al., Journal of Neurology, 2025, doi:10.1007/s00415-025-13258-y) describes the first documented use of efgartigimod (an FcRn antagonist, approved for myasthenia gravis via the ADAPT trial) in LEMS. A 64-year-old man with small cell lung cancer (SCLC)-associated LEMS progressed to respiratory failure (QMG 33, MG-ADL 23) despite tumor control via chemotherapy and sequential treatment with plasma exchange, intravenous immunoglobulin (IVIG), and high-dose corticosteroids.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disordersnew finding

Rostedt Punga et al. (The Lancet Neurology, 2022, https://doi.org/10.1016/S1474-4422(21)00297-0), a Series review on autoimmune nerve-to-muscle junction (NMJ) disorders, gives LEMS-specific incidence of 0.17-0.4 per million/year and prevalence of 2.32-2.5 per million from large countrywide studies (broadly consistent with, though slightly lower than, the evidence collection's existing 2.6-3.3/million US VA and 3.42/million France figures) and explicitly flags these as underestimates given LEMS is often initially misdiagnosed.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patientnew finding

Duplaine et al. (Neurological Sciences, 2021, https://doi.org/10.1007/s10072-021-05557-9) report what they describe as the first case of combined myasthenia gravis/Lambert-Eaton overlap syndrome triggered by an immune checkpoint inhibitor (nivolumab), in a man treated for metastatic melanoma.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
Nationwide survey of Lambert-Eaton myasthenic syndrome in Japannew finding

Japan (primary source, nationwide survey): Yoshikawa et al. (BMJ Neurology Open, 2022, https://doi.org/10.1136/bmjno-2022-000291) conducted the first nationwide MHLW-sponsored epidemiological survey of LEMS in Japan (2017 data), independently confirming the previously secondary-cited government figures: an estimated 348 patients nationally (95% CI 247-449), prevalence 2.7/million (95% CI 1.9-3.5) — consistent with the Netherlands (2.5/million, Wirtz 2004) and US VA (2.6/million) estimates.…

For cliniciansOpen-access full textCC BY-NC 4.0
Neuromuscular Active Zone Structure and Function in Healthy and Lambert-Eaton Myasthenic Syndrome Statesnew finding

Mechanism (active zone biology, review synthesis): Ginebaugh et al. (Biomolecules, 2022, https://doi.org/10.3390/biom12060740) synthesize active-zone (AZ) structural biology and passive-transfer mouse-model data that extend the mechanism picture beyond simple calcium-channel antibody (VGCC) loss.…

For cliniciansOpen-access full textCC BY 4.0
Paraneoplastic Lambert–Eaton myasthenic syndrome associated with non-small cell lung cancer: data from the European LEMS registry and systematic reviewnew finding

A European LEMS registry study (Preßler et al., Neurological Research and Practice, 2025, doi:10.1186/s42466-025-00453-5) combined with a PRISMA systematic review found that cancer-associated LEMS extends meaningfully beyond small cell lung cancer (SCLC).…

For cliniciansOpen-access full textCC BY 4.0
Postexercise reflex facilitation in Lambert-Eaton myasthenic syndromenew finding

Case report and review (Practical Neurology, 2024, Singapore) of a 62-year-old woman diagnosed with LEMS via postexercise reflex facilitation (knee/ankle jerks absent at baseline, restored to 2+ after brief exercise) plus electrical muscle-response measurement (CMAP) facilitation >100% and positive P/Q-calcium-channel antibody (VGCC) antibodies; malignancy workup identified a rare extrapulmonary small cell neuroendocrine carcinoma of the gallbladder (SOX-1 antibody negative), treated with carboplatin/etoposide/atezolizumab with partial radiologic response.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
Safety, efficacy and steroid-sparing effect of amifampridine in Lambert-Eaton myasthenic syndrome patients — real world datanew finding

A real-world retrospective study of 14 non-neoplastic LEMS patients (Poland; mean age 48.8±11.4 years, 42.9% female) treated with amifampridine found significant improvement after a mean 21.1±12.0 weeks of follow-up: muscle-strength score (QMG) score improved by a mean 5.1±2.0 points, electrical muscle-response measurement (CMAP) amplitude increased a mean 2.1±1.6-fold, and post-exercise facilitation (>100% increment) fell from present in essentially all patients pre-treatment to 78.6% (11/14) post-treatment.…

For cliniciansOpen-access full textCC BY-NC-ND 4.0
Severe progression of a young-onset non-paraneoplastic Lambert-Eaton myasthenic syndromenew finding

Single case report (Acta Neurologica Belgica, 2025) describes a 21-year-old woman with not cancer-associated (extensively tumor-screened negative) LEMS whose disease progressed over roughly 2.5 years despite pyridostigmine, 3,4-DAP, intravenous immunoglobulin (IVIG), prednisolone, azathioprine, and methotrexate, culminating in severe bulbar dysfunction and respiratory failure requiring intubation/tracheostomy, plus dysphagia requiring gastrostomy.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniquesnew finding

Vabanesi et al. (Journal of Neurology, 2023, https://doi.org/10.1007/s00415-022-11523-y), a retrospective single-center (French PNS Reference Center) study of 77 patients with isolated SOX1-antibody positivity (2009-2019), found only 23/77 (29.9%) met criteria for definite cancer-associated neurological syndrome; all 23 had lung cancer (mostly small-cell), with Lambert-Eaton myasthenic syndrome in 10/23 and rapidly progressive cerebellar ataxia in 6/23.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
SOX‐1 antibodies positive Lambert–Eaton myasthenic syndrome with occult small cell lung cancer: A case reportnew finding

Case report (Clinical Respiratory Journal, 2024, China) of a 56-year-old man with calcium-channel antibody (VGCC)-antibody-seronegative but SOX-1-antibody-positive LEMS; initial tumor screening (CT, PET/CT, bronchoscopy) at diagnosis was negative, but small cell lung cancer (SCLC) was pathologically confirmed via needle biopsy 10 months later after continued surveillance.…

For cliniciansOpen-access full textCC BY 4.0
Type 2 Respiratory Failure as an Initial Manifestation of Lambert–Eaton Myasthenic Syndrome Complicated by Paraneoplastic Autoimmune Encephalitisnew finding

Case report (Cureus, 2025, Kobe, Japan) of a 79-year-old woman whose LEMS first presented as acute type 2 respiratory failure (confusion, seizure, respiratory acidosis requiring non-invasive ventilation) — authors state this is only the second such case reported in the literature.…

For cliniciansOpen-access full textOpen access

Other annotated LEMS-primary papers

The remaining papers in the LEMS-primary group that carry a written annotation.

Show 8 additional LEMS article takeaways
Autopsy-Confirmed Non-Paraneoplastic Lambert–Eaton Myasthenic Syndrome with Cerebellar Degeneration: A Case Reportread in full

First autopsy-confirmed case of non-tumor LEMS (NT-LEMS) with cerebellar degeneration — a 79-year-old man, progressive ataxia over 40 months, no malignancy found even at comprehensive autopsy. Postmortem showed severe Purkinje cell loss with Bergmann gliosis, previously documented only in cancer-associated (tumor-associated) LEMS. Establishes that non-tumor LEMS can reach the same calcium-channel antibody (VGCC)-associated cerebellar endpoint as cancer-associated LEMS, just via a different (non-tumor) trigger.

For cliniciansOpen-access full textCC BY 4.0
Clinical Spectrum and Outcomes of SOX1 Antibody‐Associated Paraneoplastic Neurological Syndromes: A Chinese Cohort Studyread in full

Chinese SOX1-antibody-positive PNS cohort (n=13): Western cohorts are 65–80% LEMS among SOX1+ PNS cases; this cohort instead skewed neuropsychiatric (seizures, psychiatric symptoms), with LEMS comparatively underrepresented — the authors note calcium-channel antibody (VGCC) antibody testing wasn't done for their cohort, which may have led to undercounting co-existing LEMS.…

For cliniciansOpen-access full textCC BY 4.0
3 Things You Should Know About Treating Paraneoplastic Lambert-Eaton Myasthenic Syndromeread in full

The most clinically detailed single source in this batch: gives the actual FDA pivotal-trial data behind amifampridine's approval — LMS-002 (NCT01377922, n=38) and LMS-003 (NCT02970162, n=26), with muscle-strength score (QMG)/SGI effect sizes and p-values — a specific titration protocol (start 15–30 mg/day divided, +5 mg every 3–4 days, max single dose 20 mg, max total 100 mg/day; seizure risk specifically at 100 mg/day), and older but concrete response-rate data for intravenous immunoglobulin (IVIG) (Bain et al.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
The Case of a 28‐Year‐Old Man With Gradually Progressive Proximal Leg Weaknessread in full

Teaching case of autoimmune (not cancer-associated) LEMS in a 28-year-old man — unremarkable diagnostically, but its "Take-Home Points" include a clinical pearl not previously in this evidence collection: pain is a reported symptom in myasthenic syndromes and "should not be disregarded."

For cliniciansOpen-access full textCC BY-NC-ND 4.0
A Case of Voltage‐Gated Calcium Channel and TG6 Antibody–Positive Cerebellar Ataxiaread in full

Case of calcium-channel antibody (VGCC)-antibody cerebellar ataxia without LEMS or any neuromuscular junction symptoms — a 20-something woman, also TG6-antibody positive (a marker of gluten sensitivity), whose cerebellar MR spectroscopy improved after starting a gluten-free diet alongside immunotherapy.…

For cliniciansPublisher / database full textInstitutional or personal access may be required
Lung adenocarcinoma presenting with dual paraneoplastic manifestations: dermatomyositis and Lambert–Eaton myasthenic syndrome

Rare dual cancer-associated presentation: dermatomyositis and LEMS co-occurring in the same patient (lung adenocarcinoma, woman in her 70s) — illustrates how overlapping cancer-associated syndromes can obscure each other's contribution to weakness. Included as a case-report data point on cancer-associated-syndrome overlap.

For cliniciansPublisher / database full textInstitutional or personal access may be required
An interesting collection of paraneoplastic syndromes in a patient with a malignant thymoma

Malignant thymoma presenting with a cluster of cancer-associated syndromes including myasthenia gravis–LEMS overlap syndrome, polymyositis, and chronic GI pseudo-obstruction. Notable fact: the authors could find only 3 prior reported cases of LEMS with thymoma in the literature, and only 1 prior case of MG-LEMS overlap syndrome with thymoma — thymoma is a classic MG association, not a LEMS one, making this constellation genuinely rare. Included as a striking case-report data point.

For cliniciansPublisher / database full textInstitutional or personal access may be required
Lambert–Eaton myasthenic syndrome and solitary cerebellar metastasis in a patient with occult small-cell lung cancer: a rare experienceread in full

Case of LEMS with a solitary cerebellar metastasis, both preceding detection of the primary (occult) small-cell lung cancer. Clinically useful beyond the case itself: explains and applies the DELTA-P score (Titulaer et al., J Clin Oncol 2011) — one point each for age of onset ≥50, current smoking, weight loss ≥5%, bulbar involvement, erectile dysfunction, and Karnofsky performance status <70 — used to predict small cell lung cancer (SCLC) association in LEMS at diagnosis.…

For cliniciansPublisher / database full textInstitutional or personal access may be required

The catalog by category

Counts and how much of each group has a written annotation. Select a category name to return to its readable synthesis.

CategoryArticlesAnnotated
LEMS-primary4828
Paraneoplastic neurological syndromes (broader)932
ICI-related neurotoxicity / paraneoplastic syndromes921
Myasthenia gravis (adjacent NMJ disease)1110
Congenital Myasthenic Syndromes40
CAR-T / engineered cell therapy in autoimmune neurology100
Neuromuscular junction biology & channelopathies300
Ion Channel & Synaptic Pharmacology230
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent)210
SCLC & Oncologic Screening280
Autoimmune Encephalitis & CNS Neuroimmunology250
Neuromuscular Differential Diagnoses730
Immunotherapy & Immunomodulation (non-LEMS)230
Autonomic Dysfunction / Dysautonomia (non-LEMS)70
Quality of Life / Disease Burden (non-LEMS)10
Genuinely tangential / search artifact960

Browse & filter

Annotated articles have a short reader-facing takeaway. Catalog-only records say so plainly and inherit only the category context—no conclusion is guessed from a title. Filter by category or search ordinary words; professional research filters are optional.

Category
Full text
Research filters (optional)
Relevance tier
Evidence level

Autopsy-Confirmed Non-Paraneoplastic Lambert–Eaton Myasthenic Syndrome with Cerebellar Degeneration: A Case Report

2026
LEMS-primary · Diagnostics

First autopsy-confirmed case of non-tumor LEMS (NT-LEMS) with cerebellar degeneration — a 79-year-old man, progressive ataxia over 40 months, no malignancy found even at comprehensive autopsy. Postmortem showed severe Purkinje cell loss with Bergmann gliosis, previously documented only in cancer-associated (tumor-associated) LEMS. Establishes that non-tumor LEMS can reach the same calcium-channel antibody (VGCC)-associated cerebellar endpoint as cancer-associated LEMS, just via a different (non-tumor) trigger.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Iwata Hajime et al, Diagnostics, 2026 · Open-access full text

Clinical Spectrum and Outcomes of SOX1 Antibody‐Associated Paraneoplastic Neurological Syndromes: A Chinese Cohort Study

2026
LEMS-primary · Annals of Clinical and Translational Neurology

Chinese SOX1-antibody-positive PNS cohort (n=13): Western cohorts are 65–80% LEMS among SOX1+ PNS cases; this cohort instead skewed neuropsychiatric (seizures, psychiatric symptoms), with LEMS comparatively underrepresented — the authors note calcium-channel antibody (VGCC) antibody testing wasn't done for their cohort, which may have led to undercounting co-existing LEMS.…

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Cohort Study · Relevance tier: Tier 1
Ye, Jin‐Long et al, Annals of Clinical and Translational Neurology, 2026 · Open-access full text

3 Things You Should Know About Treating Paraneoplastic Lambert-Eaton Myasthenic Syndrome

2026
LEMS-primary · Oncology

The most clinically detailed single source in this batch: gives the actual FDA pivotal-trial data behind amifampridine's approval — LMS-002 (NCT01377922, n=38) and LMS-003 (NCT02970162, n=26), with muscle-strength score (QMG)/SGI effect sizes and p-values — a specific titration protocol (start 15–30 mg/day divided, +5 mg every 3–4 days, max single dose 20 mg, max total 100 mg/day; seizure risk specifically at 100 mg/day), and older but concrete response-rate data for intravenous immunoglobulin (IVIG) (Bain et al.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Narrative Review (CME) · Relevance tier: Tier 1
Authors not listed, Oncology, 2026 · Publisher / database full text

The Case of a 28‐Year‐Old Man With Gradually Progressive Proximal Leg Weakness

2026
LEMS-primary · Annals of Clinical and Translational Neurology

Teaching case of autoimmune (not cancer-associated) LEMS in a 28-year-old man — unremarkable diagnostically, but its "Take-Home Points" include a clinical pearl not previously in this evidence collection: pain is a reported symptom in myasthenic syndromes and "should not be disregarded."

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Asukile, Melody T. et al, Annals of Clinical and Translational Neurology, 2026 · Open-access full text

A Case of Voltage‐Gated Calcium Channel and TG6 Antibody–Positive Cerebellar Ataxia

2026
LEMS-primary · Case Reports in Neurological Medicine

Case of calcium-channel antibody (VGCC)-antibody cerebellar ataxia without LEMS or any neuromuscular junction symptoms — a 20-something woman, also TG6-antibody positive (a marker of gluten sensitivity), whose cerebellar MR spectroscopy improved after starting a gluten-free diet alongside immunotherapy.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Cifelli, Alberto et al, Case Reports in Neurological Medicine, 2026 · Publisher / database full text

Lung adenocarcinoma presenting with dual paraneoplastic manifestations: dermatomyositis and Lambert–Eaton myasthenic syndrome

2025
LEMS-primary · BMJ Case Reports

Rare dual cancer-associated presentation: dermatomyositis and LEMS co-occurring in the same patient (lung adenocarcinoma, woman in her 70s) — illustrates how overlapping cancer-associated syndromes can obscure each other's contribution to weakness. Included as a case-report data point on cancer-associated-syndrome overlap.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Qadeer Rabia et al, BMJ Case Reports, 2025 · Publisher / database full text

An interesting collection of paraneoplastic syndromes in a patient with a malignant thymoma

2025
LEMS-primary · BMJ Case Reports

Malignant thymoma presenting with a cluster of cancer-associated syndromes including myasthenia gravis–LEMS overlap syndrome, polymyositis, and chronic GI pseudo-obstruction. Notable fact: the authors could find only 3 prior reported cases of LEMS with thymoma in the literature, and only 1 prior case of MG-LEMS overlap syndrome with thymoma — thymoma is a classic MG association, not a LEMS one, making this constellation genuinely rare. Included as a striking case-report data point.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Kidher, Emaddin S et al, BMJ Case Reports, 2025 · Publisher / database full text

Lambert–Eaton myasthenic syndrome and solitary cerebellar metastasis in a patient with occult small-cell lung cancer: a rare experience

2025
LEMS-primary · BMJ Case Reports

Case of LEMS with a solitary cerebellar metastasis, both preceding detection of the primary (occult) small-cell lung cancer. Clinically useful beyond the case itself: explains and applies the DELTA-P score (Titulaer et al., J Clin Oncol 2011) — one point each for age of onset ≥50, current smoking, weight loss ≥5%, bulbar involvement, erectile dysfunction, and Karnofsky performance status <70 — used to predict small cell lung cancer (SCLC) association in LEMS at diagnosis.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Ray Sayantan et al, BMJ Case Reports, 2025 · Publisher / database full text

3 Things You Should Know About Recognizing LEMS in Patients With SCLC

2025
LEMS-primary · Oncology

A CME review (Oncology, 2025, Catalyst Pharmaceuticals-supported) adds granularity to several evidence summaries. It cites a retrospective analysis of 81 patients showing small cell lung cancer (SCLC)-LEMS patients had significantly longer overall survival than non-LEMS small cell lung cancer (SCLC) patients (17 vs 7.0 months, P<.0001), despite significantly worse physical-health quality-of-life scores (55.9 vs 76.3, P<.0001) — cited secondarily, not independently verified here.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Narrative Review (CME) · Relevance tier: Tier 1
ONCOLOGY Staff, Oncology, 2025 · Publisher / database full text

3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials

2021
LEMS-primary · BMC Neurology

A systematic review and meta-analysis (Zhang et al., BMC Neurology, 2021, https://doi.org/10.1186/s12883-021-02405-3) pooled 6 RCTs of 3,4-DAP/amifampridine in 115 adult LEMS patients (McEvoy 1989, Sanders 2000, Oh 2009, Wirtz 2009, Oh 2016 [Phase 3, likely = LMS-002], and Shieh 2019 [confirmatory Phase 3 = LMS-003]).…

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Meta-Analysis · Relevance tier: Tier 1
Zhang, Na et al, BMC Neurology, 2021 · Open-access full text

A Case of Paraneoplastic Lambert Eaton Myasthenic Syndrome Associated with Tonsillar Carcinoma

2022
LEMS-primary · SN Comprehensive Clini cal Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Lorah, Victoria et al, SN Comprehensive Clini cal Medicine, 2022 · Publisher / database full text

A Rare Case of Lambert-Eaton Myasthenia Syndrome Associated with Non-Hodgkin’s Lymphoma: A Case Report and Review of the Literature

2023
LEMS-primary · Case Reports in Oncology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Abu-Tineh, Mohammad et al, Case Reports in Oncology, 2023 · Publisher / database full text

A Rare Case of Lambert-Eaton Myasthenia Syndrome With Dysphasia and Dysarthria

2025
LEMS-primary · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Hridya, Harimohan et al, Cureus, 2025 · Open-access full text

A Unique Case of Non-paraneoplastic Lambert-Eaton Myasthenic Syndrome Treated With Subcutaneous Immunoglobulin: A Case Report and Review of Literature

2024
LEMS-primary · Cureus

A single case report describes a 27-year-old woman with not cancer-associated LEMS (initially misdiagnosed as fibromyalgia/chronic fatigue syndrome) who could not tolerate intravenous immunoglobulin (IVIG) (headache, myalgias) and was successfully transitioned to subcutaneous immunoglobulin (SCIG, 400mg/kg/week), with excellent clinical response — improved proximal motor strength (hip flexion/extension 3-4/5 to 5/5) and reflexes sustained at one-year follow-up, plus improved post-exercise electrical muscle-response measurement (CMAP) facilitation on repeat electrical nerve-and-muscle testing (EMG).…

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Park, Sojung K et al, Cureus, 2024 · Open-access full text

Acute Respiratory Failure Resulting From Lambert-Eaton Myasthenic Syndrome: A Case Report and Literature Review

2024
LEMS-primary · Cureus

The first systematic literature review of LEMS presenting with respiratory failure (reviewing 15 prior published cases plus a new small cell lung cancer (SCLC)-associated case) found: ambulatory dysfunction in 33% (5/15), dyspnea in 27% (4/15), and generalized weakness in 27% (4/15) as presenting features; 66% (10/15) were diagnosed with small cell lung cancer (SCLC) during the same hospitalization (one additional case postmortem); 93% (14/15) showed the classic electrical nerve-and-muscle testing (EMG) post-exercise/high-frequency facilitation pattern; and 33% (5/15) died during hospitalization.…

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Case Series / Literature Review · Relevance tier: Tier 1
Spicer, Alan R et al, Cureus, 2024 · Open-access full text

Amifampridine overdose leading to refractory status epilepticus

2024
LEMS-primary · The American Journal of Emergency Medicine

Gooley et al. (American Journal of Emergency Medicine, 2024, https://doi.org/10.1016/j.ajem.2024.04.023) report what they state is the first published case of acute 3,4-DAP/amifampridine overdose toxicity: a 67-year-old man with LEMS ingested 100 mg amifampridine (10x his prescribed 10 mg dose) plus 24.5 g acetaminophen in a suicide attempt.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Gooley, Brian et al, The American Journal of Emergency Medicine, 2024 · Publisher / database full text

An unusual case of delayed recovery from spinal anesthesia in a patient with Lambert-Eaton myasthenic syndrome—a case report

2023
LEMS-primary · Ain - Shams Journal of Anesthesiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Mukherjee, Souvik et al, Ain - Shams Journal of Anesthesiology, 2023 · Open-access full text

Atezolizumab-Induced Lambert-Eaton Myasthenic Syndrome in a Patient With Small-Cell Lung Cancer

2023
LEMS-primary · Cureus

Case report of a 70-year-old man who developed LEMS as an immune-related adverse event (immune-related side effect) during maintenance atezolizumab therapy for extensive-stage small cell lung cancer (SCLC) (onset after 9 cycles/8 months of atezolizumab), diagnosed via positive P/Q-type calcium-channel antibody (VGCC) antibodies and repetitive nerve stimulation (waning phenomenon at 3Hz, 688.5% waxing increment at 50Hz).…

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Yamazoe Masami et al, Cureus, 2023 · Open-access full text

Atypical presentation of Lambert–Eaton myasthenic syndrome associated with oesophageal squamous cell carcinoma

2025
LEMS-primary · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Ana-Maria Bubuioc et al, BMJ Case Reports, 2025 · Publisher / database full text

Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient’s perspective

2024
LEMS-primary · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Cohort Study · Relevance tier: Tier 2
Lehnerer, Sophie et al, Journal of Neurology, 2024 · Open-access full text

Combined treatment with radiotherapy, chemotherapy and avelumab results in regression of metastatic Merkel cell carcinoma and improvement of associated Lambert-Eaton myasthenic syndrome: A case report

2022
LEMS-primary · Oncology Letters

Immune-checkpoint-inhibitor treatment of cancer-associated LEMS (single case): Green et al. (Oncology Letters, 2022, https://doi.org/10.3892/ol.2022.13513) report a 67-year-old man with Merkel cell carcinoma (MCC)-associated LEMS (VGCC Ab 65.2 pmol/L) — the first case of MCC-LEMS treated with avelumab (anti-PD-L1 checkpoint inhibitor) reported by this group, and only the second MCC-LEMS-avelumab case in the literature overall.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Green, Caroline et al, Oncology Letters, 2022 · Publisher / database full text

Dilated fixed pupils and respiratory failure: a rare clinical course of Lambert-Eaton myasthenic syndrome

2023
LEMS-primary · BMJ Neurology Open

A case report of a 62-year-old woman with LEMS presenting with early respiratory failure (post-cardiac-arrest) AND bilateral dilated, fixed pupils (7-8mm) — an atypical autonomic manifestation rarely described in LEMS and not typically included in standard differential diagnoses of fixed dilated pupils; pupils normalized with 3,4-DAP/IVIg treatment, supporting a cholinergic autonomic-dysfunction mechanism analogous to the muscle weakness.…

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Michelle FM ten Brinck et al, BMJ Neurology Open, 2023 · Open-access full text

Efgartigimod for the treatment of Lambert–Eaton syndrome: a case report

2025
LEMS-primary · Journal of Neurology

A case report (Zhang et al., Journal of Neurology, 2025, doi:10.1007/s00415-025-13258-y) describes the first documented use of efgartigimod (an FcRn antagonist, approved for myasthenia gravis via the ADAPT trial) in LEMS. A 64-year-old man with small cell lung cancer (SCLC)-associated LEMS progressed to respiratory failure (QMG 33, MG-ADL 23) despite tumor control via chemotherapy and sequential treatment with plasma exchange, intravenous immunoglobulin (IVIG), and high-dose corticosteroids.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Zhang, Lili et al, Journal of Neurology, 2025 · Publisher / database full text

Electrodiagnostic Evolution in a Case of Paraneoplastic Lambert-Eaton Myasthenic Syndrome in the Intensive Care Unit

2022
LEMS-primary · Canadian Journal of Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Shergill, Simran S et al, Canadian Journal of Neurological Sciences, 2022 · Publisher / database full text

Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders

2022
LEMS-primary · The Lancet Neurology

Rostedt Punga et al. (The Lancet Neurology, 2022, https://doi.org/10.1016/S1474-4422(21)00297-0), a Series review on autoimmune nerve-to-muscle junction (NMJ) disorders, gives LEMS-specific incidence of 0.17-0.4 per million/year and prevalence of 2.32-2.5 per million from large countrywide studies (broadly consistent with, though slightly lower than, the evidence collection's existing 2.6-3.3/million US VA and 3.42/million France figures) and explicitly flags these as underestimates given LEMS is often initially misdiagnosed.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Narrative Review (Series) · Relevance tier: Tier 1
Anna Rostedt Punga et al, The Lancet Neurology, 2022 · Publisher / database full text

Guideline for the management of myasthenic syndromes

2023
LEMS-primary · Therapeutic Advances in Neurological Disorders

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Guideline · Relevance tier: Tier 2
Wiendl Heinz et al, Therapeutic Advances in Neurological Disorders, 2023 · Open-access full text

Lambert-Eaton myasthenic syndrome

2025
LEMS-primary · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Narrative Review · Relevance tier: Tier 2
Petty, R, BMJ Case Reports, 2025 · Publisher / database full text

Lambert-Eaton myasthenic syndrome with primary thymic marginal zone B-cell lymphoma: A case report

2023
LEMS-primary · Respirology Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Soma, Toshihiko et al, Respirology Case Reports, 2023 · Open-access full text

Late onset cerebellar ataxia syndrome after non-paraneoplastic Lambert-Eaton myasthenic syndrome: a case study

2025
LEMS-primary · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Randall, David P et al, BMC Neurology, 2025 · Open-access full text

Long-Standing Lambert–Eaton Myasthenic Syndrome Caused by Undetectable Small-Cell Lung Cancer: Why We Should Follow-Up LEMS

2022
LEMS-primary · Diagnostics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Bo Young Hong et al, Diagnostics, 2022 · Open-access full text

Mild clinical expression of Lambert–Eaton myasthenic syndrome in a patient with HIV infection

2025
LEMS-primary · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Truffert, Andre et al, BMJ Case Reports, 2025 · Publisher / database full text

Multiple autoimmunity: neuromyelitis optica spectrum disorder with Lambert-Eaton myasthenic syndrome

2025
LEMS-primary · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Platt, Isobel Sarah et al, Practical Neurology, 2025 · Publisher / database full text

Muscular pathological features in patients with Lambert-Eaton myasthenic syndrome associated with small cell lung carcinoma

2021
LEMS-primary · Clinical Neuropathology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Series · Relevance tier: Tier 2
Zhang, Yutong et al, Clinical Neuropathology, 2021 · Publisher / database full text

Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient

2021
LEMS-primary · Neurological Sciences

Duplaine et al. (Neurological Sciences, 2021, https://doi.org/10.1007/s10072-021-05557-9) report what they describe as the first case of combined myasthenia gravis/Lambert-Eaton overlap syndrome triggered by an immune checkpoint inhibitor (nivolumab), in a man treated for metastatic melanoma.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Duplaine Alexandra et al, Neurological Sciences, 2021 · Publisher / database full text

Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan

2022
LEMS-primary · BMJ Neurology Open

Japan (primary source, nationwide survey): Yoshikawa et al. (BMJ Neurology Open, 2022, https://doi.org/10.1136/bmjno-2022-000291) conducted the first nationwide MHLW-sponsored epidemiological survey of LEMS in Japan (2017 data), independently confirming the previously secondary-cited government figures: an estimated 348 patients nationally (95% CI 247-449), prevalence 2.7/million (95% CI 1.9-3.5) — consistent with the Netherlands (2.5/million, Wirtz 2004) and US VA (2.6/million) estimates.…

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Cohort / Registry Study · Relevance tier: Tier 1
Yoshikawa, Hiroaki et al, BMJ Neurology Open, 2022 · Open-access full text

Neuromuscular Active Zone Structure and Function in Healthy and Lambert-Eaton Myasthenic Syndrome States

2022
LEMS-primary · Biomolecules

Mechanism (active zone biology, review synthesis): Ginebaugh et al. (Biomolecules, 2022, https://doi.org/10.3390/biom12060740) synthesize active-zone (AZ) structural biology and passive-transfer mouse-model data that extend the mechanism picture beyond simple calcium-channel antibody (VGCC) loss.…

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Narrative Review · Relevance tier: Tier 1
Ginebaugh, Scott P et al, Biomolecules, 2022 · Open-access full text

Paraneoplastic Lambert-Eaton myasthenic syndrome: a diagnostic challenge

2023
LEMS-primary · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Viveiros, Luísa et al, BMJ Case Reports, 2023 · Publisher / database full text

Paraneoplastic Lambert–Eaton myasthenic syndrome associated with non-small cell lung cancer: data from the European LEMS registry and systematic review

2025
LEMS-primary · Neurological Research and Practice

A European LEMS registry study (Preßler et al., Neurological Research and Practice, 2025, doi:10.1186/s42466-025-00453-5) combined with a PRISMA systematic review found that cancer-associated LEMS extends meaningfully beyond small cell lung cancer (SCLC).…

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Registry Study + Systematic Review · Relevance tier: Tier 1
Preßler, Hannah et al, Neurological Research and Practice, 2025 · Open-access full text

Physiological Roles of the Autoantibodies to the 78-Kilodalton Glucose-Regulated Protein (GRP78) in Cancer and Autoimmune Diseases

2022
LEMS-primary · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Narrative Review · Relevance tier: Tier 2
Gonzalez-Gronow, Mario et al, Biomedicines, 2022 · Open-access full text

Postexercise Facilitation of Reflexes in the Lambert–Eaton Myasthenic Syndrome

2025
LEMS-primary · The New England Journal of Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Florijn, Barend W et al, The New England Journal of Medicine, 2025 · Publisher / database full text

Postexercise reflex facilitation in Lambert-Eaton myasthenic syndrome

2024
LEMS-primary · Practical Neurology

Case report and review (Practical Neurology, 2024, Singapore) of a 62-year-old woman diagnosed with LEMS via postexercise reflex facilitation (knee/ankle jerks absent at baseline, restored to 2+ after brief exercise) plus electrical muscle-response measurement (CMAP) facilitation >100% and positive P/Q-calcium-channel antibody (VGCC) antibodies; malignancy workup identified a rare extrapulmonary small cell neuroendocrine carcinoma of the gallbladder (SOX-1 antibody negative), treated with carboplatin/etoposide/atezolizumab with partial radiologic response.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Poh, Mervyn et al, Practical Neurology, 2024 · Publisher / database full text

Safety, efficacy and steroid-sparing effect of amifampridine in Lambert-Eaton myasthenic syndrome patients — real world data

2024
LEMS-primary · Neurologia i Neurochirurgia Polska

A real-world retrospective study of 14 non-neoplastic LEMS patients (Poland; mean age 48.8±11.4 years, 42.9% female) treated with amifampridine found significant improvement after a mean 21.1±12.0 weeks of follow-up: muscle-strength score (QMG) score improved by a mean 5.1±2.0 points, electrical muscle-response measurement (CMAP) amplitude increased a mean 2.1±1.6-fold, and post-exercise facilitation (>100% increment) fell from present in essentially all patients pre-treatment to 78.6% (11/14) post-treatment.…

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Cohort Study · Relevance tier: Tier 1
Szczudlik, Piotr et al, Neurologia i Neurochirurgia Polska, 2024 · Open-access full text

Severe progression of a young-onset non-paraneoplastic Lambert-Eaton myasthenic syndrome

2025
LEMS-primary · Acta Neurologica Belgica

Single case report (Acta Neurologica Belgica, 2025) describes a 21-year-old woman with not cancer-associated (extensively tumor-screened negative) LEMS whose disease progressed over roughly 2.5 years despite pyridostigmine, 3,4-DAP, intravenous immunoglobulin (IVIG), prednisolone, azathioprine, and methotrexate, culminating in severe bulbar dysfunction and respiratory failure requiring intubation/tracheostomy, plus dysphagia requiring gastrostomy.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Schön, Miguel et al, Acta Neurologica Belgica, 2025 · Publisher / database full text

Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA/anti-SOX1 and VGCC antibodies

2021
LEMS-primary · Neurological Research and Practice

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 2
Feldheim Jonas et al, Neurological Research and Practice, 2021 · Open-access full text

SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques

2023
LEMS-primary · Journal of Neurology

Vabanesi et al. (Journal of Neurology, 2023, https://doi.org/10.1007/s00415-022-11523-y), a retrospective single-center (French PNS Reference Center) study of 77 patients with isolated SOX1-antibody positivity (2009-2019), found only 23/77 (29.9%) met criteria for definite cancer-associated neurological syndrome; all 23 had lung cancer (mostly small-cell), with Lambert-Eaton myasthenic syndrome in 10/23 and rapidly progressive cerebellar ataxia in 6/23.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Cohort Study · Relevance tier: Tier 1
Vabanesi, Marco et al, Journal of Neurology, 2023 · Publisher / database full text

SOX‐1 antibodies positive Lambert–Eaton myasthenic syndrome with occult small cell lung cancer: A case report

2024
LEMS-primary · The Clinical Respiratory Journal

Case report (Clinical Respiratory Journal, 2024, China) of a 56-year-old man with calcium-channel antibody (VGCC)-antibody-seronegative but SOX-1-antibody-positive LEMS; initial tumor screening (CT, PET/CT, bronchoscopy) at diagnosis was negative, but small cell lung cancer (SCLC) was pathologically confirmed via needle biopsy 10 months later after continued surveillance.…

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Zhao, Liming et al, The Clinical Respiratory Journal, 2024 · Open-access full text

Tackling paraneoplastic and non-paraneoplastic Lambert-Eaton myastenic syndromes: when timing is key. Comment on schőn et al. report

2025
LEMS-primary · Acta Neurologica Belgica

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The strongest recurring finding is that amifampridine improves nerve-to-muscle signalling and symptoms. Much of the newer material—unusual symptoms, newer immune treatments and non-lung cancers—still comes from small studies or individual cases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Case Series · Relevance tier: Tier 2
Galassi, Giuliana et al, Acta Neurologica Belgica, 2025 · Publisher / database full text

Type 2 Respiratory Failure as an Initial Manifestation of Lambert–Eaton Myasthenic Syndrome Complicated by Paraneoplastic Autoimmune Encephalitis

2025
LEMS-primary · Cureus

Case report (Cureus, 2025, Kobe, Japan) of a 79-year-old woman whose LEMS first presented as acute type 2 respiratory failure (confusion, seizure, respiratory acidosis requiring non-invasive ventilation) — authors state this is only the second such case reported in the literature.…

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Case Report · Relevance tier: Tier 1
Uemura Sota et al, Cureus, 2025 · Open-access full text

Case Report: A case of paraneoplastic autoimmune encephalitis with concurrent anti-GABABR and anti-SOX1 antibody positivity

2026
Paraneoplastic neurological syndromes (broader) · Frontiers in Cellular Neuroscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Liu, Feng et al, Frontiers in Cellular Neuroscience, 2026 · Open-access full text

Paraneoplastic Neurological Syndromes in Ovarian Cancer: Case Report and Narrative Review for Diagnostic and Clinical Implications

2026
Paraneoplastic neurological syndromes (broader) · Healthcare

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Restaino Stefano et al, Healthcare, 2026 · Open-access full text

Current and Future Biomarkers in the Diagnosis of Autoimmune Encephalitis: A Review of Biomarker Detection Techniques and Their Performance

2026
Paraneoplastic neurological syndromes (broader) · Medicina

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Patricija, Plačenytė et al, Medicina, 2026 · Open-access full text

Anti-amphiphysin antibody positive autoimmune syndrome: case series and literature review

2026
Paraneoplastic neurological syndromes (broader) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wang, Linran et al, Frontiers in Immunology, 2026 · Open-access full text

Anti-AMPAR limbic encephalitis as the initial presentation of metastatic small cell cancer

2026
Paraneoplastic neurological syndromes (broader) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kakarala, Chandra L et al, BMJ Case Reports, 2026 · Publisher / database full text

Recurrent Steroid‐Responsive Exophthalmos as a Paraneoplastic Manifestation of Esophageal Adenocarcinoma

2026
Paraneoplastic neurological syndromes (broader) · Case Reports in Oncological Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tovar, Yara E. et al, Case Reports in Oncological Medicine, 2026 · Publisher / database full text

Paraneoplastic Motor Neuropathy in Nodular Sclerosis Hodgkin’s Lymphoma: Case Report

2026
Paraneoplastic neurological syndromes (broader) · Case Reports in Hematology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Menon, Jayesh et al, Case Reports in Hematology, 2026 · Publisher / database full text

Case Report: Anti-neural cell adhesion molecule 1 antibody-positive encephalitis presenting with schizophrenia-like symptoms and an ovarian teratoma

2026
Paraneoplastic neurological syndromes (broader) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yamanaka, Nanami et al, Frontiers in Immunology, 2026 · Open-access full text

Clinical characteristics and prognosis of paraneoplastic syndromes: a single-center cohort study in Northern China

2026
Paraneoplastic neurological syndromes (broader) · Frontiers in Immunology

Northern China PNS cohort (n=114): LEMS was the 3rd most common PNS subtype at 16.7% (19/114), behind encephalomyelitis (34.2%) and limbic encephalitis (17.5%) — a data point on where LEMS sits within the broader PNS spectrum, not used for a LEMS-specific estimate (which already has LEMS-specific epidemiology from dedicated LEMS cohorts, a better source for LEMS-specific rates than its share of a mixed-PNS cohort).

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hu, Minzhe et al, Frontiers in Immunology, 2026 · Open-access full text

Case Report: Anti-SOX1 antibody-associated limbic encephalitis with hippocampal sclerosis: the first autopsy case

2025
Paraneoplastic neurological syndromes (broader) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Izumi, Rina et al, Frontiers in Immunology, 2025 · Open-access full text

Incidence of paraneoplastic antibodies in United Kingdom – An estimate from a regional centre

2025
Paraneoplastic neurological syndromes (broader) · Clinical Neurology and Neurosurgery

UK regional incidence study of high-risk cancer-associated antibodies (2012–2021, Walton Centre, Liverpool) — but note its headline incidence figure (3.8/million/year) covers only antibodies classified high-risk (>70% cancer association) under the Graus et al. 2021 criteria.…

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chadwick, C.A. et al, Clinical Neurology and Neurosurgery, 2025 · Publisher / database full text

A Case of a Splitting Headache: Paraneoplastic Rhombencephalitis

2022
Paraneoplastic neurological syndromes (broader) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gotera Nico et al, Cureus, 2022 · Open-access full text

A case of anti-gamma-aminobutyric acid-B receptor encephalitis coexisting with ankylosing spondylitis

2020
Paraneoplastic neurological syndromes (broader) · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Li, Aiqing et al, Neurological Sciences, 2020 · Open-access full text

Acquired Hemophilia as a Paraneoplastic Syndrome in a Patient With Small Cell Lung Carcinoma

2022
Paraneoplastic neurological syndromes (broader) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lyon, James F et al, Cureus, 2022 · Open-access full text

Additional Value of [18F]FDG PET/CT in Detection of Suspected Malignancy in Patients with Paraneoplastic Neurological Syndromes Having Negative Results of Conventional Radiological Imaging

2022
Paraneoplastic neurological syndromes (broader) · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Opalińska, Marta et al, Journal of Clinical Medicine, 2022 · Open-access full text

Adenocarcinoma of the right lung, potential cause of seronegative paraneoplastic encephalitis

2025
Paraneoplastic neurological syndromes (broader) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Samartha, C S et al, BMJ Case Reports, 2025 · Publisher / database full text

Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies

2023
Paraneoplastic neurological syndromes (broader) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Arnaldos-Pérez, Cristina et al, Frontiers in Immunology, 2023 · Open-access full text

Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review

2020
Paraneoplastic neurological syndromes (broader) · Journal of International Medical Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yan, Jinhua et al, Journal of International Medical Research, 2020 · Open-access full text

Anti-GABAB receptor encephalitis: clinical and laboratory characteristics, imaging, treatments and prognosis

2024
Paraneoplastic neurological syndromes (broader) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Li, Dongrui et al, Frontiers in Immunology, 2024 · Open-access full text

Anti-Hu (ANNA-1) Associated Paraneoplastic Sensory Neuronopathy in a Large Cell Neuroendocrine Carcinoma of the Lung

2023
Paraneoplastic neurological syndromes (broader) · Canadian Journal of Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gupta, Navnika et al, Canadian Journal of Neurological Sciences, 2023 · Publisher / database full text

Anti-Ma2 Antibody-Associated Paraneoplastic Neurological Syndromes: A Pilot Study

2021
Paraneoplastic neurological syndromes (broader) · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Guo, Yi et al, Brain Sciences, 2021 · Open-access full text

Anti-SOX-1 Antibody-Positive Paraneoplastic Limbic Encephalitis Diagnosed During Small Cell Lung Cancer Treatment

Year not captured
Paraneoplastic neurological syndromes (broader) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yoshino Toru et al, Cureus · Open-access full text

Anti-Yo paraneoplastic cerebellar degeneration in a patient with stage IV ovarian adenocarcinoma during bevacizumab maintenance therapy

2023
Paraneoplastic neurological syndromes (broader) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Giucca, Alice et al, BMJ Case Reports, 2023 · Publisher / database full text

Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome: Epidemiology and Outcome of Neuronal Antibody Testing in Sweden

2023
Paraneoplastic neurological syndromes (broader) · Acta Neurologica Scandinavica

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kosek, Sonja et al, Acta Neurologica Scandinavica, 2023 · Open-access full text

Autoimmune encephalitis

2025
Paraneoplastic neurological syndromes (broader) · Nature Reviews. Disease Primers

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
de Bruijn, Marienke A. A. M. et al, Nature Reviews. Disease Primers, 2025 · Publisher / database full text

Autoimmune Encephalitis and Related Syndromes

2023
Paraneoplastic neurological syndromes (broader) · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Graus, Francesc, Journal of Clinical Medicine, 2023 · Open-access full text

Autoimmune Encephalitis in Tunisia: Report of a Pediatric Cohort

2021
Paraneoplastic neurological syndromes (broader) · Journal of Immunology Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Douma, Bissene et al, Journal of Immunology Research, 2021 · Open-access full text

Autoimmune encephalitis with coexisting antibodies to GABABR, GAD65, SOX1 and Ma2

2024
Paraneoplastic neurological syndromes (broader) · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Li, Pankui et al, BMC Neurology, 2024 · Open-access full text

Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management

2021
Paraneoplastic neurological syndromes (broader) · Journal of Neurology, Neurosurgery and Psychiatry

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Abboud, Hesham et al, Journal of Neurology, Neurosurgery and Psychiatry, 2021 · Open-access full text

Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management

2021
Paraneoplastic neurological syndromes (broader) · Journal of Neurology, Neurosurgery and Psychiatry

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Abboud, Hesham et al, Journal of Neurology, Neurosurgery and Psychiatry, 2021 · Open-access full text

Autoimmune Encephalitis—A Multifaceted Pathology

2023
Paraneoplastic neurological syndromes (broader) · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Neațu, Monica et al, Biomedicines, 2023 · Open-access full text

Bilateral Paraneoplastic Vitritis: A Case Report

2021
Paraneoplastic neurological syndromes (broader) · Beyoglu Eye Journal

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC-SA 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ezgi Karataş Yiğitaslan et al, Beyoglu Eye Journal, 2021 · Open-access full text

Brain blood vessel autoantibodies in patients with NMDA and GABAA receptor encephalitis: identification of unconventional Myosin-X as target antigen

2023
Paraneoplastic neurological syndromes (broader) · Frontiers in Cellular Neuroscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Li, Lucie Y et al, Frontiers in Cellular Neuroscience, 2023 · Open-access full text

Cancer Therapy-Induced Encephalitis

2024
Paraneoplastic neurological syndromes (broader) · Cancers

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Desbaillets, Nicolas P et al, Cancers, 2024 · Open-access full text

Case Report: Anti-Yo antibody mediated paraneoplastic cerebellar degeneration in a patient with squamous cell lung carcinoma

2025
Paraneoplastic neurological syndromes (broader) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chen-Hao, Yang et al, Frontiers in Immunology, 2025 · Open-access full text

CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity

2023
Paraneoplastic neurological syndromes (broader) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Vorasoot, Nisa et al, Frontiers in Immunology, 2023 · Open-access full text

Clinical characteristics of autoimmune encephalitis with co-existence of multiple anti-neuronal antibodies

2024
Paraneoplastic neurological syndromes (broader) · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhou, Yiyi et al, BMC Neurology, 2024 · Open-access full text

Clinical characteristics of paraneoplastic neurological syndrome related to different pathological lung cancers

2021
Paraneoplastic neurological syndromes (broader) · Thoracic Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ma, Jun et al, Thoracic Cancer, 2021 · Open-access full text

Clinical characteristics of paraneoplastic syndromes in patients with head and neck cancer

2022
Paraneoplastic neurological syndromes (broader) · Laryngoscope Investigative Otolaryngology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Diao, Wenwen et al, Laryngoscope Investigative Otolaryngology, 2022 · Open-access full text

Coexistence of anti-SOX1 and anti-GABAB receptor antibodies with paraneoplastic limbic encephalitis presenting with seizures and memory impairment in small cell lung cancer: A case report

2022
Paraneoplastic neurological syndromes (broader) · Frontiers i n Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gong, Sizhu et al, Frontiers i n Immunology, 2022 · Open-access full text

Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes

2023
Paraneoplastic neurological syndromes (broader) · Antibodies

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chiu, Daniel et al, Antibodies, 2023 · Open-access full text

Diagnostic Significance of Paraneoplastic Neuronal Antibodies in Japanese Adults with Autoimmune Encephalitis: A Case Series Study in an Adult Epilepsy Clinic

2025
Paraneoplastic neurological syndromes (broader) · Clinical Pharmacology : Advances and Applications

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kinoshita, M et al, Clinical Pharmacology : Advances and Applications, 2025 · Open-access full text

Digital gangrene as an unusual paraneoplastic manifestation of hodgkins lymphoma—a rare case report

2021
Paraneoplastic neurological syndromes (broader) · The Egyptian Journal of Internal Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Deme, Swaroopa et al, The Egyptian Journal of Internal Medicine, 2021 · Open-access full text

Dysautonomia in anti-Hu paraneoplastic neurological syndromes

2024
Paraneoplastic neurological syndromes (broader) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Villagrán-García, Macarena et al, Journal of Neurology, 2024 · Publisher / database full text

Evaluation of the Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes in China

2022
Paraneoplastic neurological syndromes (broader) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Meng-Ting, Cai et al, Frontiers in Immunology, 2022 · Open-access full text

Expanding the spectrum of SOX1-antibodies in neuropathy: the coexistence of anti-SOX1 and Guillain-Barré syndrome—a case report

2022
Paraneoplastic neurological syndromes (broader) · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Coniglio, S et al, Neurological Sciences, 2022 · Publisher / database full text

Favorable Outcomes in a Case of Non-paraneoplastic DNER Ataxia Treated with Immunotherapy

2024
Paraneoplastic neurological syndromes (broader) · The Cerebellum

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Duan, Ruo-Nan et al, The Cerebellum, 2024 · Publisher / database full text

Focal Seizures Induced by Paraneoplastic Syndrome Leading to a Diagnosis of Small Cell Lung Carcinoma

2024
Paraneoplastic neurological syndromes (broader) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Blackbourn, Lisle W et al, Cureus, 2024 · Open-access full text

Gastric cancer complicated by paraneoplastic neurological syndrome which presented with extremity numbness: a case report

2022
Paraneoplastic neurological syndromes (broader) · Surgical Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yoshida Takuto et al, Surgical Case Reports, 2022 · Open-access full text

Gastroesophageal reflux disease and paraneoplastic neurological syndrome associated with long‐term survival in limited stage small‐cell lung cancer

2022
Paraneoplastic neurological syndromes (broader) · Thoracic Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Vinicius Ernani et al, Thoracic Cancer, 2022 · Open-access full text

Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy

2021
Paraneoplastic neurological syndromes (broader) · Cancer Immunology, Immunotherapy

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Cancer Immunology, Immunotherapy, 2021 · Publisher / database full text

HLA- DR3  ~  DQ2 associates with sensory neuropathy in paraneoplastic neurological syndromes with Hu antibodies

2024
Paraneoplastic neurological syndromes (broader) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Muñiz-Castrillo, Sergio et al, Journal of Neurology, 2024 · Open-access full text

Identification of SKOR2 IgG as a novel biomarker of paraneoplastic neurologic syndrome

2023
Paraneoplastic neurological syndromes (broader) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Rezk, Mohamed et al, Frontiers in Immunology, 2023 · Open-access full text

Immunophenotypical characterization of paraneoplastic neurological syndrome patients: a multicentric study

2021
Paraneoplastic neurological syndromes (broader) · Journal of Biosciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lorusso, Lorenzo et al, Journal of Biosciences, 2021 · Publisher / database full text

Leucine-rich glioma-inactivated protein 1 antibody-positive limbic encephalitis in a patient with an early-stage asymptomatic breast cancer

2025
Paraneoplastic neurological syndromes (broader) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Niño Uribe, Maria Fernanda et al, BMJ Case Reports, 2025 · Open-access full text

Long-term outcomes in antibody-negative autoimmune encephalitis: a retrospective study

2024
Paraneoplastic neurological syndromes (broader) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mangioris, Georgios et al, Journal of Neurology, 2024 · Publisher / database full text

Long-Term Survivor with Paraneoplastic Cerebellar Ataxia and Small-Cell Lung Cancer

2025
Paraneoplastic neurological syndromes (broader) · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tsoukalas, Konstantinos et al, Journal of Clinical Medicine, 2025 · Open-access full text

MiR-155-5p suppresses SOX1 to promote proliferation of cholangiocarcinoma via RAF/MEK/ERK pathway

2021
Paraneoplastic neurological syndromes (broader) · Cancer Cell International

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wang, Da et al, Cancer Cell International, 2021 · Open-access full text

Missed Diagnosis of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) as a Paraneoplastic Syndrome in Small Cell Lung Cancer: A Case Report

2025
Paraneoplastic neurological syndromes (broader) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Naas, Mohamed et al, Cureus, 2025 · Open-access full text

Myasthenia gravis after glioblastoma resection: paraneoplastic syndrome or coincidence? A unique case report and review of the literature

2022
Paraneoplastic neurological syndromes (broader) · Acta Neurochirurgica

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Slegers, R J et al, Acta Neurochirurgica, 2022 · Open-access full text

Neuropsychiatric Disorders Due to Limbic Encephalitis: Immunologic Aspect

2021
Paraneoplastic neurological syndromes (broader) · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, International Journal of Molecular Sciences, 2021 · Open-access full text

Ocular flutter as the cardinal feature of anti-GM2 rhombencephalitis

2021
Paraneoplastic neurological syndromes (broader) · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Daponte Ariadne et al, Neurological Sciences, 2021 · Publisher / database full text

Overview of Paraneoplastic Autoantibody-Mediated Cognitive Impairment and Behavioral Changes: A Narrative Review

2024
Paraneoplastic neurological syndromes (broader) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Alkhayat Duaa et al, Cureus, 2024 · Open-access full text

Paraneoplastic Amyotrophic Lateral Sclerosis: Case Series and Literature Review

2022
Paraneoplastic neurological syndromes (broader) · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhao, Yang et al, Brain Sciences, 2022 · Open-access full text

Paraneoplastic Anti-Neuronal Nuclear Antibody Type 3 Neurologic Autoimmunity

2024
Paraneoplastic neurological syndromes (broader) · Canadian Journal of Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chandna, Nicholas et al, Canadian Journal of Neurological Sciences, 2024 · Open-access full text

Paraneoplastic Cerebellar Degeneration Associated with Breast Cancer: A Case Report and a Narrative Review

2024
Paraneoplastic neurological syndromes (broader) · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Rosario Luca Norrito et al, Brain Sciences, 2024 · Open-access full text

Paraneoplastic cerebellar degeneration — raising awareness for early diagnosis

2024
Paraneoplastic neurological syndromes (broader) · Neurologia i Neurochirurgia Polska

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Roszkowska, Zuzanna et al, Neurologia i Neurochirurgia Polska, 2024 · Open-access full text

Paraneoplastic neurological syndrome and its impact on the treatment outcomes of small‐cell lung cancer: A single‐center retrospective analysis

2024
Paraneoplastic neurological syndromes (broader) · Thoracic Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sato, Yuki et al, Thoracic Cancer, 2024 · Open-access full text

Paraneoplastic neurological syndrome associated with a pulmonary carcinoid tumor: a case report

2025
Paraneoplastic neurological syndromes (broader) · Journal of Surgical Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yeni Arroyave Guerrero et al, Journal of Surgical Case Reports, 2025 · Open-access full text

Paraneoplastic Neurological Syndromes as Initial Presentation of Tumors: An Eight-Year Single-Center Experience

2024
Paraneoplastic neurological syndromes (broader) · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Melanis, Konstantinos et al, Journal of Clinical Medicine, 2024 · Open-access full text

Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review

2023
Paraneoplastic neurological syndromes (broader) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Villagrán-García, Macarena et al, Journal of Neurology, 2023 · Publisher / database full text

Paraneoplastic neurological syndromes: a practical approach to diagnosis and management

2022
Paraneoplastic neurological syndromes (broader) · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Binks, Sophie et al, Practical Neurology, 2022 · Publisher / database full text

Paraneoplastic ocular syndrome: a pandora’s box of underlying malignancies

2022
Paraneoplastic neurological syndromes (broader) · Eye

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sarkar, Prathama et al, Eye, 2022 · Publisher / database full text

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a Rare Presentation of Small-Cell Lung Cancer

2022
Paraneoplastic neurological syndromes (broader) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Moreira Inês et al, Cureus, 2022 · Open-access full text

Paraneoplastic sensorimotor neuropathy and ventral cauda equina nerve root enhancement as initial presentation of small cell lung carcinoma: a case study

2021
Paraneoplastic neurological syndromes (broader) · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Alsaeed, Meshari et al, BMC Neurology, 2021 · Open-access full text

Paraneoplastic Syndrome Case Presented As Nystagmus and Ataxia

2024
Paraneoplastic neurological syndromes (broader) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Darwesh, Khaled M, Cureus, 2024 · Open-access full text

Paraneoplastic syndrome in neuroophthalmology

2022
Paraneoplastic neurological syndromes (broader) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kang, Longdan et al, Journal of Neurology, 2022 · Publisher / database full text

Paraneoplastic Syndromes in Gallbladder Cancer: A Systematic Review

2025
Paraneoplastic neurological syndromes (broader) · Medicina

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Beth Shin Rei Lau et al, Medicina, 2025 · Open-access full text

Paraneoplastic syndromes in patients with melanoma

2024
Paraneoplastic neurological syndromes (broader) · Postepy Dermatologii i Alergologii

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC-SA 4
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hio Fong Leong et al, Postepy Dermatologii i Alergologii, 2024 · Open-access full text

PET/CT and Paraneoplastic Syndromes: A Comprehensive Review

2025
Paraneoplastic neurological syndromes (broader) · Cancers

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Daraghma Motaz et al, Cancers, 2025 · Open-access full text

Predicting disability and mortality in CV2/CRMP5-IgG associated paraneoplastic neurologic disorders

2024
Paraneoplastic neurological syndromes (broader) · Annals of Clinical and Translational Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Uysal, Sanem P et al, Annals of Clinical and Translational Neurology, 2024 · Open-access full text

Presynaptic Paraneoplastic Disorders of the Neuromuscular Junction: An Update

Year not captured
Paraneoplastic neurological syndromes (broader) · journal not recorded

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessFind full text on PubMedNo direct article URL was captured
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, journal not recorded · Find full text on PubMed

Prospective study of cancer survival in patients with HuD-antibody-associated paraneoplastic neurological disorders

2021
Paraneoplastic neurological syndromes (broader) · Journal of Neurology, Neurosurgery and Psychiatry

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Maddison, Paul et al, Journal of Neurology, Neurosurgery and Psychiatry, 2021 · Publisher / database full text

Pulmonary Mucoepidermoid Carcinoma With Multiple Paraneoplastic Syndromes

2023
Paraneoplastic neurological syndromes (broader) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Boon, Tay Sok et al, Cureus, 2023 · Open-access full text

Review of Diagnostic Challenges and Literature Data in Paraneoplastic Limbic Encephalitis: A Case Presentation

2024
Paraneoplastic neurological syndromes (broader) · Ars Medica Tomitana

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Codreanu-Balaban, Ramona Andreea et al, Ars Medica Tomitana, 2024 · Open-access full text

Rhombencephalomyelitis due to possible paraneoplastic syndrome associated with Hodgkin’s lymphoma

2022
Paraneoplastic neurological syndromes (broader) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Valappil, Ashraf et al, BMJ Case Reports, 2022 · Publisher / database full text

S2437 A Rare Presentation of Esophageal Squamous Cell Carcinoma Presenting as a Paraneoplastic Syndrome

2022
Paraneoplastic neurological syndromes (broader) · The American Journal of Gastroenterology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Rollins, Samantha et al, The American Journal of Gastroenterology, 2022 · Publisher / database full text

Single-Center Retrospective Analysis of Paraneoplastic Syndromes with Peripheral Nerve Damage

2022
Paraneoplastic neurological syndromes (broader) · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tian, Jing et al, Brain Sciences, 2022 · Open-access full text

SOX-1 antibodies in a patient with Crohn’s disease: a case report

2022
Paraneoplastic neurological syndromes (broader) · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Polilli, Ennio et al, BMC Neurology, 2022 · Open-access full text

SOX1 Antibody in a Patient With Serotonin Syndrome

2023
Paraneoplastic neurological syndromes (broader) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hoffer, Julia et al, Cureus, 2023 · Open-access full text

Stiff Person Syndrome: A Case Report with Sudden Onset and Coexistence of Sero-Positive Antibodies to Glutamic Acid Decarboxylase and Anti-SOX1 Antibodies

2022
Paraneoplastic neurological syndromes (broader) · Case Reports in Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY-NC 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nguyen, Phuong Minh et al, Case Reports in Neurology, 2022 · Open-access full text

The Association of Ovarian Teratoma and Anti-N-Methyl-D-Aspartate Receptor Encephalitis: An Updated Integrative Review

2021
Paraneoplastic neurological syndromes (broader) · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cheng-Yang, Wu et al, International Journal of Molecular Sciences, 2021 · Open-access full text

Update on Paraneoplastic Cerebellar Degeneration

2021
Paraneoplastic neurological syndromes (broader) · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain why LEMS can be a clue to an underlying cancer and how tumor-related antibodies and screening fit into the broader oncology picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Loehrer, Philipp Alexander et al, Brain Sciences, 2021 · Open-access full text

Successful rescue therapy with eculizumab for probable tislelizumab-related MMM overlap syndrome with dual positivity for anti-acetylcholine receptor and anti-titin antibodies: a case report and literature review

2026
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yi-Xiao, Li et al, Frontiers in Immunology, 2026 · Open-access full text

Pharmacologic Management of Spasticity

2026
ICI-related neurotoxicity / paraneoplastic syndromes · Medsurg Nursing

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Inocian, Ergie P et al, Medsurg Nursing, 2026 · Publisher / database full text

Successful Treatment of Immune Checkpoint Inhibitor‐Induced Myocarditis, Myositis, and Myasthenia Overlap Syndrome With Baricitinib and Abatacept

2026
ICI-related neurotoxicity / paraneoplastic syndromes · Clinical Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Alnahas, Zeinab et al, Clinical Case Reports, 2026 · Open-access full text

Case Report and literature review: immune checkpoint inhibitor-associated myasthenia gravis and myocarditis

2026
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Cardiovascular Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Shang, Zhiyue et al, Frontiers in Cardiovascular Medicine, 2026 · Open-access full text

Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database

2026
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cao, Lin et al, Frontiers in Immunology, 2026 · Open-access full text

Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management

2026
ICI-related neurotoxicity / paraneoplastic syndromes · Antibodies

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dimitrov Stoimen et al, Antibodies, 2026 · Open-access full text

Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study

2026
ICI-related neurotoxicity / paraneoplastic syndromes · CNS Neuroscience & Therapeutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tang, Bufu et al, CNS Neuroscience & Therapeutics, 2026 · Open-access full text

Debates over orphan drug pricing: a meta-narrative literature review

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Orphanet Journal of Rare Diseases

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hanchard, Matthew S, Orphanet Journal of Rare Diseases, 2025 · Open-access full text

Evaluation of warning strategies for paraneoplastic neurological syndromes associated with PD-1/PD-L1 inhibitors

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Immunology

Retrospective study of 224 patients with PD-1/PD-L1 inhibitor-related cancer-associated neurological syndromes: among neuromuscular-junction diseases specifically, LEMS was the most frequently triggered by checkpoint inhibitors. Relevant background on immune checkpoint cancer treatment-induced (drug-triggered) LEMS as distinct from tumor-driven cancer-associated LEMS — included as relevant context if immunotherapy ever enters the picture.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ren, Zhuangzhuang et al, Frontiers in Immunology, 2025 · Open-access full text

A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Medical Toxicology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chhabra Neeraj et al, Journal of Medical Toxicology, 2021 · Publisher / database full text

A systematic review of telemedicine for neuromuscular diseases: components and determinants of practice

2024
ICI-related neurotoxicity / paraneoplastic syndromes · BMC Digital Health

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Senyel, Deniz et al, BMC Digital Health, 2024 · Open-access full text

Abstracts from the 2021 Annual Meeting of the Society of General Internal Medicine

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of General Internal Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Journal of General Internal Medicine, 2021 · Publisher / database full text

Abstracts from the 2024 Annual Meeting of the Society of General Internal Medicine

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of General Internal Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Journal of General Internal Medicine, 2024 · Publisher / database full text

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhou, Huanyu et al, Frontiers in Immunology, 2022 · Open-access full text

Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report

2021
ICI-related neurotoxicity / paraneoplastic syndromes · OncoTargets and Therapy

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY-NC 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Li, Jiamo et al, OncoTargets and Therapy, 2021 · Open-access full text

Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Journal of Neurology, 2025 · Publisher / database full text

Are Neuromuscular Disorders That Cause Fatigue a Contraindication to Sports Participation? A Case Report and Narrative Review of the Literature

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Applied Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Papadopoulou Marianna et al, Applied Sciences, 2025 · Open-access full text

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer

2020
ICI-related neurotoxicity / paraneoplastic syndromes · Thoracic Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kataoka, Nobutaka et al, Thoracic Cancer, 2020 · Open-access full text

Atypical presentation of Wernicke encephalopathy due to thiamine deficiency in a patient post sleeve gastrectomy

2024
ICI-related neurotoxicity / paraneoplastic syndromes · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Scharf, Keith et al, BMJ Case Reports, 2024 · Publisher / database full text

Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Medicina

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Civardi, Giuseppe et al, Medicina, 2024 · Open-access full text

Autoimmune Encephalitis: A Physician’s Guide to the Clinical Spectrum Diagnosis and Management

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Patel, Arpan et al, Brain Sciences, 2022 · Open-access full text

BDNF Prodomain Inhibits Neurotransmitter Quantal Release in Mouse Motor Synapses with the Necessary Participation of Sortilin and Adenosine A 1 -Receptors

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Evolutionary Biochemistry and Physiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Molchanova, A. I. et al, Journal of Evolutionary Biochemistry and Physiology, 2024 · Publisher / database full text

Beneficial autoimmunity improves cancer prognosis

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Nature Reviews. Clinical Oncology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zitvogel, Laurence et al, Nature Reviews. Clinical Oncology, 2021 · Publisher / database full text

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Thoracic Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ni, Jun et al, Thoracic Cancer, 2022 · Open-access full text

Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Journal for Immunotherapy of Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nassar, Amin H et al, Journal for Immunotherapy of Cancer, 2024 · Open-access full text

Clinician and patient experience of neurology telephone consultations during the COVID-19 pandemic

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Postgraduate Medical Journal

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nakornchai, Tagore et al, Postgraduate Medical Journal, 2022 · Publisher / database full text

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Journal for Immunotherapy of Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Guidon, Amanda C et al, Journal for Immunotherapy of Cancer, 2021 · Open-access full text

Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Neural Transmission

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dressler, Dirk et al, Journal of Neural Transmission, 2021 · Open-access full text

Diagnostic Dilemma of Paraneoplastic Rheumatic Disorders: Case Series and Narrative Review

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cho, Youngmin et al, Cureus, 2021 · Open-access full text

Diaphragmatic Palsy Due to a Paraneoplastic Autoimmune Syndrome Revealed by Checkpoint Inhibitors

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Jean-Baptiste Destival et al, Reports, 2024 · Open-access full text

Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sheikh, Shuja et al, Journal of Clinical Medicine, 2021 · Open-access full text

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

2020
ICI-related neurotoxicity / paraneoplastic syndromes · Journal for Immunotherapy of Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Pakkala, Suchita et al, Journal for Immunotherapy of Cancer, 2020 · Open-access full text

Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Medical Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cham, Jason et al, Journal of Medical Case Reports, 2021 · Open-access full text

Dysautonomia associated with immune checkpoint inhibitors

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tezuka, Toshiki et al, Journal of Neurology, 2023 · Publisher / database full text

Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Clinical & Translational Oncology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mi, Song et al, Clinical & Translational Oncology, 2024 · Publisher / database full text

Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wu, Kevin Y et al, Biomedicines, 2024 · Open-access full text

Equity in neuromuscular research: a 20-year analysis of race, ethnicity, sex, and age representation

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Fontanelli, Lorenzo et al, Journal of Neurology, 2025 · Publisher / database full text

Exacerbation of Paraneoplastic Neurologic Syndrome After Immune Checkpoint Inhibitor Treatment in Advanced Small Cell Lung Cancer: A Case Report

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hamada Toru et al, Cureus, 2025 · Open-access full text

How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Vogrig Alberto et al, Journal of Neurology, 2022 · Publisher / database full text

Immune Characteristics of Small Cell Lung Cancer

2020
ICI-related neurotoxicity / paraneoplastic syndromes · Zhongguo Fei Ai Za Zhi

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
ZHU, Yan et al, Zhongguo Fei Ai Za Zhi, 2020 · Open-access full text

Immune checkpoint inhibitor-induced anti-Hu antibody-associated gastrointestinal pseudo-obstruction: a case report and literature review

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Guang-Qing Shi et al, Frontiers in Immunology, 2025 · Open-access full text

Immune Checkpoint Inhibitor-Induced Limbic Encephalitis during Treatment with Atezolizumab in a Patient with Small-Cell Lung Cancer: A Case Report and Review of the Literature

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Case Reports in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nakashima, Koki et al, Case Reports in Immunology, 2022 · Open-access full text

Immune checkpoints: new insights into the pathogenesis of thyroid eye disease

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Xingyi Shu et al, Frontiers in Immunology, 2024 · Open-access full text

Immune-checkpoint inhibitors: long-term implications of toxicity

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Nature Reviews. Clinical Oncology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Nature Reviews. Clinical Oncology, 2022 · Publisher / database full text

Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Cancer Research & Clinical Oncology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Journal of Cancer Research & Clinical Oncology, 2021 · Publisher / database full text

Immune-Related Adverse Events in a Patient Treated with Pembrolizumab: A Case Report from the Point of View of a Geriatrician

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Geriatrics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Oft, Philipp et al, Geriatrics, 2024 · Open-access full text

Immunotherapy Advances in Small Cell Lung Cancer

2020
ICI-related neurotoxicity / paraneoplastic syndromes · Zhongguo Fei Ai Za Zhi

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
XU, Yangyang et al, Zhongguo Fei Ai Za Zhi, 2020 · Open-access full text

Increased Access to Immunoglobulin Replacement Therapy for Patients with Primary Immunodeficiency in Poland Based on Clinical Usage Data of Immunoglobulin G over a 5-Year Period

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Więsik-Szewczyk, Ewa et al, Journal of Clinical Medicine, 2023 · Open-access full text

Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Antibodies

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Velikova, Tsvetelina et al, Antibodies, 2023 · Open-access full text

Introducing Radiotherapy in Metastatic Merkel Cell Carcinoma Patients with Limited Progression on Avelumab: An Effective Step against Primary and Secondary Immune Resistance?

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Personalized Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ferini Gianluca et al, Journal of Personalized Medicine, 2023 · Open-access full text

Lipin 1 deficiency causes adult-onset myasthenia with motor neuron dysfunction in humans and neuromuscular junction defects in zebrafish

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Theranostics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lu, Shuxian et al, Theranostics, 2021 · Open-access full text

Lung cancer immunotherapy: progress, pitfalls, and promises

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Molecular Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lahiri, Aritraa et al, Molecular Cancer, 2023 · Open-access full text

Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sánchez-Camacho, Alberto et al, Frontiers in Immunology, 2025 · Open-access full text

Mechanisms of autoimmune-mediated paraneoplastic syndromes: immune tolerance and disease pathogenesis

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Pérez-Bucio, César et al, Frontiers in Immunology, 2025 · Open-access full text

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Pharmacology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Liu, Hao et al, Frontiers in Pharmacology, 2023 · Open-access full text

Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ricciardi Dario et al, Neurological Sciences, 2021 · Publisher / database full text

Myasthenia gravis: the future is here

2024
ICI-related neurotoxicity / paraneoplastic syndromes · The Journal of Clinical Investigation

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kaminski, Henry J et al, The Journal of Clinical Investigation, 2024 · Open-access full text

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Neuroscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhou, Yanting et al, Frontiers in Neuroscience, 2023 · Open-access full text

Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes

2024
ICI-related neurotoxicity / paraneoplastic syndromes · The Lancet Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Farina, Antonio et al, The Lancet Neurology, 2024 · Publisher / database full text

Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Pharmaceuticals

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zammit, François et al, Pharmaceuticals, 2024 · Open-access full text

Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Vilaseca, Andreu et al, Journal of Neurology, 2024 · Publisher / database full text

Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sotiria Stavropoulou De Lorenzo et al, Biomedicines, 2024 · Open-access full text

Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Neurology, Neurosurgery and Psychiatry

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Willis, Mark D et al, Journal of Neurology, Neurosurgery and Psychiatry, 2025 · Open-access full text

Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Demichelis Chiara et al, Neurological Sciences, 2021 · Open-access full text

Neuromuscular recovery from botulism involves multiple forms of compensatory plasticity

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Cellular Neuroscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Machamer, James B et al, Frontiers in Cellular Neuroscience, 2023 · Open-access full text

Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Villagrán-García, M et al, Neurological Sciences, 2022 · Publisher / database full text

Non-coding variants in VAMP2 and SNAP25 affect gene expression: potential implications in migraine susceptibility: Official Journal of the Italian Society for the Study of Headaches

2023
ICI-related neurotoxicity / paraneoplastic syndromes · The Journal of Headache and Pain:

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Felício, Daniela et al, The Journal of Headache and Pain:, 2023 · Open-access full text

Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses

2022
ICI-related neurotoxicity / paraneoplastic syndromes · The Cerebellum

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Muñiz-Castrillo, Sergio et al, The Cerebellum, 2022 · Publisher / database full text

Ocular adverse events associated with immune checkpoint inhibitors, a scoping review

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Ophthalmic Inflammation and Infection

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Martens, A. et al, Journal of Ophthalmic Inflammation and Infection, 2023 · Open-access full text

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhou, Lin et al, Frontiers in Immunology, 2021 · Publisher / database full text

Ocular Toxicity of Targeted Anticancer Agents

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Drugs

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Fortes, Blake H et al, Drugs, 2021 · Publisher / database full text

Origins and immunopathogenesis of autoimmune central nervous system disorders

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Nature Reviews. Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ramanathan, Sudarshini et al, Nature Reviews. Neurology, 2023 · Publisher / database full text

Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Neurotherapeutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Duong, Sophie L. et al, Neurotherapeutics, 2022 · Open-access full text

Paraneoplastic disorders of the nervous system

2021
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Flanagan, Eoin P, Journal of Neurology, 2021 · Publisher / database full text

Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Investigational New Drugs

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wang, Lan et al, Investigational New Drugs, 2022 · Open-access full text

Paraneoplastic neurological syndrome: growing spectrum and relevance

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Harikrishna, Ganaraja Valakunja et al, Neurological Sciences, 2022 · Publisher / database full text

Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Marsili, Luca et al, Biomedicines, 2023 · Open-access full text

Peripheral nervous system immune-related adverse events due to checkpoint inhibition

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Nature Reviews. Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
O’Hare, Meabh et al, Nature Reviews. Neurology, 2024 · Publisher / database full text

Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Nature Reviews. Clinical Oncology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tang, Li-Bo et al, Nature Reviews. Clinical Oncology, 2025 · Publisher / database full text

Rituximab in Refractory Myositis and Acute Neuropathy Secondary to Checkpoint Inhibitor Therapy

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Jain Varun et al, Cureus, 2022 · Open-access full text

Spinal Epidural Abscess: Raising the Index of Suspicion

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Prabahkar, Daniel et al, Cureus, 2025 · Open-access full text

Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Segú-Vergés, Cristina et al, Frontiers in Immunology, 2022 · Open-access full text

The Adrenal Pheochromocytoma Cell Line PC12 Efficiently Promotes the Regeneration Capability of Adipose Tissue-Derived Mesenchymal Stem Cells in Myogenesis: A Particular Approach to Improving Skeletal Muscle Cell Regeneration

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Iranian Journal of Medical Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Iranian Journal of Medical Sciences, 2024 · Publisher / database full text

The Era of Precision Medicine: Advancing Treatment Paradigms for Small Cell Lung Cancer

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Cancers

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Corica, Derek A et al, Cancers, 2025 · Open-access full text

The Immune System’s Echo: The Phenomenon of Delayed Neurological Immune-Related Adverse Events (NirAEs) in Adjuvant Immunotherapy

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gohel Shruti et al, Cureus, 2023 · Publisher / database full text

The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events

2023
ICI-related neurotoxicity / paraneoplastic syndromes · Cancers

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mytareli, Chrysoula et al, Cancers, 2023 · Open-access full text

Tossicità neurologiche di alto grado da inibitori del checkpoint immunitario: focus sul trattamento delle forme refrattarie alla terapia corticosteroidea

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Rivista Di Neurologia

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Malvaso, Antonio et al, Rivista Di Neurologia, 2024 · Publisher / database full text

Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p

2022
ICI-related neurotoxicity / paraneoplastic syndromes · Cells

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Beretta, Francesca et al, Cells, 2022 · Open-access full text

Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action

2024
ICI-related neurotoxicity / paraneoplastic syndromes · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Malvaso, Antonio et al, Brain Sciences, 2024 · Open-access full text

Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia

2025
ICI-related neurotoxicity / paraneoplastic syndromes · PharmacoEconomics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chen, Qunfei et al, PharmacoEconomics, 2025 · Publisher / database full text

Velopharyngeal Insufficiency and Impaired Tongue Movement Indicate Neuromuscular Disorders: A 10-Year Statistical Study in a Single Tertiary Institution

2025
ICI-related neurotoxicity / paraneoplastic syndromes · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Fujisaki, Aiko et al, Journal of Clinical Medicine, 2025 · Open-access full text

What Are the Biomarkers for Immunotherapy in SCLC?

2021
ICI-related neurotoxicity / paraneoplastic syndromes · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mostly safety and recognition evidence from case reports. It matters in a cancer-treatment setting, but does not describe the usual course of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Longo, Vito et al, International Journal of Molecular Sciences, 2021 · Open-access full text

Ofatumumab Treatment for Refractory Generalized Myasthenia Gravis Post‐Lung Adenocarcinoma Resection: A Case Report and Mechanistic Insight

2026
Myasthenia gravis (adjacent NMJ disease) · Immunity, Inflammation and Disease

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Long, Xia et al, Immunity, Inflammation and Disease, 2026 · Open-access full text

Clinical and quality-of-life outcomes associated with efgartigimod in patients with generalized myasthenia gravis transitioning from intravenous immunoglobulin

2026
Myasthenia gravis (adjacent NMJ disease) · Clinical Neurology and Neurosurgery

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yasaka, Aki et al, Clinical Neurology and Neurosurgery, 2026 · Publisher / database full text

Neuroinflammation: a critical bridge linking peripheral pathology and age-related degeneration in myasthenia gravis

2026
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Fan-yu, Liu et al, Frontiers in Medicine, 2026 · Open-access full text

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

2026
Myasthenia gravis (adjacent NMJ disease) · Annals of Clinical and Translational Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Jin, Lei et al, Annals of Clinical and Translational Neurology, 2026 · Open-access full text

Real-world experience with efgartigimod in generalized myasthenia gravis: a single-center retrospective study in China

2026
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Niu, Zhenyu et al, Frontiers in Immunology, 2026 · Open-access full text

Comparative study of ocular and generalized myasthenia gravis in a South Korean cohort

2026
Myasthenia gravis (adjacent NMJ disease) · PLoS One

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kwon, Chaerin et al, PLoS One, 2026 · Open-access full text

The Relationship Between Immune Semaphorins and Myasthenia Gravis

2026
Myasthenia gravis (adjacent NMJ disease) · Brain and Behavior

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kotan, Dilcan et al, Brain and Behavior, 2026 · Open-access full text

Telitacicept for refractory AChR-positive generalized myasthenia gravis: a retrospective real-world study

2026
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Xi Rong et al, Frontiers in Immunology, 2026 · Open-access full text

Development of the first myasthenia gravis patient registry in Latvia: a single-centre experience

2026
Myasthenia gravis (adjacent NMJ disease) · Scientific Reports (Nature Publisher Group)

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gro smane-Bataraga, Arta et al, Scientific Reports (Nature Publisher Group), 2026 · Open-access full text

Therapeutic approach to myasthenia gravis treatment in the era of new biologics — review of existing and upcoming therapies

2026
Myasthenia gravis (adjacent NMJ disease) · Neurologia i Neurochirurgia Polska

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sobieszczuk, Ewa et al, Neurologia i Neurochirurgia Polska, 2026 · Open-access full text

Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma

2026
Myasthenia gravis (adjacent NMJ disease) · Nature Communications

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ueda, Hiroyuki et al, Nature Communications, 2026 · Open-access full text

Diagnostic performance and safety of the edrophonium test in myasthenia gravis: a retrospective case-control study

2026
Myasthenia gravis (adjacent NMJ disease) · Neurological Research and Practice

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Keritam, Omar et al, Neurological Research and Practice, 2026 · Open-access full text

Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data

2025
Myasthenia gravis (adjacent NMJ disease) · Orphanet Journal of Rare Diseases

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Slioui, Abderhmane et al, Orphanet Journal of Rare Diseases, 2025 · Open-access full text

MicroRNAs as Diagnostic Biomarkers of Myasthenia Gravis: A Systematic Review and Meta-Analysis

2025
Myasthenia gravis (adjacent NMJ disease) · Cellular and Molecular Neurobiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Paudel, Prayash et al, Cellular and Molecular Neurobiology, 2025 · Open-access full text

Utility of the Predictive Summary Index for Comparison of Diagnostic Protocols in Myasthenia Gravis With Repetitive Nerve Stimulation and Concentric Needle Jitter

2025
Myasthenia gravis (adjacent NMJ disease) · Brain and Behavior

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Trillenberg, Peter et al, Brain and Behavior, 2025 · Open-access full text

Hickam's dictum: Myasthenia Gravis presenting concurrently with Graves' disease

2025
Myasthenia gravis (adjacent NMJ disease) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sehgal Shekhar et al, BMJ Case Reports, 2025 · Publisher / database full text

Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)

2025
Myasthenia gravis (adjacent NMJ disease) · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Saiju, Jacob et al, Practical Neurology, 2025 · Publisher / database full text

Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?

2025
Myasthenia gravis (adjacent NMJ disease) · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Rossini, Elena et al, Brain Sciences, 2025 · Open-access full text

A Case Report on Pseudo-Internuclear Ophthalmoplegia: A Rare Manifestation of Myasthenia Gravis

2023
Myasthenia gravis (adjacent NMJ disease) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Munasinghe K.V.P. et al, Cureus, 2023 · Open-access full text

AChR-seropositive myasthenia gravis in muscular dystrophy: diagnostic pitfalls and clinical management challenges

2025
Myasthenia gravis (adjacent NMJ disease) · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Neurological Sciences, 2025 · Publisher / database full text

Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma

2025
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Pharmacology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Liu, Zhou et al, Frontiers in Pharmacology, 2025 · Open-access full text

Advances in Understanding and Managing Myasthenia Gravis: Current Trends and Future Directions

2024
Myasthenia gravis (adjacent NMJ disease) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Jaiswal Shreya et al, Cureus, 2024 · Open-access full text

Altered Cardiac Autonomic Regulation in Individuals with Myasthenia Gravis—A Systematic Review and Meta-Analysis

2023
Myasthenia gravis (adjacent NMJ disease) · Neurology International

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zawadka-Kunikowska, Monika et al, Neurology International, 2023 · Open-access full text

Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis

2021
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wang, Shumin et al, Frontiers in Immunology, 2021 · Open-access full text

Antibody Response to HERV-K and HERV-W Envelope Epitopes in Patients with Myasthenia Gravis

2024
Myasthenia gravis (adjacent NMJ disease) · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Simula, Elena Rita et al, International Journal of Molecular Sciences, 2024 · Open-access full text

Association Between Initial Corticosteroid Regimen and Treatment Response Time in Acetylcholine Receptor Antibody–Positive Myasthenia Gravis

2024
Myasthenia gravis (adjacent NMJ disease) · Acta Neurologica Scandinavica

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kim, Jinhee et al, Acta Neurologica Scandinavica, 2024 · Open-access full text

Burden of disease in myasthenia gravis: taking the patient’s perspective

2022
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lehnerer, Sophie et al, Journal of Neurology, 2022 · Open-access full text

C5 complement inhibition and FcRn modulation in generalized myasthenia gravis. Fast-acting but short-lived therapies the use of which should prompt assertive escalation of conventional treatments

2025
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology, Neurosurgery and Psychiatry

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
McConville, John, Journal of Neurology, Neurosurgery and Psychiatry, 2025 · Publisher / database full text

Case Report: Therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis

2025
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Watanabe, Keiko et al, Frontiers in Immunology, 2025 · Open-access full text

Case Series of Canine Myasthenia Gravis: A Classification Approach With Consideration of Seronegative Dogs

2025
Myasthenia gravis (adjacent NMJ disease) · Journal of Veterinary Internal Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dos Santos, Rui Xavier et al, Journal of Veterinary Internal Medicine, 2025 · Open-access full text

Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis

2025
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hewamadduma, Channa et al, Journal of Neurology, 2025 · Open-access full text

Clinical characteristics and treatment outcomes in patients with double‐seronegative myasthenia gravis

2024
Myasthenia gravis (adjacent NMJ disease) · European Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Martinez‐Harms, Rodrigo et al, European Journal of Neurology, 2024 · Open-access full text

Clinical features of double seronegative ocular myasthenia gravis

2024
Myasthenia gravis (adjacent NMJ disease) · Graefe's Archive for Clinical and Experimental Ophthalmology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Goto, Takuma et al, Graefe's Archive for Clinical and Experimental Ophthalmology, 2024 · Publisher / database full text

Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis

2023
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kwon, Young Nam et al, Journal of Neurology, 2023 · Open-access full text

Coexistence of myasthenia gravis and lichen planus: A case report and systematic review of related case reports from 1971 to 2024

2024
Myasthenia gravis (adjacent NMJ disease) · Clinical Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Jameie, Melika et al, Clinical Case Reports, 2024 · Open-access full text

Cutoffs on severity metrics for minimal manifestations or better status in patients with generalized myasthenia gravis

2024
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Watanabe, Genya et al, Frontiers in Immunology, 2024 · Open-access full text

Decoding myasthenia gravis: advanced diagnosis with infrared spectroscopy and machine learning

2024
Myasthenia gravis (adjacent NMJ disease) · Scientific Reports (Nature Publisher Group)

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Severcan, Feride et al, Scientific Reports (Nature Publisher Group), 2024 · Open-access full text

Development of a Model Care Pathway for Myasthenia Gravis

2021
Myasthenia gravis (adjacent NMJ disease) · International Journal of Environmental Research and Public Health

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Anil babu Payedimarri et al, International Journal of Environmental Research and Public Health, 2021 · Open-access full text

Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease

2021
Myasthenia gravis (adjacent NMJ disease) · Orphanet Journal of Rare Diseases

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cleanthous, Sophie et al, Orphanet Journal of Rare Diseases, 2021 · Open-access full text

Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows

2023
Myasthenia gravis (adjacent NMJ disease) · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Vinciguerra, Claudia et al, Brain Sciences, 2023 · Open-access full text

Diagnosis of Myasthenia Gravis

2021
Myasthenia gravis (adjacent NMJ disease) · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Rousseff, Rossen T et al, Journal of Clinical Medicine, 2021 · Open-access full text

Distal muscle weakness as the main onset symptom in thymoma-associated myasthenia gravis: a case report and literature review

2025
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wu, Xuan et al, Frontiers in Immunology, 2025 · Open-access full text

Double seronegative myasthenia gravis and mimics: a retrospective cross-sectional study by two tertiary centers in the Southern Italy

2025
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Journal of Neurology, 2025 · Publisher / database full text

Dropped Head Syndrome: The Importance of Neurophysiology in Distinguishing Myasthenia Gravis from Parkinson’s Disease

2024
Myasthenia gravis (adjacent NMJ disease) · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mangiardi, Marilena et al, Biomedicines, 2024 · Open-access full text

Eculizumab versus rituximab in generalised myasthenia gravis

2022
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology, Neurosurgery and Psychiatry

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nelke, Christopher et al, Journal of Neurology, Neurosurgery and Psychiatry, 2022 · Open-access full text

Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study

2022
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Pharmacology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ceccanti, Marco et al, Frontiers in Pharmacology, 2022 · Open-access full text

Efficacy and safety of different dosages of rituximab for myasthenia gravis: a single-arm meta-analysis

2025
Myasthenia gravis (adjacent NMJ disease) · Daru

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Li, Jianchun et al, Daru, 2025 · Publisher / database full text

Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real‐World Cohort of 77 Patients

2025
Myasthenia gravis (adjacent NMJ disease) · CNS Neuroscience & Therapeutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hao, Sijia et al, CNS Neuroscience & Therapeutics, 2025 · Open-access full text

Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series

2024
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Song, Jie et al, Frontiers in Immunology, 2024 · Open-access full text

Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report

2024
Myasthenia gravis (adjacent NMJ disease) · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ohara, Hiroya et al, BMC Neurology, 2024 · Open-access full text

Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China

2024
Myasthenia gravis (adjacent NMJ disease) · Annals of Clinical and Translational Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Luo, Sushan et al, Annals of Clinical and Translational Neurology, 2024 · Open-access full text

Epigenome-wide DNA methylation analysis of myasthenia gravis

2023
Myasthenia gravis (adjacent NMJ disease) · FEBS Open Bio

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lin, Jingjing et al, FEBS Open Bio, 2023 · Open-access full text

Eye-Opener- A case report of eyelid taping as presenting symptom of Myasthenia Gravis

2025
Myasthenia gravis (adjacent NMJ disease) · Journal of Education & Teaching in Emergency Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
McGoldrick, Mary et al, Journal of Education & Teaching in Emergency Medicine, 2025 · Open-access full text

Fatigue and associated factors in myasthenia gravis: a nationwide registry study

2024
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Funke, Mattea et al, Journal of Neurology, 2024 · Open-access full text

Female sex and overweight are associated with a lower quality of life in patients with myasthenia gravis: a single center cohort study

2023
Myasthenia gravis (adjacent NMJ disease) · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wilcke, Hannah et al, BMC Neurology, 2023 · Open-access full text

Gastrointestinal Dysmotility as the First Manifestation of Myasthenia Gravis

2023
Myasthenia gravis (adjacent NMJ disease) · Canadian Journal of Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Alnajjar, Sara et al, Canadian Journal of Neurological Sciences, 2023 · Publisher / database full text

Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis

2021
Myasthenia gravis (adjacent NMJ disease) · Journal of Translational Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Salari, Nader et al, Journal of Translational Medicine, 2021 · Open-access full text

Impact of 2014 Japanese practice guidelines on treatment patterns in patients with myasthenia gravis: an insurance claims database study

2025
Myasthenia gravis (adjacent NMJ disease) · BMJ Open

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Konno, Shingo et al, BMJ Open, 2025 · Open-access full text

Impact of COVID-19 infection among myasthenia gravis patients- a Cerner Real-World Data TM study

2022
Myasthenia gravis (adjacent NMJ disease) · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lakshmi Prasanna Digala et al, BMC Neurology, 2022 · Open-access full text

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis

2022
Myasthenia gravis (adjacent NMJ disease) · BMC Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Xiao Huan et al, BMC Immunology, 2022 · Open-access full text

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

2022
Myasthenia gravis (adjacent NMJ disease) · Journal of Neuroinflammation

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nelke, Christopher et al, Journal of Neuroinflammation, 2022 · Open-access full text

Inspiratory muscle training and aerobic exercise for respiratory muscle strength in myasthenia gravis post-hospitalization- a randomized controlled trial

2025
Myasthenia gravis (adjacent NMJ disease) · BMC Pulmonary Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chang, Chia-Ling et al, BMC Pulmonary Medicine, 2025 · Open-access full text

Iranian Consensus Recommendations for Treatment of Myasthenia Gravis

2022
Myasthenia gravis (adjacent NMJ disease) · Archives of Iranian Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nafissi, Shahriar et al, Archives of Iranian Medicine, 2022 · Open-access full text

Lower Urinary Tract Symptoms in Myasthenia Gravis

2021
Myasthenia gravis (adjacent NMJ disease) · Case Reports in Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tateno, Fuyuki et al, Case Reports in Neurology, 2021 · Publisher / database full text

Management of patients with generalised myasthenia gravis and COVID-19: four case reports

2020
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology, Neurosurgery and Psychiatry

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hübers, Annemarie et al, Journal of Neurology, Neurosurgery and Psychiatry, 2020 · Publisher / database full text

MuSK Myasthenia Gravis—Potential Pathomechanisms and Treatment Directed against Specific Targets

2024
Myasthenia gravis (adjacent NMJ disease) · Cells

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dziadkowiak, Edyta et al, Cells, 2024 · Open-access full text

Myasthenia gravis and independent risk factors for recurrent infection: a retrospective cohort study

2023
Myasthenia gravis (adjacent NMJ disease) · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chia-Yin Chien et al, BMC Neurology, 2023 · Open-access full text

Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report

2023
Myasthenia gravis (adjacent NMJ disease) · Experimental and Therapeutic Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Stingu, Elena et al, Experimental and Therapeutic Medicine, 2023 · Publisher / database full text

Myasthenia gravis associated with a pelvic follicular lymphoma

2022
Myasthenia gravis (adjacent NMJ disease) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Willis, Charlotte et al, BMJ Case Reports, 2022 · Publisher / database full text

Myasthenia gravis complicated by intestinal pseudo-obstruction: a case report and literature review

2025
Myasthenia gravis (adjacent NMJ disease) · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lin, Yangtao et al, BMC Neurology, 2025 · Open-access full text

Myasthenia gravis in 2025: five new things and four hopes for the future

2025
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Journal of Neurology, 2025 · Publisher / database full text

Myasthenia Gravis Presenting With Vocal Cord Paralysis As the Initial Symptom Occurring One Week Following Herpes Zoster Vaccination: A Case Report and Review of the Literature

2025
Myasthenia gravis (adjacent NMJ disease) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Asada Shimpei et al, Cureus, 2025 · Open-access full text

Myasthenia gravis that has developed long after radical resection of lung cancer: A case report

2022
Myasthenia gravis (adjacent NMJ disease) · Experimental and Therapeutic Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Okauchi, Shinichiro et al, Experimental and Therapeutic Medicine, 2022 · Publisher / database full text

Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience

2022
Myasthenia gravis (adjacent NMJ disease) · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zdraljevic, Mirjana et al, Neurological Sciences, 2022 · Publisher / database full text

Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment

2020
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Molecular Neuroscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cao, Michelangelo et al, Frontiers in Molecular Neuroscience, 2020 · Open-access full text

Myasthenia gravis: the changing treatment landscape in the era of molecular therapies

2024
Myasthenia gravis (adjacent NMJ disease) · Nature Reviews. Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Iorio, Raffaele et al, Nature Reviews. Neurology, 2024 · Publisher / database full text

Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up

2021
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wanschitz, Julia V et al, Journal of Neurology, 2021 · Publisher / database full text

New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making

2025
Myasthenia gravis (adjacent NMJ disease) · BioDrugs

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gerischer, Lea et al, BioDrugs, 2025 · Publisher / database full text

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis

2021
Myasthenia gravis (adjacent NMJ disease) · Journal of Translational Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhao, Rui et al, Journal of Translational Medicine, 2021 · Open-access full text

Ocular Myasthenia Gravis: A Current Overview

2023
Myasthenia gravis (adjacent NMJ disease) · Eye and Brain

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Behbehani, R, Eye and Brain, 2023 · Open-access full text

Oculomotor fatigability with decrements of saccade and smooth pursuit for diagnosis of myasthenia gravis

2023
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nguyen, Thanh Tin et al, Journal of Neurology, 2023 · Open-access full text

Oculopharyngeal muscular dystrophy, myasthenia gravis, systemic lupus erythematosus: overlap and interactions

2024
Myasthenia gravis (adjacent NMJ disease) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Barbosa, Joana M et al, BMJ Case Reports, 2024 · Publisher / database full text

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review

2022
Myasthenia gravis (adjacent NMJ disease) · Therapeutics and Clinical Risk Management

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Waheed, W et al, Therapeutics and Clinical Risk Management, 2022 · Open-access full text

Predictive Factors for Poor Outcomes Associated with COVID-19 in a Retrospective Cohort of Myasthenia Gravis Patients

2024
Myasthenia gravis (adjacent NMJ disease) · Journal of Inflammation Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Bi Z et al, Journal of Inflammation Research, 2024 · Open-access full text

Prevalence of Elevated CK Levels, Myositis-Specific and Myositis-Associated Antibodies, Myositis, and Other Neuromuscular Diseases in Myasthenia Gravis Patients—Experience from an Eastern European Tertiary Center

2025
Myasthenia gravis (adjacent NMJ disease) · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kozák, Márk et al, Journal of Clinical Medicine, 2025 · Open-access full text

Prevalence of restless legs and association with patient-reported outcome measures in myasthenia gravis

2025
Myasthenia gravis (adjacent NMJ disease) · Journal of Clinical Sleep Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
AlGaeed, Mohanad et al, Journal of Clinical Sleep Medicine, 2025 · Publisher / database full text

Pyridostigmine-induced coronary artery spasm in early-onset myasthenia gravis: a case presentation and review of the literature

2022
Myasthenia gravis (adjacent NMJ disease) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chuapakdee, Oranuch et al, BMJ Case Reports, 2022 · Publisher / database full text

Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control

2024
Myasthenia gravis (adjacent NMJ disease) · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Konno, Shingo et al, Biomedicines, 2024 · Open-access full text

Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation

2025
Myasthenia gravis (adjacent NMJ disease) · Neurology and Therapy

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Neurology and Therapy, 2025 · Publisher / database full text

Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis

2023
Myasthenia gravis (adjacent NMJ disease) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Stascheit, Frauke et al, Journal of Neurology, 2023 · Open-access full text

Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis

2022
Myasthenia gravis (adjacent NMJ disease) · Orphanet Journal of Rare Diseases

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Su, Manqiqige et al, Orphanet Journal of Rare Diseases, 2022 · Open-access full text

Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis

2025
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
He, Dingxian et al, Frontiers in Immunology, 2025 · Open-access full text

Sorting nexin 17 increases low-density lipoprotein receptor-related protein 4 membrane expression: A novel mechanism of acetylcholine receptor aggregation in myasthenia gravis

2022
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
He, Xiaoxiao et al, Frontiers in Immunology, 2022 · Open-access full text

Taste disorders and alopecia in myasthenia gravis

2024
Myasthenia gravis (adjacent NMJ disease) · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Uzawa, Akiyuki et al, BMC Neurology, 2024 · Open-access full text

The Association Between Myasthenia Gravis and Higher Extrathymic Cancer Risk

2025
Myasthenia gravis (adjacent NMJ disease) · Brain and Behavior

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Khateb, Mohamed et al, Brain and Behavior, 2025 · Open-access full text

The burden of disease in seronegative myasthenia gravis: a patient-centered perspective

2025
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lehnerer, Sophie et al, Frontiers in Immunology, 2025 · Open-access full text

The epidemiology of myasthenia gravis

2021
Myasthenia gravis (adjacent NMJ disease) · Journal of Medicine and Life

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Bubuioc, Ana-Maria et al, Journal of Medicine and Life, 2021 · Publisher / database full text

The impact of diagnosis delay on European patients with generalised myasthenia gravis

2024
Myasthenia gravis (adjacent NMJ disease) · Annals of Clinical and Translational Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cortés‐Vicente, Elena et al, Annals of Clinical and Translational Neurology, 2024 · Open-access full text

The impact of thymectomy in subgroups of Myasthenia gravis patients: a single center longitudinal observation

2023
Myasthenia gravis (adjacent NMJ disease) · Neurological Research and Practice

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Menghesha, Hruy et al, Neurological Research and Practice, 2023 · Open-access full text

The impacts of the COVID-19 pandemic on Australia’s myasthenia gravis patients: A self-reported survey study

2025
Myasthenia gravis (adjacent NMJ disease) · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Neurological Sciences, 2025 · Publisher / database full text

The Incidence of Myasthenia Gravis in the Province of Ferrara, Italy, in the Period of 2008–2022: An Update on a 40-Year Observation and the Influence of the COVID-19 Pandemic

2024
Myasthenia gravis (adjacent NMJ disease) · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Antonioni, Annibale et al, Journal of Clinical Medicine, 2024 · Open-access full text

The Influence of Loneliness and Anxiety Levels on MG-Specific Quality of Life in Patients with Myasthenia Gravis during the COVID-19 Pandemic

2024
Myasthenia gravis (adjacent NMJ disease) · International Journal of Behavioral Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Demirci, Pınar Yeşil et al, International Journal of Behavioral Medicine, 2024 · Publisher / database full text

The prognostic value of diagnostic tools in patients with seropositive myasthenia gravis: a retrospective study of 31 cases

2021
Myasthenia gravis (adjacent NMJ disease) · Medicni Perspektivi

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gryb, V A et al, Medicni Perspektivi, 2021 · Open-access full text

The Role of Human Microbiota in Myasthenia Gravis: A Narrative Review

2023
Myasthenia gravis (adjacent NMJ disease) · Neurology International

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Schirò, Giuseppe et al, Neurology International, 2023 · Open-access full text

Thymoma-Related Chest Pain and Dyspnea in a Middle-Aged Caucasian Female With Myasthenia Gravis and Good's Syndrome: A Case Report

2024
Myasthenia gravis (adjacent NMJ disease) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ansari, Ali Z et al, Cureus, 2024 · Publisher / database full text

To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis

2021
Myasthenia gravis (adjacent NMJ disease) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhou, Qian et al, Frontiers in Immunology, 2021 · Open-access full text

Transient acetylcholine receptor-related myasthenia gravis, post multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19 infection

2021
Myasthenia gravis (adjacent NMJ disease) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Essajee, Farida et al, BMJ Case Reports, 2021 · Publisher / database full text

Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review

2024
Myasthenia gravis (adjacent NMJ disease) · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Jenny Linnea Victoria Lindroos et al, Journal of Clinical Medicine, 2024 · Open-access full text

Treating myasthenia gravis beyond the eye clinic

2024
Myasthenia gravis (adjacent NMJ disease) · Eye

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Jacob, Saiju et al, Eye, 2024 · Open-access full text

Unusual presentations of myasthenia gravis and misdiagnosis

2025
Myasthenia gravis (adjacent NMJ disease) · Scientific Reports (Nature Publisher Group)

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Scientific Reports (Nature Publisher Group), 2025 · Publisher / database full text

Unveiling Myasthenia Gravis: A Comprehensive Analysis of Diagnostic Tools and Clinical Insights

2023
Myasthenia gravis (adjacent NMJ disease) · Dicle Tip Dergisi

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. MG research can suggest useful tests, outcome measures or treatment ideas, but findings cannot automatically be carried over to LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Öncel, Samet et al, Dicle Tip Dergisi, 2023 · Open-access full text

Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes—A Comprehensive Review

2023
Congenital Myasthenic Syndromes · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Their main value here is helping distinguish autoimmune LEMS from genetic conditions, especially in younger patients or unusual presentations.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ohno, Kinji et al, International Journal of Molecular Sciences, 2023 · Open-access full text

Congenital Myasthenic Syndrome With Adult Onset Due to the Novel Heterozygous c.1399_1404del Variant in the Downstream of Tyrosine Kinase-7 (DOK7): A Case Report

2025
Congenital Myasthenic Syndromes · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Their main value here is helping distinguish autoimmune LEMS from genetic conditions, especially in younger patients or unusual presentations.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Finsterer Josef, Cureus, 2025 · Open-access full text

Congenital myasthenic syndromes

2024
Congenital Myasthenic Syndromes · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Their main value here is helping distinguish autoimmune LEMS from genetic conditions, especially in younger patients or unusual presentations.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Henehan, Leighann et al, Practical Neurology, 2024 · Publisher / database full text

Severe congenital myasthenic syndromes caused by agrin mutations affecting secretion by motoneurons

2022
Congenital Myasthenic Syndromes · Acta Neuropathologica

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Their main value here is helping distinguish autoimmune LEMS from genetic conditions, especially in younger patients or unusual presentations.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Jacquier, Arnaud et al, Acta Neuropathologica, 2022 · Open-access full text

Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases

2026
CAR-T / engineered cell therapy in autoimmune neurology · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhou, Sijie et al, Frontiers in Immunology, 2026 · Open-access full text

CAR-T cells in the treatment of neurological autoimmune diseases

2026
CAR-T / engineered cell therapy in autoimmune neurology · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Vonberg, Frederick W et al, Practical Neurology, 2026 · Publisher / database full text

Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models

2026
CAR-T / engineered cell therapy in autoimmune neurology · Nature Communications

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
von Wardenburg, Niels et al, Nature Communications, 2026 · Open-access full text

Therapeutic effect of T-cell engager in two patients with autoimmune neuropathy

2026
CAR-T / engineered cell therapy in autoimmune neurology · Nature Communications

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wickel, Jonathan et al, Nature Communications, 2026 · Open-access full text

Neurological implications of chimeric antigen receptor-T cell therapy

2026
CAR-T / engineered cell therapy in autoimmune neurology · BMJ Neurology Open

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Raffoul, Daniel G et al, BMJ Neurology Open, 2026 · Open-access full text

CAR-T cell therapy for treatment-refractory rheumatic autoimmune diseases: a systematic review of clinical outcomes and safety profiles

2026
CAR-T / engineered cell therapy in autoimmune neurology · RMD Open

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Santosa Anindita et al, RMD Open, 2026 · Open-access full text

Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects

2025
CAR-T / engineered cell therapy in autoimmune neurology · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zheng, Mingxuan et al, Frontiers in Immunology, 2025 · Open-access full text

Chimeric Antigen Receptor T‐Cell Therapy and Autoimmune Diseases in the Nervous System

2025
CAR-T / engineered cell therapy in autoimmune neurology · Immunity, Inflammation and Disease

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yao, Shun‐yu et al, Immunity, Inflammation and Disease, 2025 · Open-access full text

CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?

2024
CAR-T / engineered cell therapy in autoimmune neurology · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Rangel-Peláez, Carlos et al, Frontiers in Immunology, 2024 · Open-access full text

CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Systemic Autoimmune Diseases

2024
CAR-T / engineered cell therapy in autoimmune neurology · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They show where immune treatment research may be heading, but do not establish a current LEMS treatment option.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cingireddy, Ananya Reddy et al, Cureus, 2024 · Open-access full text

Latrophilin-1-Mediated G αq Signaling, Store-Operated Ca 2+ Entry, and Ca V 2.1 Activation Control Spontaneous Exocytosis at the Mouse Neuromuscular Junction

2026
Neuromuscular junction biology & channelopathies · Cells

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Petitto Evelina et al, Cells, 2026 · Open-access full text

Episodic Ataxia Type 2 Presenting with Fluctuating Weakness in a Child with a De Novo CACNA1A Variant

2026
Neuromuscular junction biology & channelopathies · Children

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Park Sungyeon et al, Children, 2026 · Open-access full text

Spatiotemporal Remodeling of Presynaptic Terminals in Human Neuromuscular Junctions

2026
Neuromuscular junction biology & channelopathies · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Liang Zhanyang et al, International Journal of Molecular Sciences, 2026 · Open-access full text

New Insights into Neuromuscular Junction Biology: Evidence from Human and Animal Research

2026
Neuromuscular junction biology & channelopathies · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Liang Zhanyang et al, International Journal of Molecular Sciences, 2026 · Open-access full text

Syntaphilin loss enhances mitochondrial axonal transport and neuromuscular junction formation in a human stem cell derived neuromuscular assembloid model

2025
Neuromuscular junction biology & channelopathies · Molecular Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Salzinger, Andrea et al, Molecular Medicine, 2025 · Open-access full text

Adaptive Remodeling of the Neuromuscular Junction with Aging

2022
Neuromuscular junction biology & channelopathies · Cells

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Deschenes, Michael R et al, Cells, 2022 · Open-access full text

Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders

2022
Neuromuscular junction biology & channelopathies · The Lancet Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Verschuuren, Jan JGM et al, The Lancet Neurology, 2022 · Publisher / database full text

Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders

2022
Neuromuscular junction biology & channelopathies · The Lancet Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Huijbers, Maartje G et al, The Lancet Neurology, 2022 · Publisher / database full text

Antibiotic neuromuscular junction myasthenic mimetics

2022
Neuromuscular junction biology & channelopathies · The Lancet Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Uzoigwe, Chika Edward et al, The Lancet Neurology, 2022 · Publisher / database full text

Antibiotic neuromuscular junction myasthenic mimetics – Authors' reply

2022
Neuromuscular junction biology & channelopathies · The Lancet Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, The Lancet Neurology, 2022 · Publisher / database full text

Cellular and Subcellular Characteristics of Neuromuscular Junctions in Muscles with Disparate Duty Cycles and Myofiber Profiles

2023
Neuromuscular junction biology & channelopathies · Cells

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Deschenes, Michael R et al, Cells, 2023 · Open-access full text

Critical Pronociceptive Role of Family 2 Voltage-Gated Calcium Channels in a Novel Mouse Model of HIV-Associated Sensory Neuropathy

2023
Neuromuscular junction biology & channelopathies · Molecular Neurobiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lückemeyer, Debora Denardin et al, Molecular Neurobiology, 2023 · Publisher / database full text

Disruption of Neuromuscular Junction Following Spinal Cord Injury and Motor Neuron Diseases

2024
Neuromuscular junction biology & channelopathies · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nemeth, Colin et al, International Journal of Molecular Sciences, 2024 · Open-access full text

Early Alterations in Structural and Functional Properties in the Neuromuscular Junctions of Mutant FUS Mice

2023
Neuromuscular junction biology & channelopathies · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mukhamedyarov, Marat A et al, International Journal of Molecular Sciences, 2023 · Open-access full text

Impairment Mechanisms and Intervention Approaches for Aged Human Neuromuscular Junctions

2020
Neuromuscular junction biology & channelopathies · Frontiers in Molecular Neuroscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Badawi, Yomna et al, Frontiers in Molecular Neuroscience, 2020 · Open-access full text

Involvement of the Voltage-Gated Calcium Channels L- P/Q- and N-Types in Synapse Elimination During Neuromuscular Junction Development

2022
Neuromuscular junction biology & channelopathies · Molecular Neurobiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Garcia, Neus et al, Molecular Neurobiology, 2022 · Open-access full text

Modulation of the Acetylcholine Receptor Clustering Pathway Improves Neuromuscular Junction Structure and Muscle Strength in a Mouse Model of Congenital Myasthenic Syndrome

2020
Neuromuscular junction biology & channelopathies · Frontiers in Molecular Neuroscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Spendiff, Sally et al, Frontiers in Molecular Neuroscience, 2020 · Open-access full text

Munc13-1 restoration mitigates presynaptic pathology in spinal muscular atrophy

2025
Neuromuscular junction biology & channelopathies · Nature Communications

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Moradi, Mehri et al, Nature Communications, 2025 · Open-access full text

Neuromuscular junction disorders: mimics and chameleons

2024
Neuromuscular junction biology & channelopathies · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
El-Wahsh, Shadi et al, Practical Neurology, 2024 · Publisher / database full text

Neuromuscular junction involvement in inherited motor neuropathies: genetic heterogeneity and effect of oral salbutamol treatment

2023
Neuromuscular junction biology & channelopathies · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
McMacken, Grace et al, Journal of Neurology, 2023 · Open-access full text

P/Q type (Ca v 2.1) Calcium Channel Blocker ω-Agatoxin IVA Alters Cleaved Caspase-3 and BDNF Expressions in the Rat Brain and Suppresses Seizure Activity

2024
Neuromuscular junction biology & channelopathies · Molecular Neurobiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Inan, Salim Yalcin et al, Molecular Neurobiology, 2024 · Publisher / database full text

Post-synaptic specialization of the neuromuscular junction: junctional folds formation, function, and disorders

2022
Neuromuscular junction biology & channelopathies · Cell & Bioscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zou, Suqi et al, Cell & Bioscience, 2022 · Open-access full text

Secreted Signaling Molecules at the Neuromuscular Junction in Physiology and Pathology

2021
Neuromuscular junction biology & channelopathies · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, International Journal of Molecular Sciences, 2021 · Open-access full text

Similarity and Diversity of Presynaptic Molecules at Neuromuscular Junctions and Central Synapses

2022
Neuromuscular junction biology & channelopathies · Biomolecules

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Takikawa, Kenji et al, Biomolecules, 2022 · Open-access full text

Sympathetic innervation in skeletal muscle and its role at the neuromuscular junction

2024
Neuromuscular junction biology & channelopathies · Journal of Muscle Research and Cell Motility

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Rudolf, Rüdiger et al, Journal of Muscle Research and Cell Motility, 2024 · Open-access full text

The Mechanism of α2 adrenoreceptor-dependent Modulation of Neurotransmitter Release at the Neuromuscular Junctions

2024
Neuromuscular junction biology & channelopathies · Neurochemical Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tsentsevitsky, Andrei N. et al, Neurochemical Research, 2024 · Publisher / database full text

The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis

2020
Neuromuscular junction biology & channelopathies · Frontiers in Molecular Neuroscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Rodríguez Cruz, Pedro M et al, Frontiers in Molecular Neuroscience, 2020 · Open-access full text

The Neuromuscular Junction: Roles in Aging and Neuromuscular Disease

Year not captured
Neuromuscular junction biology & channelopathies · journal not recorded

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessFind full text on PubMedNo direct article URL was captured
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, journal not recorded · Find full text on PubMed

Total Plasma Exchange in Neuromuscular Junction Disorders—A Single-Center, Retrospective Analysis of the Efficacy, Safety and Potential Diagnostic Properties in Doubtful Diagnosis

2022
Neuromuscular junction biology & channelopathies · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Totzeck, Andreas et al, Journal of Clinical Medicine, 2022 · Open-access full text

Voltage-Dependent Calcium Channels in Mammalian Motor Synapses: Triggers and Modulators of Neuromuscular Transmission

2024
Neuromuscular junction biology & channelopathies · Journal of Evolutionary Biochemistry and Physiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They make the LEMS mechanism easier to understand and may point toward future therapies, but many findings come from laboratory models or other diseases.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gaydukov, A. E. et al, Journal of Evolutionary Biochemistry and Physiology, 2024 · Publisher / database full text

Ultrastructural Signs of High Functional Activity of Neuromuscular Synapses in Aging Rats After Photobiomodulation

2026
Ion Channel & Synaptic Pharmacology · Cells

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Vasyagina Tatyana et al, Cells, 2026 · Open-access full text

A New Proton Transfer Complex Between 3,4-Diaminopyridine Drug and 2,6-Dichloro-4-nitrophenol: Synthesis, Spectroscopic Characterization, DFT Studies, DNA Binding Analysis, and Antitumor Activity

2024
Ion Channel & Synaptic Pharmacology · Molecules

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Alghanmi, Reem M et al, Molecules, 2024 · Open-access full text

A Preclinical Study on Brugada Syndrome with a CACNB2 Variant Using Human Cardiomyocytes from Induced Pluripotent Stem Cells

2022
Ion Channel & Synaptic Pharmacology · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhong, Rujia et al, International Journal of Molecular Sciences, 2022 · Open-access full text

Activation of Voltage-Gated Na + Current by GV-58, a Known Activator of Ca V Channels

2022
Ion Channel & Synaptic Pharmacology · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hsin-Yen Cho et al, Biomedicines, 2022 · Open-access full text

Advancements in Targeting Ion Channels for the Treatment of Neurodegenerative Diseases

2024
Ion Channel & Synaptic Pharmacology · Pharmaceuticals

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Li, Yuxuan et al, Pharmaceuticals, 2024 · Open-access full text

Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial

2022
Ion Channel & Synaptic Pharmacology · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Journal of Neurology, 2022 · Publisher / database full text

Aminopiridines in the treatment of multiple sclerosis and other neurological disorders

2020
Ion Channel & Synaptic Pharmacology · Neurodegenerative Disease Management

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
De Giglio, Laura et al, Neurodegenerative Disease Management, 2020 · Publisher / database full text

Cannabinerol (CBNR) Influences Synaptic Genes Associated with Cytoskeleton and Ion Channels in NSC-34 Cell Line: A Transcriptomic Study

2024
Ion Channel & Synaptic Pharmacology · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Artimagnella, Osvaldo et al, Biomedicines, 2024 · Open-access full text

Experimental Zebrafish Models of Synaptopathies

2023
Ion Channel & Synaptic Pharmacology · Journal of Evolutionary Biochemistry and Physiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lebedev, A. S. et al, Journal of Evolutionary Biochemistry and Physiology, 2023 · Publisher / database full text

Function of Drosophila Synaptotagmins in membrane trafficking at synapses

2021
Ion Channel & Synaptic Pharmacology · Cellular and Molecular Life Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Cellular and Molecular Life Sciences, 2021 · Publisher / database full text

Guanidine aptamers are present in vertebrate RNAs associated with calcium signaling and neuromuscular function

2025
Ion Channel & Synaptic Pharmacology · Nature Communications

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kavita, Kumari et al, Nature Communications, 2025 · Open-access full text

Investigation of N -Acetyltransferase 2-Mediated Drug Interactions of Amifampridine: In Vitro and In Vivo Evidence of Drug Interactions with Acetaminophen

2023
Ion Channel & Synaptic Pharmacology · Pharmaceutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Park, Yeo-Dim et al, Pharmaceutics, 2023 · Open-access full text

Modulating ion channels with nanobodies

2025
Ion Channel & Synaptic Pharmacology · Synthetic and Systems Biotechnology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ali, Sher et al, Synthetic and Systems Biotechnology, 2025 · Open-access full text

Modulation of Voltage-Gated Na + Channel Currents by Small Molecules: Effects on Amplitude and Gating During High-Frequency Stimulation

2025
Ion Channel & Synaptic Pharmacology · Scientia Pharmaceutica

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cheng-Yuan, Lin et al, Scientia Pharmaceutica, 2025 · Open-access full text

Neurological manifestations of hypermagnesemia: a narrative review

2025
Ion Channel & Synaptic Pharmacology · Acta Neurologica Belgica

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tosto, Federico et al, Acta Neurologica Belgica, 2025 · Publisher / database full text

New Charge Transfer Complexes of K + -Channel-Blocker Drug (Amifampridine; AMFP) for Sensitive Detection; Solution Investigations and DFT Studies

2021
Ion Channel & Synaptic Pharmacology · Molecules

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Alghanmi, Reem M et al, Molecules, 2021 · Open-access full text

Pursuing High-Resolution Structures of Nicotinic Acetylcholine Receptors: Lessons Learned from Five Decades

2021
Ion Channel & Synaptic Pharmacology · Molecules

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Delgado-Vélez, Manuel et al, Molecules, 2021 · Open-access full text

Recent Advances in Computer-Aided Structure-Based Drug Design on Ion Channels

2023
Ion Channel & Synaptic Pharmacology · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Pliushcheuskaya, Palina et al, International Journal of Molecular Sciences, 2023 · Open-access full text

Recent Advances in Ionic Mechanisms in Pituitary Cells: Implications for Electrophysiological and Electropharmacological Research

2025
Ion Channel & Synaptic Pharmacology · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sheng-Nan, Wu et al, Journal of Clinical Medicine, 2025 · Open-access full text

Reduced Fatigue Symptoms in the Post-COVID Syndrome With Amifampridine: A Collective Casuistry With Double-Blind Discontinuation Trials

2024
Ion Channel & Synaptic Pharmacology · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Boehmeke, Thomas, Cureus, 2024 · Open-access full text

Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension

2022
Ion Channel & Synaptic Pharmacology · Biomolecules

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Santos-Gomes, Joana et al, Biomolecules, 2022 · Open-access full text

Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion

2021
Ion Channel & Synaptic Pharmacology · Advanced Science

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Huang, Yulun et al, Advanced Science, 2021 · Open-access full text

Structural insights into VAChT neurotransmitter recognition and inhibition

2024
Ion Channel & Synaptic Pharmacology · Cell Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. Useful for understanding how medicines might alter signalling; usually not evidence that a particular medicine is safe or effective for LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhang, Yang et al, Cell Research, 2024 · Open-access full text

Efficacy and Safety of IncobotulinumtoxinA for the Treatment of Blepharospasm: A Multicenter, Phase 3 Study in Japan

2026
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Toxins

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Goseki Toshiaki et al, Toxins, 2026 · Open-access full text

Advances in Clostridial Neurotoxins: Passage of the Intestinal Barrier and Targeting of Specific Neuronal Cells

2026
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Toxins

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Popoff, Michel R, Toxins, 2026 · Open-access full text

Adult Botulism of Unknown Source with Post-Toxin Anti-GQ1b Antibodies: Implications for Molecular Mimicry—A Case Report

2026
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Neurology International

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cohen Regev et al, Neurology International, 2026 · Open-access full text

Combined treatment with antitoxin and 3,4-diaminopyridine improves survival outcomes after lethal botulinum neurotoxin challenge

2025
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Molecular Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
O’Brien, Sean W. et al, Molecular Medicine, 2025 · Open-access full text

Three-Dimensional Photogrammetric Assessment of Facial Symmetry Improvement Following Botulinum Toxin Treatment in Patients with Facial Palsy: An Observational Study

2025
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Pradel, Robin et al, Journal of Clinical Medicine, 2025 · Open-access full text

Foodborne botulism from consumption of homemade spoiled eggs: a case series and literature review

2025
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Frontiers in Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wei, Suyu et al, Frontiers in Medicine, 2025 · Open-access full text

Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine

2022
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Molecular Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Molecular Medicine, 2022 · Open-access full text

Botulinum Neurotoxins (BoNTs) and Their Biological, Pharmacological, and Toxicological Issues: A Scoping Review

2021
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Applied Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Corsalini, Massimo et al, Applied Sciences, 2021 · Open-access full text

Botulinum Neurotoxins as Two-Faced Janus Proteins

2025
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chimienti, Silvia et al, Biomedicines, 2025 · Open-access full text

Botulism in emergency department

2023
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Internal and Emergency Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Barbato, Francesco et al, Internal and Emergency Medicine, 2023 · Publisher / database full text

Botulism outbreak after the consumption of vegetarian pâté in the south of Viet Nam [version 1; peer review: awaiting peer review]

2020
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Wellcome Open Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nguyen Thi Thuy Ngan et al, Wellcome Open Research, 2020 · Open-access full text

Early diagnosis and critical management of wound botulism in the emergency department: a single center experience and literature review

2021
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · International Journal of Emergency Medicine (Online)

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Neeki, Michael M et al, International Journal of Emergency Medicine (Online), 2021 · Open-access full text

Efficacy, Safety, and Subject Satisfaction of PrabotulinumtoxinA for Moderate-to-Severe Crow’s Feet: A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial

2023
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lee, Soo-Kyung et al, Journal of Clinical Medicine, 2023 · Open-access full text

High risk and low prevalence diseases: Botulism

2024
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · The American Journal of Emergency Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Heilmann, Adam et al, The American Journal of Emergency Medicine, 2024 · Publisher / database full text

Iatrogenic botulism after intragastric botulinum neurotoxin injections – a major outbreak

2024
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Neurological Research and Practice

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Goerttler, Tsepo et al, Neurological Research and Practice, 2024 · Open-access full text

Infant Botulism: Checklist for Timely Clinical Diagnosis and New Possible Risk Factors Originated from a Case Report and Literature Review

2021
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Toxins

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dilena, Robertino et al, Toxins, 2021 · Open-access full text

Knockin mouse models demonstrate differential contributions of synaptotagmin-1 and -2 as receptors for botulinum neurotoxins

2021
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · PLoS Pathogens

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hatim Thaker https://orcid.org/ et al, PLoS Pathogens, 2021 · Open-access full text

The Esthetic Use of Botulinum Toxins in Cancer Patients: Providing a Foundation for Future Indications

2025
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Toxins

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Papagni, Marco et al, Toxins, 2025 · Open-access full text

Three men in a boat: The comparison of the combination therapy of botulinum toxin and greater occipital nerve block with bupivacaine, with botulinum toxin monotherapy in the management of chronic migraine

2023
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Clinical Neurology and Neurosurgery

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Karaoğlan, Mustafa, Clinical Neurology and Neurosurgery, 2023 · Publisher / database full text

Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update

2022
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Archives of Toxicology. Archiv für Toxikologie

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Pirazzini, Marco et al, Archives of Toxicology. Archiv für Toxikologie, 2022 · Open-access full text

Wound Botulism Caused by Botulinum Neurotoxin Type A in a Chronic Parenteral Drug Abuser

2020
Botulinum/clostridial neurotoxin pharmacology (presynaptic NMJ-adjacent) · Case Reports in Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. This is mainly a biological comparison and medication-safety context, not a source of LEMS treatments.

Article accessOpen-access full textCC BY-NC 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Awsare, Sohun et al, Case Reports in Neurology, 2020 · Open-access full text

Mechanisms of cancer-induced neurophysiological dysfunction and therapeutic strategies

2025
SCLC & Oncologic Screening · Discover Oncology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mujinya, Regan et al, Discover Oncology, 2025 · Open-access full text

SUN-277 An Unexpected Manifestation of NonIslet Cell Tumor Hypoglycemia in Pancreatic Ductal Adenocarcinoma

2025
SCLC & Oncologic Screening · Journal of the Endocrine Society

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kaur, Jasmine et al, Journal of the Endocrine Society, 2025 · Open-access full text

A Rapid Review of Adenocarcinoma and Pulmonary Tumor Thrombotic Microangiopathy: A Deadly Duo

2025
SCLC & Oncologic Screening · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gayibov Emin et al, Cureus, 2025 · Open-access full text

A systematic review and meta-analysis of lung cancer risk prediction models

2025
SCLC & Oncologic Screening · Acta Oncologica

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Khalife, Ghida et al, Acta Oncologica, 2025 · Open-access full text

An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer

Year not captured
SCLC & Oncologic Screening · Cancer Cell International

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zhang, Zhihui et al, Cancer Cell International · Open-access full text

Antibody Diversity in Cancer: Translational Implications and Beyond

2022
SCLC & Oncologic Screening · Vaccines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Reddy, Raghuram et al, Vaccines, 2022 · Open-access full text

Autoimmune Responses in Oncology: Causes and Significance

Year not captured
SCLC & Oncologic Screening · journal not recorded

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessFind full text on PubMedNo direct article URL was captured
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, journal not recorded · Find full text on PubMed

Distinct roles for SOX2 and SOX21 in differentiation, distribution and maturation of pulmonary neuroendocrine cells

2023
SCLC & Oncologic Screening · Cellular and Molecular Life Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Cellular and Molecular Life Sciences, 2023 · Publisher / database full text

Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancer

2023
SCLC & Oncologic Screening · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Broderick, Amanda et al, BMJ Case Reports, 2023 · Publisher / database full text

Genome Sequencing of Multiple Primary Lung Cancers Harbouring Mixed Histology and Spontaneously Regressing Small-Cell Lung Cancer

2024
SCLC & Oncologic Screening · Journal of Personalized Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Thomas, Valentina et al, Journal of Personalized Medicine, 2024 · Open-access full text

Imaging of central nervous system emergencies in oncology

2023
SCLC & Oncologic Screening · Emergency Radiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Bhattacharya, Kajari et al, Emergency Radiology, 2023 · Publisher / database full text

Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy

2022
SCLC & Oncologic Screening · Diagnostics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Albarrán-Artahona, Víctor et al, Diagnostics, 2022 · Open-access full text

Incomplete Unilateral Horner’s Syndrome Due to Superior Vena Cava Compression Syndrome Caused by Small Cell Lung Carcinoma

2024
SCLC & Oncologic Screening · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Finsterer Josef, Cureus, 2024 · Open-access full text

Initial screening for neuronal autoantibodies and their putative impact on survival in patients with small-cell lung cancer

2024
SCLC & Oncologic Screening · Thoracic Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Anne With Mikkelsen et al, Thoracic Cancer, 2024 · Open-access full text

Intramedullary spinal cord metastases from non-small cell lung carcinoma (NSCLC) associated with carcinomatous meningitis: a case report

2023
SCLC & Oncologic Screening · Journal of Radiotherapy in Practice

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
R D’Silva et al, Journal of Radiotherapy in Practice, 2023 · Publisher / database full text

Investigating suspected lung cancer

2022
SCLC & Oncologic Screening · BMJ : British Medical Journal (Online)

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Bradley, Stephen H et al, BMJ : British Medical Journal (Online), 2022 · Publisher / database full text

Lung Cancer: Diagnosis, Treatment Principles, and Screening

2022
SCLC & Oncologic Screening · American Family Physician

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kim, Jeffrey et al, American Family Physician, 2022 · Publisher / database full text

Lung neuroendocrine tumors: A systematic literature review (Review)

2022
SCLC & Oncologic Screening · Experimental and Therapeutic Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Savu, Cornel et al, Experimental and Therapeutic Medicine, 2022 · Publisher / database full text

Merkel cell carcinoma overlapping Bowen’s disease: two cases report and literature review

2024
SCLC & Oncologic Screening · Journal of Cancer Research & Clinical Oncology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Journal of Cancer Research & Clinical Oncology, 2024 · Publisher / database full text

Morphologic and molecular classification of lung neuroendocrine neoplasms

2021
SCLC & Oncologic Screening · Virchows Archiv

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Metovic Jasna et al, Virchows Archiv, 2021 · Open-access full text

Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications

2025
SCLC & Oncologic Screening · Signal Transduction and Targeted Therapy

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Signal Transduction and Targeted Therapy, 2025 · Publisher / database full text

Neuroendocrine neoplasms of the thymus

2024
SCLC & Oncologic Screening · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Barone, Paul D et al, Frontiers in Immunology, 2024 · Open-access full text

Redefining the Fight Against SCLC: Standards, Innovations, and New Horizons

2025
SCLC & Oncologic Screening · Cancers

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kemper, Marcel et al, Cancers, 2025 · Open-access full text

Signal pathways and precision therapy of small-cell lung cancer

2022
SCLC & Oncologic Screening · Signal Transduction and Targeted Therapy

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yuan, Min et al, Signal Transduction and Targeted Therapy, 2022 · Open-access full text

Subacute sensory neuronopathy associated with Merkel cell carcinoma with unknown primary: a case report with literature review

2022
SCLC & Oncologic Screening · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Milani, Riccardo et al, Journal of Neurology, 2022 · Publisher / database full text

Systemtherapie für das kleinzellige Lungenkarzinom im Stadium IV

2021
SCLC & Oncologic Screening · Der Onkologe

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Horn, Marlitt et al, Der Onkologe, 2021 · Publisher / database full text

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer

2023
SCLC & Oncologic Screening · Nature Communications

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ji, Yiyi et al, Nature Communications, 2023 · Open-access full text

The Surgical Management of Lung Neuroendocrine Neoplasms

2023
SCLC & Oncologic Screening · Cancers

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide context for why cancer evaluation matters after a LEMS diagnosis. They do not determine the screening schedule appropriate for an individual patient.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Soldath, Patrick et al, Cancers, 2023 · Open-access full text

A Breakdown of Immune Tolerance in the Cerebellum

2022
Autoimmune Encephalitis & CNS Neuroimmunology · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hampe, Christiane S et al, Brain Sciences, 2022 · Open-access full text

A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments

2023
Autoimmune Encephalitis & CNS Neuroimmunology · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lucian Eva et al, Biomedicines, 2023 · Open-access full text

A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution

2024
Autoimmune Encephalitis & CNS Neuroimmunology · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kudo, Akihiko et al, Journal of Neurology, 2024 · Publisher / database full text

Advances in the Pathogenesis of Auto-antibody-Induced Cerebellar Synaptopathies

2023
Autoimmune Encephalitis & CNS Neuroimmunology · The Cerebellum

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mitoma, Hiroshi et al, The Cerebellum, 2023 · Open-access full text

Autoantibodies in neurological disease

2021
Autoimmune Encephalitis & CNS Neuroimmunology · Nature Reviews. Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Nature Reviews. Immunology, 2021 · Publisher / database full text

Autoimmune astrocytopathy double negative for AQP4‐IgG and GFAP‐IgG: Retrospective research of clinical practice, biomarkers, and pathology

2024
Autoimmune Encephalitis & CNS Neuroimmunology · CNS Neuroscience & Therapeutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lin, Pei‐Hao et al, CNS Neuroscience & Therapeutics, 2024 · Open-access full text

Blood–Brain Barrier Disruption in Neuroimmunological Disease

2024
Autoimmune Encephalitis & CNS Neuroimmunology · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Shimizu, Fumitaka et al, International Journal of Molecular Sciences, 2024 · Open-access full text

Cerebellar long-term depression and auto-immune target of auto-antibodies: the concept of LTDpathies

2021
Autoimmune Encephalitis & CNS Neuroimmunology · Molecular Biomedicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mitoma, Hiroshi et al, Molecular Biomedicine, 2021 · Open-access full text

Clinical Characteristics and Management of 50 Patients with Anti-GAD Ataxia: Gluten-Free Diet Has a Major Impact

2021
Autoimmune Encephalitis & CNS Neuroimmunology · The Cerebellum

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hadjivassiliou, M et al, The Cerebellum, 2021 · Open-access full text

Clinical Features and Neuroimaging Findings of Neuropil Antibody–Positive Idiopathic Sporadic Ataxia of Unknown Etiology

2023
Autoimmune Encephalitis & CNS Neuroimmunology · The Cerebellum

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Takekoshi, Akira et al, The Cerebellum, 2023 · Publisher / database full text

Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China

2025
Autoimmune Encephalitis & CNS Neuroimmunology · CNS Neuroscience & Therapeutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Qiu, Zhandong et al, CNS Neuroscience & Therapeutics, 2025 · Open-access full text

Comparison of commercial and in-house tissue-based and cell-based assays for the detection of autoantibodies targeting neuronal surface proteins: a prospective cohort study

2025
Autoimmune Encephalitis & CNS Neuroimmunology · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Goncalves, David et al, Frontiers in Immunology, 2025 · Open-access full text

Consensus Paper: Latent Autoimmune Cerebellar Ataxia (LACA)

2024
Autoimmune Encephalitis & CNS Neuroimmunology · The Cerebellum

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Manto, Mario et al, The Cerebellum, 2024 · Open-access full text

Considering a new clinical presentation of the anti-Tr/DNER antibody-associated cerebellar ataxia

2023
Autoimmune Encephalitis & CNS Neuroimmunology · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Campana, Igor Gusmão et al, Neurological Sciences, 2023 · Publisher / database full text

Downbeat Nystagmus: Case Report, Updated Review, Therapeutics, and Neurorehabilitation

2025
Autoimmune Encephalitis & CNS Neuroimmunology · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Maxwell, Parker T et al, Brain Sciences, 2025 · Open-access full text

From Multiple Sclerosis to Organ-Specific Autoimmune Disorders: Insights into the Molecular and Clinical Implications of Comorbidity

2025
Autoimmune Encephalitis & CNS Neuroimmunology · Molecular Neurobiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Molecular Neurobiology, 2025 · Publisher / database full text

Gaze-holding and anti-GAD antibody: prototypic heterogeneous motor dysfunction in immune disease

2022
Autoimmune Encephalitis & CNS Neuroimmunology · The Cerebellum

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wanchat, Theeranaew et al, The Cerebellum, 2022 · Publisher / database full text

Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments

2023
Autoimmune Encephalitis & CNS Neuroimmunology · Applied Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Subramanian Thangaleela et al, Applied Sciences, 2023 · Open-access full text

Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective

2022
Autoimmune Encephalitis & CNS Neuroimmunology · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ndondo, Alvin Pumelele et al, Frontiers in Immunology, 2022 · Open-access full text

Rare Etiologies in Immune-Mediated Cerebellar Ataxias: Diagnostic Challenges

2022
Autoimmune Encephalitis & CNS Neuroimmunology · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hadjivassiliou, Marios et al, Brain Sciences, 2022 · Open-access full text

Sleep Disturbances Associated with Neurological Autoimmunity

2021
Autoimmune Encephalitis & CNS Neuroimmunology · Neurotherapeutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Devine, Michelle F et al, Neurotherapeutics, 2021 · Publisher / database full text

Steroid-responsive encephalopathy associated with autoimmune thyroiditis presenting with a postpartum psychosis

2022
Autoimmune Encephalitis & CNS Neuroimmunology · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Silva, Tânia et al, BMJ Case Reports, 2022 · Publisher / database full text

Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2

2020
Autoimmune Encephalitis & CNS Neuroimmunology · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Michael, Sophia et al, Practical Neurology, 2020 · Open-access full text

The Neuropathology of Autoimmune Ataxias

2022
Autoimmune Encephalitis & CNS Neuroimmunology · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Clark, H Brent, Brain Sciences, 2022 · Open-access full text

The study of neural antibodies in neurology: A practical summary

2022
Autoimmune Encephalitis & CNS Neuroimmunology · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. The category is useful for understanding overlapping antibodies or rare combined syndromes, not for describing typical LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Fernández-Fournier, Mireya et al, Frontiers in Immunology, 2022 · Open-access full text

Arthrogryposis Multiplex Congenita: Comprehensive Review from a Neuromuscular Standpoint

2026
Neuromuscular Differential Diagnoses · Genes

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Seneor Daniel Delgado et al, Genes, 2026 · Open-access full text

The Eyes Have It: A Man with Ophthalmoplegia and Dyspnea

2026
Neuromuscular Differential Diagnoses · NEJM Clinician

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gayed, Salma M.A. et al, NEJM Clinician, 2026 · Publisher / database full text

The Eyes Have It

2026
Neuromuscular Differential Diagnoses · The New England Journal of Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gayed, Salma M.A. et al, The New England Journal of Medicine, 2026 · Publisher / database full text

Blood–Nerve Barrier Breakdown Induced by Immunoglobulin G in Typical and Multifocal Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy

2026
Neuromuscular Differential Diagnoses · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Shimizu Fumitaka et al, International Journal of Molecular Sciences, 2026 · Open-access full text

Autoimmune Neuromuscular Disorders at a Molecular Crossroad: Linking Pathogenesis to Targeted Immunotherapy

2025
Neuromuscular Differential Diagnoses · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Anca-Maria, Florea et al, International Journal of Molecular Sciences, 2025 · Open-access full text

From gastrointestinal upset to neuromuscular collapse

2025
Neuromuscular Differential Diagnoses · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Faraaz, Ahmed et al, Practical Neurology, 2025 · Publisher / database full text

A case of anti-myelin-associated glycoprotein polyneuropathy and multiple sclerosis: one disease instead of two?

2025
Neuromuscular Differential Diagnoses · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sotgiu Stefano et al, BMJ Case Reports, 2025 · Publisher / database full text

A Comprehensive Review of Neuromuscular Manifestations of COVID-19 and Management of Pre-Existing Neuromuscular Disorders in Children

2022
Neuromuscular Differential Diagnoses · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Goetschius, Daniel J et al, Journal of Clinical Medicine, 2022 · Open-access full text

Acute and chronic dysimmune polyneuropathies in the context of the COVID-19 pandemic: pathogenesis, features of the clinical picture, diagnosis and therapy (literature review)

2021
Neuromuscular Differential Diagnoses · Nervno-Myše čnye Bolezni= Neuromuscular Diseases

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Khrulev, A E et al, Nervno-Myše čnye Bolezni= Neuromuscular Diseases, 2021 · Open-access full text

Acute Respiratory Failure Due to Inaugural Myasthenia Crisis

2024
Neuromuscular Differential Diagnoses · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ntawuruhunga, Irene N et al, Cureus, 2024 · Open-access full text

Advancing research in autoimmune neuromuscular disorders

2022
Neuromuscular Differential Diagnoses · The Lancet Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sanders, Donald B, The Lancet Neurology, 2022 · Publisher / database full text

Aggregating the Loose Threads

2024
Neuromuscular Differential Diagnoses · The New England Journal of Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Davey, Sonya et al, The New England Journal of Medicine, 2024 · Publisher / database full text

An Overview of Mitochondrial Protein Defects in Neuromuscular Diseases

2021
Neuromuscular Differential Diagnoses · Biomolecules

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Marra, Federica et al, Biomolecules, 2021 · Open-access full text

An Uncommon Presentation of Guillain-Barré Syndrome With Lhermitte Sign

2025
Neuromuscular Differential Diagnoses · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Santos Madalena et al, Cureus, 2025 · Open-access full text

Autoimmune Neurogenic Dysphagia

2022
Neuromuscular Differential Diagnoses · Dysphagia

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Stathopoulos, Panos et al, Dysphagia, 2022 · Open-access full text

Axial muscle weakness

2021
Neuromuscular Differential Diagnoses · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Waheed, Waqar et al, Practical Neurology, 2021 · Publisher / database full text

Bedside and laboratory diagnostic testing in myasthenia

2022
Neuromuscular Differential Diagnoses · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yoganathan Katie et al, Journal of Neurology, 2022 · Open-access full text

Biomarkers in 5q-associated spinal muscular atrophy—a narrative review

2023
Neuromuscular Differential Diagnoses · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lapp, H. S. et al, Journal of Neurology, 2023 · Open-access full text

Bulbar Onset Amyotrophic Lateral Sclerosis in an African American Older Adult

2023
Neuromuscular Differential Diagnoses · The Ochsner Journal

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kasindi, Arielle et al, The Ochsner Journal, 2023 · Open-access full text

Case 19-2023: An 80-Year-Old Man with Left Foot Drop

2023
Neuromuscular Differential Diagnoses · The New England Journal of Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
González-Pérez, Paloma et al, The New England Journal of Medicine, 2023 · Publisher / database full text

Case 3-2024: An 8-Week-Old Male Infant with Inconsolable Crying and Weakness

2024
Neuromuscular Differential Diagnoses · The New England Journal of Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Berkwitt, Adam et al, The New England Journal of Medicine, 2024 · Publisher / database full text

Case 32-2024: A 72-Year-Old Woman with Dyspnea, Dysphagia, and Dysarthria

2024
Neuromuscular Differential Diagnoses · The New England Journal of Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sherman, Stephanie V et al, The New England Journal of Medicine, 2024 · Publisher / database full text

Challenges in the Diagnosis and Management of the Miller Fisher Variant of Guillain-Barré Syndrome: A Case Report

2025
Neuromuscular Differential Diagnoses · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ehsan Evan et al, Cureus, 2025 · Open-access full text

Characteristics of pupil palsy in miller-fisher syndrome: case reports and review of the literature

2021
Neuromuscular Differential Diagnoses · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lee Jang Ho et al, Neurological Sciences, 2021 · Publisher / database full text

Chronic Inflammatory Demyelinating Polyneuropathy With Reversible Severe Cognitive Impairment and Gastrointestinal Dysfunction

2023
Neuromuscular Differential Diagnoses · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Patrick, Madison M et al, Cureus, 2023 · Open-access full text

Circulating Biomarkers in Neuromuscular Disorders: What Is Known, What Is New

Year not captured
Neuromuscular Differential Diagnoses · journal not recorded

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessFind full text on PubMedNo direct article URL was captured
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, journal not recorded · Find full text on PubMed

Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience

2023
Neuromuscular Differential Diagnoses · Life

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Shalata, Walid et al, Life, 2023 · Open-access full text

Development of a high-throughput tailored imaging method in zebrafish to understand and treat neuromuscular diseases

2022
Neuromuscular Differential Diagnoses · Frontiers in Molecular Neuroscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lescouzères, Léa et al, Frontiers in Molecular Neuroscience, 2022 · Open-access full text

Diagnosis and treatment of neurogenic dysphagia – S1 guideline of the German Society of Neurology

2021
Neuromuscular Differential Diagnoses · Neurological Research and Practice

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dziewas Rainer et al, Neurological Research and Practice, 2021 · Open-access full text

Diagnostic Pitfalls in Guillain–Barré Syndrome: Case Report and Literature Review

2022
Neuromuscular Differential Diagnoses · Children

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lupu, Vasile Valeriu et al, Children, 2022 · Open-access full text

Die Bedeutung neurophysiologischer Methoden in der Abklärung neuropädiatrischer und neuromuskulärer Erkrankungen

2023
Neuromuscular Differential Diagnoses · Monatsschrift Kinderheilkunde

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Broser, P. J. et al, Monatsschrift Kinderheilkunde, 2023 · Publisher / database full text

Distal upper limb involvement in myasthenia-myositis association

2023
Neuromuscular Differential Diagnoses · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lauletta, Antonio et al, Neurological Sciences, 2023 · Publisher / database full text

Dropped head as presenting sign of acute motor and sensory neuropathy with reversible conduction failure

2023
Neuromuscular Differential Diagnoses · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Fabbrini, Andrea et al, Neurological Sciences, 2023 · Publisher / database full text

Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment

2020
Neuromuscular Differential Diagnoses · Frontiers in Pharmacology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Menduti, Giovanna et al, Frontiers in Pharmacology, 2020 · Open-access full text

Dysphagia caused by ptosis

2025
Neuromuscular Differential Diagnoses · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tsunoda, Koichi et al, BMJ Case Reports, 2025 · Publisher / database full text

Essential neuromuscular advice for pathologists (first of two parts)

2024
Neuromuscular Differential Diagnoses · Surgical and Experimental Pathology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Surgical and Experimental Pathology, 2024 · Open-access full text

Gasping for Strength

2025
Neuromuscular Differential Diagnoses · The New England Journal of Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zarhin, Daniel et al, The New England Journal of Medicine, 2025 · Publisher / database full text

Genetic Profile of Patients with Limb-Girdle Muscle Weakness in the Chilean Population

2022
Neuromuscular Differential Diagnoses · Genes

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Cerino, Mathieu et al, Genes, 2022 · Open-access full text

Guillain–Barré syndrome in low-income and middle-income countries: challenges and prospects

2021
Neuromuscular Differential Diagnoses · Nature Reviews. Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Nature Reviews. Neurology, 2021 · Publisher / database full text

Guillain–Barré syndrome – diagnosis and treatment based on the 2023 EAN/PNS criteria

2025
Neuromuscular Differential Diagnoses · Current Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Golińska, Maria, Current Neurology, 2025 · Publisher / database full text

High risk and low prevalence diseases: Guillain-Barré syndrome

2024
Neuromuscular Differential Diagnoses · The American Journal of Emergency Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Madden, Joshua et al, The American Journal of Emergency Medicine, 2024 · Publisher / database full text

Ice Pack Test Eased Ptosis in a Patient Presenting with a Possible Oculomotor Nerve Schwannoma: A Case Report

2021
Neuromuscular Differential Diagnoses · Neurology International

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Buechner, Susanne et al, Neurology International, 2021 · Open-access full text

In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy

2021
Neuromuscular Differential Diagnoses · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Brain Sciences, 2021 · Open-access full text

In‐depth peripheral CD4+ T profile correlates with myasthenic crisis

2021
Neuromuscular Differential Diagnoses · Annals of Clinical and Translational Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Xiao Huan et al, Annals of Clinical and Translational Neurology, 2021 · Open-access full text

Isolated proximal weakness of the legs due to neuroborreliosis

2021
Neuromuscular Differential Diagnoses · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nibourg, Simone et al, BMJ Case Reports, 2021 · Publisher / database full text

Longitudinal prospective cohort study to assess peripheral motor function with extensive electrophysiological techniques in patients with Spinal Muscular Atrophy (SMA): the SMA Motor Map protocol

2023
Neuromuscular Differential Diagnoses · BMC Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ros, Leandra A A et al, BMC Neurology, 2023 · Open-access full text

Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic

2021
Neuromuscular Differential Diagnoses · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Costamagna Gianluca et al, Journal of Neurology, 2021 · Open-access full text

Mapping the current evidence on the anesthetic management of adult patients with neuromuscular disorders—a scoping review

2022
Neuromuscular Differential Diagnoses · Canadian Journal of Anesthesia

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
van den Bersselaar Luuk R et al, Canadian Journal of Anesthesia, 2022 · Open-access full text

Mitochondrial Chronic Progressive External Ophthalmoplegia

2024
Neuromuscular Differential Diagnoses · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ali, Ali et al, Brain Sciences, 2024 · Open-access full text

MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation

2021
Neuromuscular Differential Diagnoses · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
König, Nicole et al, Journal of Neurology, 2021 · Open-access full text

Myotonic dystrophy: a cause of acute breathlessness not to be missed

2021
Neuromuscular Differential Diagnoses · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kramarz, Caroline et al, Practical Neurology, 2021 · Publisher / database full text

Neurological Mystery Post Travel: An Atypical Presentation and Partial Recovery With Immunotherapy

2025
Neuromuscular Differential Diagnoses · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Pootharamanna Variyath Mukundan Prasobh et al, Cureus, 2025 · Open-access full text

Neurosurgical Intervention for Nerve and Muscle Biopsies

2024
Neuromuscular Differential Diagnoses · Diagnostics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mohamed, Ali A et al, Diagnostics, 2024 · Open-access full text

Objective Evaluation of Clinical Actionability for Genes Involved in Myopathies: 63 Genes with a Medical Value for Patient Care

2022
Neuromuscular Differential Diagnoses · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Vecten, Maude et al, International Journal of Molecular Sciences, 2022 · Open-access full text

Post-traumatic (and postsurgical) Guillain-Barré Syndrome: a rare, but treatable entity

2021
Neuromuscular Differential Diagnoses · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Grote, Helen et al, BMJ Case Reports, 2021 · Publisher / database full text

Problem-solving in clinical practice: breathing difficulty and muscle weakness following allogeneic haematopoietic stem cell transplantation

2021
Neuromuscular Differential Diagnoses · Archives of Disease in Ch ildhood. Education and Practice Edition

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Albulushi, Bashaer et al, Archives of Disease in Ch ildhood. Education and Practice Edition, 2021 · Publisher / database full text

Progressive motor quadriparesis with wasting: a diagnostic conundrum

2022
Neuromuscular Differential Diagnoses · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Panda, Samhita et al, BMJ Case Reports, 2022 · Publisher / database full text

Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges

2024
Neuromuscular Differential Diagnoses · Genes

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Umme Sabrina Haque et al, Genes, 2024 · Open-access full text

Sensory Ganglionopathy

2020
Neuromuscular Differential Diagnoses · The New England Journal of Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ropper, Allan H, The New England Journal of Medicine, 2020 · Publisher / database full text

Skin Biopsy as a Novel Diagnostic Aid in Immune-Mediated Neuropathies

2022
Neuromuscular Differential Diagnoses · Journal of Neuropathology and Experimental Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Young, Gi Min et al, Journal of Neuropathology and Experimental Neurology, 2022 · Publisher / database full text

Spinal Muscular Atrophy: Current Medications and Re-purposed Drugs

2024
Neuromuscular Differential Diagnoses · Cellular and Molecular Neurobiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Basak, Soumyadutta et al, Cellular and Molecular Neurobiology, 2024 · Open-access full text

Systematic approach to contextualize findings of flexible endoscopic evaluation of swallowing in neurogenic dysphagia– towards an integrated FEES report

2024
Neuromuscular Differential Diagnoses · Neurological Research and Practice

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dziewas, Rainer et al, Neurological Research and Practice, 2024 · Open-access full text

The role of protein glycosylation in muscle diseases

2022
Neuromuscular Differential Diagnoses · Molecular Biology Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dang, Kai et al, Molecular Biology Reports, 2022 · Publisher / database full text

Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders

2022
Neuromuscular Differential Diagnoses · Neurological Research and Practice

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Jablonka Sibylle et al, Neurological Research and Practice, 2022 · Open-access full text

Thyrotoxic Myopathy with Nonspecific Ophthalmopathy in a Two-Year-Old Child: Case Report and Literature Review

2024
Neuromuscular Differential Diagnoses · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Smółka, Katarzyna et al, Journal of Clinical Medicine, 2024 · Open-access full text

Ultrasound assessment of diaphragmatic dysfunction in non-critically ill patients: relevant indicators and update

2024
Neuromuscular Differential Diagnoses · Frontiers in Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Xin-Yu, Yao et al, Frontiers in Medicine, 2024 · Open-access full text

Unusual cause of muscle weakness, type II respiratory failure and pulmonary hypertension: a case report of ryanodine receptor type 1( RYR1) -related myopathy

2024
Neuromuscular Differential Diagnoses · BMC Pulmonary Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chen, Yinong et al, BMC Pulmonary Medicine, 2024 · Open-access full text

Usefulness and Clinical Impact of Whole-Body MRI in Detecting Autoimmune Neuromuscular Disorders

2023
Neuromuscular Differential Diagnoses · Brain Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Pace, Mario et al, Brain Sciences, 2023 · Open-access full text

Ventilatory failure in chronic neuromuscular disease

2023
Neuromuscular Differential Diagnoses · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Long, Gabriella Heloise et al, Practical Neurology, 2023 · Publisher / database full text

Very Early Involvement of Innate Immunity in Peripheral Nerve Degeneration in SOD1-G93A Mice

2020
Neuromuscular Differential Diagnoses · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Angelini, Daniela Francesca et al, Frontiers in Immunology, 2020 · Open-access full text

Weak gluteus maximus and weak iliopsoas with normal gluteus maximus: Two complementary new signs to diagnose lower limb functional weakness

2023
Neuromuscular Differential Diagnoses · Brain and Behavior

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sonoo, Masahiro et al, Brain and Behavior, 2023 · Open-access full text

Weakness in the intensive care unit

2022
Neuromuscular Differential Diagnoses · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Walters, Jon, Practical Neurology, 2022 · Publisher / database full text

Weaning and extubation failure in myasthenic crisis: a multicenter analysis

2024
Neuromuscular Differential Diagnoses · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They help explain diagnostic delay and what clinicians may need to rule out, but most do not add new facts about LEMS itself.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Neumann, Bernhard et al, Journal of Neurology, 2024 · Publisher / database full text

Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort

2026
Immunotherapy & Immunomodulation (non-LEMS) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Stögbauer, Jakob et al, Frontiers in Immunology, 2026 · Open-access full text

Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review

2025
Immunotherapy & Immunomodulation (non-LEMS) · Neurology International

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Takahashi Seiya et al, Neurology International, 2025 · Open-access full text

Anti-Idiotypic mRNA Vaccine to Treat Autoimmune Disorders

2024
Immunotherapy & Immunomodulation (non-LEMS) · Vaccines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Niazi, Sarfaraz K, Vaccines, 2024 · Open-access full text

Complement in neurological disorders and emerging complement-targeted therapeutics

2020
Immunotherapy & Immunomodulation (non-LEMS) · Nature Reviews. Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Nature Reviews. Neurology, 2020 · Publisher / database full text

Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19

2021
Immunotherapy & Immunomodulation (non-LEMS) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hofstadt-van Oy Ulrich et al, Journal of Neurology, 2021 · Publisher / database full text

Complement system activation: bridging physiology, pathophysiology, and therapy

2024
Immunotherapy & Immunomodulation (non-LEMS) · Intensive Care Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Azoulay, Elie et al, Intensive Care Medicine, 2024 · Publisher / database full text

Current Desensitization Strategies in Heart Transplantation

2021
Immunotherapy & Immunomodulation (non-LEMS) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Habal, Marlena V, Frontiers in Immunology, 2021 · Open-access full text

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement

2023
Immunotherapy & Immunomodulation (non-LEMS) · JCI Insight

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nelke, Christopher et al, JCI Insight, 2023 · Open-access full text

Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved

2025
Immunotherapy & Immunomodulation (non-LEMS) · Immuno

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Justiz-Vaillant Angel et al, Immuno, 2025 · Open-access full text

From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases

2024
Immunotherapy & Immunomodulation (non-LEMS) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Bulliard, Yannick et al, Frontiers in Immunology, 2024 · Open-access full text

Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update

2023
Immunotherapy & Immunomodulation (non-LEMS) · Bioengineering

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mariottini, Alice et al, Bioengineering, 2023 · Open-access full text

Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy

2025
Immunotherapy & Immunomodulation (non-LEMS) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Liang, Zhenguo et al, Frontiers in Immunology, 2025 · Open-access full text

Immunoglobulin use in neurology: a practical approach

2024
Immunotherapy & Immunomodulation (non-LEMS) · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kapoor, Mahima et al, Practical Neurology, 2024 · Publisher / database full text

Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature

2020
Immunotherapy & Immunomodulation (non-LEMS) · Nature Reviews. Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Korsukewitz Catharina et al, Nature Reviews. Neurology, 2020 · Publisher / database full text

Neuroprotective Effect of Polyvalent Immunoglobulins on Mouse Models of Chemotherapy-Induced Peripheral Neuropathy

2024
Immunotherapy & Immunomodulation (non-LEMS) · Pharmaceutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mroué, Mohamad et al, Pharmaceutics, 2024 · Open-access full text

P.060 Immunoglobulin Use For Neuromuscular Conditions: Updating British Columbia Provincial Guidelines Through Focused Literature Review

2021
Immunotherapy & Immunomodulation (non-LEMS) · Canadian Journal of Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tse, E K et al, Canadian Journal of Neurological Sciences, 2021 · Publisher / database full text

Plasmapheresis in the ICU

2023
Immunotherapy & Immunomodulation (non-LEMS) · Medicina

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Guleid Hussein et al, Medicina, 2023 · Open-access full text

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis

2023
Immunotherapy & Immunomodulation (non-LEMS) · Pharm aceutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wiesinger, Anna-Maria et al, Pharm aceutics, 2023 · Open-access full text

Sequential immunotherapy: towards cures for autoimmunity

2024
Immunotherapy & Immunomodulation (non-LEMS) · Nature Reviews. Drug Discovery

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ramírez-Valle, Francisco et al, Nature Reviews. Drug Discovery, 2024 · Publisher / database full text

Therapeutic Plasma Exchange: For Cancer Patients

2022
Immunotherapy & Immunomodulation (non-LEMS) · Cancer Management and Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY-NC 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Hu, Yuru et al, Cancer Management and Research, 2022 · Open-access full text

Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy

2021
Immunotherapy & Immunomodulation (non-LEMS) · Neurotherapeutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dalakas, Marinos C et al, Neurotherapeutics, 2021 · Open-access full text

Vaccination and immunotherapies in neuroimmunological diseases

2022
Immunotherapy & Immunomodulation (non-LEMS) · Nature Reviews. Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Winkelmann, Alexander et al, Nature Reviews. Neurology, 2022 · Publisher / database full text

‘Immune reset plus’: the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases

2025
Immunotherapy & Immunomodulation (non-LEMS) · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They may generate hypotheses for future LEMS research. Benefit in another autoimmune condition is not proof of benefit in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gaspal, Fabrina et al, Frontiers in Immunology, 2025 · Open-access full text

Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment

2025
Autonomic Dysfunction / Dysautonomia (non-LEMS) · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide background for symptoms that can occur in LEMS, but are not evidence about how common or treatable those symptoms are in LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Weinstock, Leonard B et al, BMJ Case Reports, 2025 · Open-access full text

35th International symposium on the autonomic nervous system

2024
Autonomic Dysfunction / Dysautonomia (non-LEMS) · Clinical Autonomic Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide background for symptoms that can occur in LEMS, but are not evidence about how common or treatable those symptoms are in LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Clinical Autonomic Research, 2024 · Publisher / database full text

A Review on Autonomic Functional Assessment in Diabetic Patients

2023
Autonomic Dysfunction / Dysautonomia (non-LEMS) · Cureus

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide background for symptoms that can occur in LEMS, but are not evidence about how common or treatable those symptoms are in LEMS.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Charushila, Rukadikar et al, Cureus, 2023 · Open-access full text

Autoimmune Autonomic Neuropathy: From Pathogenesis to Diagnosis

2024
Autonomic Dysfunction / Dysautonomia (non-LEMS) · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide background for symptoms that can occur in LEMS, but are not evidence about how common or treatable those symptoms are in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Nakane, Shunya et al, International Journal of Molecular Sciences, 2024 · Open-access full text

Nonregional small fibre neuropathy in cases of autoimmune autonomic neuropathy

2022
Autonomic Dysfunction / Dysautonomia (non-LEMS) · Journal of Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide background for symptoms that can occur in LEMS, but are not evidence about how common or treatable those symptoms are in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Maier, Andrea et al, Journal of Neurology, 2022 · Open-access full text

Reflections on the past three decades of autonomic neurology

2021
Autonomic Dysfunction / Dysautonomia (non-LEMS) · Clinical Autonomic Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide background for symptoms that can occur in LEMS, but are not evidence about how common or treatable those symptoms are in LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Low, Phillip, Clinical Autonomic Research, 2021 · Publisher / database full text

The Prevalence of Orthostatic Hypotension in Cancer Patients

2024
Autonomic Dysfunction / Dysautonomia (non-LEMS) · Cancers

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They provide background for symptoms that can occur in LEMS, but are not evidence about how common or treatable those symptoms are in LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Iwański, Mateusz A et al, Cancers, 2024 · Open-access full text

Assessing the socio-economic burden of inherited and inflammatory neuromuscular diseases (BIND study): a study protocol

2025
Quality of Life / Disease Burden (non-LEMS) · Orphanet Journal of Rare Diseases

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. It may help interpret measurement tools, but it should not be used to estimate the burden of LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Smith, Ian C. et al, Orphanet Journal of Rare Diseases, 2025 · Open-access full text

Basic Clinical Bidirectional Empowerment: Synergistic Breakthrough in Molecular Mechanisms and Clinical Management of Small Cell Cervical Carcinoma

2026
Genuinely tangential / search artifact · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Huang Mengjia et al, International Journal of Molecular Sciences, 2026 · Open-access full text

Obstructive Sleep Apnea After Supracricoid Laryngeal Surgery (OPHL II): A Monocentric Prospective Pilot Study

2026
Genuinely tangential / search artifact · Cancers

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mesolella Massimo et al, Cancers, 2026 · Open-access full text

Multivariate genetic analysis reveals three distinct pathological dimensions in musculoskeletal disorders

2026
Genuinely tangential / search artifact · Nature Communications

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gong, Weiming et al, Nature Communications, 2026 · Open-access full text

Pharmacokinetics and Drug Interactions

2026
Genuinely tangential / search artifact · Pharmaceutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Min-Koo, Choi et al, Pharmaceutics, 2026 · Open-access full text

Sleep Architecture Alterations Following High‐Dose Steroid Pulse Therapy: A Pilot Study Using a Portable Electroencephalogram‐Based Device

2025
Genuinely tangential / search artifact · Neuropsychopharmacology Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Endo, Hiroki et al, Neuropsychopharmacology Reports, 2025 · Open-access full text

Mononeuritis multiplex in a patient with B-cell prolymphocytic leukaemia: a diagnostic challenge

2025
Genuinely tangential / search artifact · BMJ Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Le Clech Lenaïg et al, BMJ Case Reports, 2025 · Publisher / database full text

Reversible Bilateral Fixed Dilated Pupils in Hypercapnic Respiratory Failure Following Chronic Graft Versus Host Disease: A Case Report and Review of Literature

2025
Genuinely tangential / search artifact · Clinical Case Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Shirani, Aria et al, Clinical Case Reports, 2025 · Open-access full text

Immunoglobulin G Subclass-Specific Glycosylation Changes in Rheumatoid Arthritis

2025
Genuinely tangential / search artifact · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Szabó Dániel et al, International Journal of Molecular Sciences, 2025 · Open-access full text

A 29-year-old woman with recurrent syncope: CMAJ

2023
Genuinely tangential / search artifact · Canadian Medical Association. Journal:

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ducas-Mowchun, Kaleigh, MD et al, Canadian Medical Association. Journal:, 2023 · Publisher / database full text

A First Case of Acute Flaccid Myelitis Related to Enterovirus D68 in Belgium: Case Report

2024
Genuinely tangential / search artifact · Case Reports in Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Rodesch, Marine et al, Case Reports in Neurology, 2024 · Publisher / database full text

A Novel Type of Extreme Insulin Resistance: Nonhypoglycemic Insulin Autoimmune Syndrome

2021
Genuinely tangential / search artifact · The Journal of Clinical Endocrinology and Metabolism

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Liu, He et al, The Journal of Clinical Endocrinology and Metabolism, 2021 · Publisher / database full text

Abstracts of the 51st Annual Conference of the Italian Society of Neurology

2020
Genuinely tangential / search artifact · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Neurological Sciences, 2020 · Publisher / database full text

Abstracts of the 52nd Annual Conference of the Italian Society of Neurology

2022
Genuinely tangential / search artifact · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Neurological Sciences, 2022 · Publisher / database full text

Abstracts of the 53 Annual Conference of the Italian Society of Neurology

2023
Genuinely tangential / search artifact · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Neurological Sciences, 2023 · Publisher / database full text

Abstracts of the 54th Annual Conference of the Italian Society of Neurology

2024
Genuinely tangential / search artifact · Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Neurological Sciences, 2024 · Publisher / database full text

Abstracts of the 79th Annual Meeting of the Japanese Cancer Association; 2020 Oct 1‐3; Hiroshima, Japan as Cancer Science, Supplement 1, Vol 112 (2021)

2021
Genuinely tangential / search artifact · Cancer Science

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Cancer Science, 2021 · Publisher / database full text

Altered glycosylation profiles of serum IgG in Takayasu arteritis

2023
Genuinely tangential / search artifact · European Journal of Medical Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Liu, Lingyu et al, European Journal of Medical Research, 2023 · Open-access full text

An Autoantigen Atlas From Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19

2022
Genuinely tangential / search artifact · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wang, Julia Y et al, Frontiers in Immunology, 2022 · Open-access full text

Autoimmune Disease Classification Based on PubMed Text Mining

2022
Genuinely tangential / search artifact · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Samuels, Hadas et al, Journal of Clinical Medicine, 2022 · Open-access full text

Autoimmune disease: a view of epigenetics and therapeutic targeting

2024
Genuinely tangential / search artifact · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mu, Siqi et al, Frontiers in Immunology, 2024 · Open-access full text

BAFF 60-mer, and Differential BAFF 60-mer Dissociating Activities in Human Serum, Cord Blood and Cerebrospinal Fluid

2020
Genuinely tangential / search artifact · Frontiers in Cell and Developmental Biology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Eslami, Mahya et al, Frontiers in Cell and Developmental Biology, 2020 · Open-access full text

Blood-Brain Barrier Dysfunction Amplifies the Development of Neuroinflammation: Understanding of Cellular Events in Brain Microvascular Endothelial Cells for Prevention and Treatment of BBB Dysfunction

2021
Genuinely tangential / search artifact · Frontiers in Cellular Neuroscience

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Takata, Fuyuko et al, Frontiers in Cellular Neuroscience, 2021 · Open-access full text

Brugada Syndrome: More than a Monogenic Channelopathy

2023
Genuinely tangential / search artifact · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Liantonio, Antonella et al, Biomedicines, 2023 · Open-access full text

Carcinomatous meningitis from ovarian serous carcinoma: A case report

2023
Genuinely tangential / search artifact · Oncology Letters

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Uchikura, Eijiro et al, Oncology Letters, 2023 · Publisher / database full text

Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases

2023
Genuinely tangential / search artifact · Journal of Pharmacokinetics and Pharmacodynamics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Durairaj, Chandrasekar et al, Journal of Pharmacokinetics and Pharmacodynamics, 2023 · Publisher / database full text

Clonal redemption of B cells in cancer

2023
Genuinely tangential / search artifact · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
McCaw, Tyler R et al, Frontiers in Immunology, 2023 · Open-access full text

Coenzyme Q10 and Autoimmune Disorders: An Overview

2024
Genuinely tangential / search artifact · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mantle, David et al, International Journal of Molecular Sciences, 2024 · Open-access full text

Comparison of B-Cell Lupus and Lymphoma Using a Novel Immune Imbalance Transcriptomics Algorithm Reveals Potential Therapeutic Targets

2024
Genuinely tangential / search artifact · Genes

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Rapier-Sharman, Naomi et al, Genes, 2024 · Open-access full text

Converged avenues: depression and Alzheimer’s disease– shared pathophysiology and novel therapeutics

2024
Genuinely tangential / search artifact · Molecular Biology Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Molecular Biology Reports, 2024 · Publisher / database full text

COVID-19 ve Nöroloji

2021
Genuinely tangential / search artifact · Dicle Tip Dergisi

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Öztürk, Ünal et al, Dicle Tip Dergisi, 2021 · Open-access full text

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

2020
Genuinely tangential / search artifact · Drugs in R & D (Online)

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Macklis, Paul C. et al, Drugs in R & D (Online), 2020 · Open-access full text

Declining use of neurological eponyms in cases where a non-eponymous alternative exists

2021
Genuinely tangential / search artifact · Clinical Neurology and Neurosurgery

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Becker, Christopher J et al, Clinical Neurology and Neurosurgery, 2021 · Publisher / database full text

Design and Validation of a Human Brain Endothelial Microvessel-on-a-Chip Open Microfluidic Model Enabling Advanced Optical Imaging

2020
Genuinely tangential / search artifact · Frontiers in Bioengineering and Biotechnology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Salman, Mootaz M et al, Frontiers in Bioengineering and Biotechnology, 2020 · Open-access full text

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR

2021
Genuinely tangential / search artifact · Journal for Immunotherapy of Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY-NC 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Bayless, Nicholas L et al, Journal for Immunotherapy of Cancer, 2021 · Open-access full text

Diagnosis and management of autoimmune diseases in the ICU

2024
Genuinely tangential / search artifact · Intensive Care Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dumas, Guillaume et al, Intensive Care Medicine, 2024 · Publisher / database full text

Diagnostyka 2-letniej pacjentki z niedomykaniem jamy ustnej i zaburzeniami funkcji oralnych o nieznanej etiologii - opis przypadku

2024
Genuinely tangential / search artifact · Paediatrics and Family Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Grobelczyk, Agnieszka et al, Paediatrics and Family Medicine, 2024 · Publisher / database full text

Drug-Induced Podocytopathies: Report of Four Cases and Review of the Literature

2023
Genuinely tangential / search artifact · Life

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Athanasopoulou, Diamanto et al, Life, 2023 · Open-access full text

Editors’ commentary

2025
Genuinely tangential / search artifact · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Smith, Phil et al, Practical Neurology, 2025 · Publisher / database full text

Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic

2021
Genuinely tangential / search artifact · Molecular Neurobiology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dewanjee Saikat et al, Molecular Neurobiology, 2021 · Publisher / database full text

Genetic Predisposition to Schizophrenia and Depressive Disorder Comorbidity

2022
Genuinely tangential / search artifact · Genes

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Shnayder, Natalia A et al, Genes, 2022 · Open-access full text

Glycobiology of rheumatic diseases

2023
Genuinely tangential / search artifact · Nature Reviews. Rheumatology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Nature Reviews. Rheumatology, 2023 · Publisher / database full text

Glycosaminoglycans, Instructive Biomolecules That Regulate Cellular Activity and Synaptic Neuronal Control of Specific Tissue Functional Properties

2025
Genuinely tangential / search artifact · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Melrose, James et al, International Journal of Molecular Sciences, 2025 · Open-access full text

Glycosylation: mechanisms, biological functions and clinical implications

2024
Genuinely tangential / search artifact · Signal Transduction and Targeted Therapy

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
He, Mengyuan et al, Signal Transduction and Targeted Therapy, 2024 · Open-access full text

Health anxiety in a neurological setting

2025
Genuinely tangential / search artifact · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Green, Huw et al, Practical Neurology, 2025 · Publisher / database full text

Immunoglobulin G N-glycan Biomarkers for Autoimmune Diseases: Current State and a Glycoinformatics Perspective

2022
Genuinely tangential / search artifact · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Flevaris, Konstantinos et al, International Journal of Molecular Sciences, 2022 · Open-access full text

Immunoglobulin Glycosylation – An Unexploited Potential for Immunomodulatory Strategies in Farm Animals

2021
Genuinely tangential / search artifact · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Zlatina, Kristina et al, Frontiers in Immunology, 2021 · Open-access full text

Indene-Derived Hydrazides Targeting Acetylcholinesterase Enzyme in Alzheimer’s: Design, Synthesis, and Biological Evaluation

2023
Genuinely tangential / search artifact · Pharmaceutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Shraddha Manish Gupta et al, Pharmaceutics, 2023 · Open-access full text

LINC00662 Promotes Proliferation and Invasion and Inhibits Apoptosis of Glioma Cells Through miR-483-3p/SOX3 Axis

2022
Genuinely tangential / search artifact · Applied Biochemistry and Biotechnology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yuan, Lei et al, Applied Biochemistry and Biotechnology, 2022 · Publisher / database full text

MANAGEMENT IMPLICATIONS FOR NEUROTOXIC EFFECTS ASSOCIATED WITH ANTIBIOTIC USE.

2022
Genuinely tangential / search artifact · NeuroQuantology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dubey, Anubhav et al, NeuroQuantology, 2022 · Publisher / database full text

Membrane-wide screening identifies potential tissue-specific determinants of SARS-CoV-2 tropism

2025
Genuinely tangential / search artifact · PLoS Pathogens

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Dinesh, Ravi K et al, PLoS Pathogens, 2025 · Open-access full text

Nanoflowers Templated CuO/Cu Hybrid Metasurface for Sensitive THz‐TDS Detection of Acetylcholine

2024
Genuinely tangential / search artifact · Advanced Sensor Research

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lee, Soo Hyun et al, Advanced Sensor Research, 2024 · Open-access full text

Neurological Complications of COVID-19: Underlying Mechanisms and Management

Year not captured
Genuinely tangential / search artifact · journal not recorded

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessFind full text on PubMedNo direct article URL was captured
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, journal not recorded · Find full text on PubMed

Neurological eponyms? Take your Pick

2024
Genuinely tangential / search artifact · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Warren, Jason D, Practical Neurology, 2024 · Publisher / database full text

Neurological gait assessment

2023
Genuinely tangential / search artifact · Practical Neurology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mermelstein, Sofia et al, Practical Neurology, 2023 · Publisher / database full text

Neurological Manifestations and Outcomes in a Retrospective Cohort of Mexican Inpatients with SARS-CoV-2 Pneumonia: Design of a Risk Profile

2021
Genuinely tangential / search artifact · Healthcare

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
García, Silvia et al, Healthcare, 2021 · Open-access full text

Non-conventional laryngeal malignancies: a multicentre review of management and outcomes

2023
Genuinely tangential / search artifact · European Archives of Oto-Rhino-Laryngology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
O’Neill, Rory J. et al, European Archives of Oto-Rhino-Laryngology, 2023 · Publisher / database full text

Orphan Drugs in Neurology—A Narrative Review

2023
Genuinely tangential / search artifact · Journal of Personalized Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sirbu, Carmen Adella et al, Journal of Personalized Medicine, 2023 · Open-access full text

P.061 Stroke Care and Neurological Emergency Response Simulation (SCaNERS): Creation and Implementation into a Resident Curriculum

2021
Genuinely tangential / search artifact · Canadian Journal of Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Archibold, K et al, Canadian Journal of Neurological Sciences, 2021 · Publisher / database full text

P.062 Does the intensity of brain parenchymal contrast staining on post-recanalization dual energy head CT (DECT) of stroke patients predict the fate of brain tissue?

2021
Genuinely tangential / search artifact · Canadian Journal of Neurological Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Alomran, B et al, Canadian Journal of Neurological Sciences, 2021 · Publisher / database full text

Perspectives on the Parathyroid–Thymus Interconnection—A Literature Review

2025
Genuinely tangential / search artifact · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Maria-Paula, Comănescu et al, International Journal of Molecular Sciences, 2025 · Open-access full text

Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature

2021
Genuinely tangential / search artifact · Journal of Personalized Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Journal of Personalized Medicine, 2021 · Open-access full text

Possessions to Discern by Every Healthcare Professional

2021
Genuinely tangential / search artifact · Asian Journal of Research in Pharmaceutical Science

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Asian Journal of Research in Pharmaceutical Science, 2021 · Publisher / database full text

Potential Neurological Outcomes in COVID-19 Patients: A Nonsystematic Review of the Literature During the First Year of the COVID-19 Pandemic

2022
Genuinely tangential / search artifact · Turk Noroloji Dergisi

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Asif, Khadija et al, Turk Noroloji Dergisi, 2022 · Open-access full text

Prevalence of anosmia among COVID-19 patients in Taif City, Kingdom of Saudi Arabia

2021
Genuinely tangential / search artifact · Saudi Medical Journal

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY-NC 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mubaraki, Adnan A et al, Saudi Medical Journal, 2021 · Open-access full text

Prodrug activation by 4,4’-bipyridine-mediated aromatic nitro reduction

2024
Genuinely tangential / search artifact · Nature Communications

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wang, Qing et al, Nature Communications, 2024 · Open-access full text

Progressive multifocal leukoencephalopathy and peripheral neuropathy in a patient with Good’s syndrome

2022
Genuinely tangential / search artifact · Journal of Neurovirology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Deng, Qinqin et al, Journal of Neurovirology, 2022 · Publisher / database full text

Quality of Life and Respiratory Performance in the Laryngectomized Patient: Role of the HME Filters during Physical Activity

2024
Genuinely tangential / search artifact · Journal of Clinical Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mesolella, Massimo et al, Journal of Clinical Medicine, 2024 · Open-access full text

Rare Gene Mutations in Romanian Hypoacusis Patients: Case Series and a Review of the Literature

2022
Genuinely tangential / search artifact · Medicina

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Alexandra-Cristina Neagu et al, Medicina, 2022 · Open-access full text

Readability analysis of ChatGPT's responses on lung cancer

2024
Genuinely tangential / search artifact · Scientific Reports (Nature Publisher Group)

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gencer, Adem, Scientific Reports (Nature Publisher Group), 2024 · Open-access full text

Response rates in clinical quality registries and databases that collect patient reported outcome measures: a scoping review

2023
Genuinely tangential / search artifact · Health and Quality of Life Outcomes

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ruseckaite, Rasa et al, Health and Quality of Life Outcomes, 2023 · Open-access full text

RETHINKING INNOVATION AT FDA

2024
Genuinely tangential / search artifact · Boston University Law Review

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sachs, Rachel E et al, Boston University Law Review, 2024 · Publisher / database full text

RETRACTED ARTICLE: Neuromuscular Specializations of the Human Hypopharyngeal Muscles

2021
Genuinely tangential / search artifact · Dysphagia

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Mohammed, Mohammed Elrabie Ahmed et al, Dysphagia, 2021 · Publisher / database full text

Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies

2022
Genuinely tangential / search artifact · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Golay, Josée et al, Frontiers in Immunology, 2022 · Open-access full text

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19

2024
Genuinely tangential / search artifact · BMC Infectious Diseases

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY-NC-ND 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Kazemi-Sufi, Siamak et al, BMC Infectious Diseases, 2024 · Open-access full text

Sleep increases leaks and asynchronies during home noninvasive ventilation: a polysomnographic study

2022
Genuinely tangential / search artifact · Journal of Clinical Sleep Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Martí, Sergi et al, Journal of Clinical Sleep Medicine, 2022 · Publisher / database full text

Society News of the European Confederation of Neuropathological Societies

2021
Genuinely tangential / search artifact · Clinical Neuropathology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Clinical Neuropathology, 2021 · Publisher / database full text

Soft Tissue Ewing Sarcoma Cell Drug Resistance Revisited: A Systems Biology Approach

2023
Genuinely tangential / search artifact · International Journal of Environmental Research and Public Health

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Seyedehsadaf Asfa et al, International Journal of Environmental Research and Public Health, 2023 · Open-access full text

Stemness of Cancer: A Study of Triple-negative Breast Cancer From a Neuroscience Perspective

2025
Genuinely tangential / search artifact · Stem Cell Reviews and Reports

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Stem Cell Reviews and Reports, 2025 · Publisher / database full text

Study on the Intervention Mechanism of Cryptotanshinone on Human A2780 Ovarian Cancer Cell Line Using GC-MS-Based Cellular Metabolomics

2023
Genuinely tangential / search artifact · Pharmaceuticals

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Wang, Tong et al, Pharmaceuticals, 2023 · Open-access full text

Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars

2020
Genuinely tangential / search artifact · Drugs

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Tesch, Megan E et al, Drugs, 2020 · Publisher / database full text

TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients

2022
Genuinely tangential / search artifact · Medicina

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Sanja Tomanovic Vujadinovic et al, Medicina, 2022 · Open-access full text

The Armadillo as a Model for Leprosy Nerve Function Impairment: Preventative and Therapeutic Interventions

2022
Genuinely tangential / search artifact · Frontiers in Medicine

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Pena, Maria Teresa et al, Frontiers in Medicine, 2022 · Open-access full text

The Curious Case of the “Neurotoxic Skink”: Scientific Literature Points to the Absence of Venom in Scincidae

2021
Genuinely tangential / search artifact · Toxins

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Toxins, 2021 · Open-access full text

The Differential Expressions and Associations of Intracellular and Extracellular GRP78/Bip with Disease Activity and Progression in Rheumatoid Arthritis

2025
Genuinely tangential / search artifact · Bioengineering

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Liu, Guoyin et al, Bioengineering, 2025 · Open-access full text

The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design

2021
Genuinely tangential / search artifact · Drug Design, Development and Therapy

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY-NC 3.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Ling, Yong et al, Drug Design, Development and Therapy, 2021 · Open-access full text

The Human Cost: Patient Contribution to Clinical Trials in Neurology

2022
Genuinely tangential / search artifact · Neurotherapeutics

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Reoma, Lauren B. et al, Neurotherapeutics, 2022 · Publisher / database full text

The Orexin/Hypocretin System, the Peptidergic Regulator of Vigilance, Orchestrates Adaptation to Stress

2024
Genuinely tangential / search artifact · Biomedicines

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Jászberényi, Miklós et al, Biomedicines, 2024 · Open-access full text

The role of antibody glycosylation in autoimmune and alloimmune kidney diseases

2024
Genuinely tangential / search artifact · Nature Reviews. Nephrology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Beyze, Anaïs et al, Nature Reviews. Nephrology, 2024 · Publisher / database full text

The theory of tumor ecosystem

2022
Genuinely tangential / search artifact · Cancer Communications

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textOpen access
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chen, Xueman et al, Cancer Communications, 2022 · Open-access full text

Transfusion Service Response to the COVID-19 Pandemic

2020
Genuinely tangential / search artifact · American Journal of Clinical Pathology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Gehrie, Eric et al, American Journal of Clinical Pathology, 2020 · Publisher / database full text

Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)

2021
Genuinely tangential / search artifact · Nature Reviews. Endocrinology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Authors not listed, Nature Reviews. Endocrinology, 2021 · Publisher / database full text

Type 3 autoimmune polyglandular syndrome (APS-3) or type 3 multiple autoimmune syndrome (MAS-3): an expanding galaxy

2023
Genuinely tangential / search artifact · Journal of Endocrinological Investigation

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Betterle, C. et al, Journal of Endocrinological Investigation, 2023 · Publisher / database full text

Understanding Autoimmunity: Mechanisms, Predisposing Factors, and Cytokine Therapies

2024
Genuinely tangential / search artifact · International Journal of Molecular Sciences

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Yasmeen, Farzana et al, International Journal of Molecular Sciences, 2024 · Open-access full text

Using induced pluripotent stem cells to investigate human neuronal phenotypes in 1q21.1 deletion and duplication syndrome

2022
Genuinely tangential / search artifact · Molecular Psychiatry

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Chapman, Gareth et al, Molecular Psychiatry, 2022 · Open-access full text

Why do patients with cancer die?

2024
Genuinely tangential / search artifact · Nature Reviews. Cancer

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessPublisher / database full textInstitutional or personal access may be required
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Boire, Adrienne et al, Nature Reviews. Cancer, 2024 · Publisher / database full text

Wound healing: insights into autoimmunity, ageing, and cancer ecosystems through inflammation and IL-6 modulation

2024
Genuinely tangential / search artifact · Frontiers in Immunology

Catalogued for its connection to this category. No distinct LEMS finding was written up beyond the title or abstract. They are retained for an honest, reproducible search record. There is no reason to read them to understand or manage LEMS.

Article accessOpen-access full textCC BY 4.0
Citation and original article
Evidence type: Not assigned · Relevance tier: Not assigned
Lacina, Lukáš et al, Frontiers in Immunology, 2024 · Open-access full text